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 Abstract 
 
The aim of this research was to formulate, characterise and assess the feasibility 
of a novel drug delivery system known as the in situ gelling matrix (ISGM) where 
a hydrophilic polymer is suspended in a non-aqueous solvent that converts into a 
gel when injected subcutaneously or intramuscularly thus giving a controlled 
release matrix for a drug.  Although the concept has been patented with claims 
that this kind of drug delivery is achievable in theory for a wide variety of 
candidate substances, actual formulation studies for making a commercially viable 
product for this technology are completely lacking in practice.   The research 
embodied in this thesis addresses this lack.  Initial studies involved conducting a 
biocompatibility study using the HET-CAM (hens egg test – chorioallantoic 
membrane) test on a range of possible ingredients for the delivery system.  The 
materials deemed biocompatible were then carried through to a screening process 
where the physical stability of the hydrophilic polymers in non-aqueous solvents 
was monitored.  It was found that the hydrophilic polymers tested sedimented 
rapidly in the non-aqueous solvents indicating such a system was not physically 
stable.  Consequently, density-inducing or viscosity-inducing agents were added 
to the non-aqueous solvents to retard the sedimentation rate.  The addition of 
polycarbophil, a viscosity-inducing agent, clearly increased the viscosity of the 
system.  However, undesirable formation of polycarbophil globules occurred 
during the manufacturing process, which caused batch-to-batch variations in the 
viscosity of the continuous phase. Various manufacturing methods were tested 
before arriving at the optimum procedure to prevent globule formation using a 
high speed dispersion tool.  A final physical sedimentation analysis of candidate 
continuous phases and hydrophilic polymers was conducted for determining the 
ideal combination of ingredients to use in the system.  These investigations finally 
led to the adoption of an optimum mix of components consisting of 10% (w/w) 
hydroxypropyl methylcellulose (HPMC) (the hydrophilic polymer) suspended in a 
continuous phase of propylene glycol (the non-aqueous solvent) containing 0.67% 
(w/w) polycarbophil (the viscosity inducing agent). 
 
Using this mix of components, the in situ gelling matrix system was then 
subjected to various characterisation studies including infrared (IR), differential 
 ii
scanning calorimetry (DSC), ultraviolet-visible (UV-Vis) spectrophotometry and 
redispersion studies.  The chemical stability of the hydrophilic polymer and the 
continuous phase (the non-aqueous solvent and polycarbophil) was monitored and 
were found to be chemically stable over a 9 month period.   
 
The feasibility of the in situ gelling matrix technology as a controlled release 
device was assessed using the drug propranolol.  In vitro drug release studies were 
conducted using a custom-built dissolution apparatus.  The effect of various 
parameters such as the concentration of the hydrophilic gelling agent on the drug 
release rate was investigated.  Increasing the concentration of the gelling agent in 
the formulation resulted in a slower rate of release.  The drug release data were 
modelled using the Higuchi relationship and a power law relationship to compare 
the effects of the various parameters on the release rate 
 
Stability studies on the drug in the in situ gelling matrix system were carried out 
by storing samples in accelerated ageing conditions of 40°C / 75% relative 
humidity for 4 weeks.  During this time, the samples were analysed each week by 
high performance liquid chromatography (HPLC).  These demonstrated that no 
apparent drug degradation had occurred over the 4-week period. This indicates 
that the drug propranolol in the in situ gelling matrix system is stable under 
ambient conditions for at least 4 weeks.   
 
The results of this study demonstrated that the in situ gelling matrix technology is 
potentially viable as a drug delivery system and provide a practical methodology 
for the commercial development of such systems. 
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CHAPTER ONE 
Introduction 
 
When administering a drug, there is an optimum concentration range for which to 
gain the drug’s maximum therapeutic benefit.  Ideally the drug level in the body 
should remain between the maximum and minimum effective levels.  Beyond the 
maximum level represents a toxic level and below the minimum the drug is no 
longer effective.  With conventional methods (such as immediate release tablets), 
a single dose will result in the instant maximum release of the drug (perhaps 
above the maximum level) which then drops back below the minimum effective 
level (Freiburg and Zhu, 2004).  Consequently multiple doses are required to 
maintain the average drug level within the optimum range (Figures 1.1a and 1.1b). 
 
Figure 1.1a – Comparison of Conventional and Controlled Release Profiles  
(Santini et al., 2000) 
 
 
 
 
 
 
 
 
 
 
Figure 1.1b –Dosage Regime for Conventional and Controlled Release Systems  
(Santini et al., 2000) 
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To overcome the need for frequent dosing, controlled release drug delivery 
systems have been developed (Matschke et al., 2002; Rothen-Weinhold et al., 
2000).  Controlled release drug delivery systems first appeared in the 1960’s and 
1970’s (Santini et al., 2000; Banker, 1996).  Since then there have been numerous 
systems developed and an entire field of scientific research is dedicated to the 
science and technology of controlled release drug delivery.   
 
Controlled release drug delivery systems can be defined as chemical, mechanical 
or electromechanical devices which deliver drugs to the systemic circulation or to 
specific target sites in the body at pre-determined and controlled rates (Smolen, 
1978; Smolen, 1981).  The ideal controlled release drug delivery system would 
deliver the drug at a rate required by the body during the treatment period and 
would also deliver the drug specifically to the site of action.  However, currently 
there is no such delivery system capable of fully achieving these aims.   
 
Conventional methods of delivering drugs such as dissolution from a tablet are not 
able to predictably control the rate of release or control the site of action.  
Targeted drug delivery systems can control the site of action but are usually 
unable to dictate the release kinetics of the drugs in a predictable manner.  
Controlled release systems generally can control the rate of drug release but 
cannot control the fate of the drug once it has been released (Li et al., 1987).   
 
Controlled release drug delivery systems have been used extensively in human 
health.  They also have wide application in the animal health industry.   In 1998 
controlled release dosage forms amounted to $1 billion out of a $7 billion market 
for veterinary pharmaceuticals.  Of the $1 billion, 40% was estimated to be from 
parenteral (i.e., delivered outside of the gastrointestinal tract) sustained release 
products (Medlicott et al., 2004).  The major market for controlled release drug 
delivery in the veterinary field is disease prevention and control by delivery of 
antimicrobial and antiparasitic agents.  Other areas applicable to the veterinary 
field are fertility control, oestrus synchronisation and supplementation of 
nutritional agents (Rothen-Weinhold et al., 2000).   
 
The advantages of controlled release drug delivery in the veterinary field are: 
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 The ease with which they are administered. 
 Less stress to the animal due to reduced restraining. 
 Less time and effort. 
 Reduced handling and need for yarding of the animals. 
 Reduced overall cost of treatment compared to the cost of multiple 
administration. 
 Knowledge that the animal is being treated for the required length of time 
(i.e., doses are not missed which can occur if treatment involves a multiple 
dosage regime). 
 The dose of drug administered is known unlike when the drug is added to 
food and water. 
 Human exposure to veterinary compounds which may be unsafe to handle 
will be minimised. 
 
 
Recent developments in dosage form design in the area of injectables for 
controlled release of drugs have focussed on the development of easily injectable 
systems that form solid implants following administration.  Recently a new and 
novel in situ forming gel technology system has been described in the patent 
literature (Bunt et al., 2003).   The patent describes a possible idea for a new in 
situ gelling matrix (ISGM) system, broadly described as a suspension of a 
hydrophilic polymer in a non-aqueous solvent.  
 
The patent awarded to Bunt et al. (2003) describes a formulation for parenteral 
administration to a subject.  The formulation described comprises at least one 
water miscible solvent, at least one gelling agent and at least one active agent.  
The gelling agent is in particulate form and suspended in the solvent.  The patent 
describes the active agent in the formulation as being any of the following agents: 
antibacterial, antifungal, fungicidal, anti-inflammatory, antiparasitic, anti-
neoplastic, analgesic, anaesthetic, antipsychotic, vaccine, central nervous system, 
growth factor, hormonal, antihistamine, osteoinductive, cardiovascular, antiulcer, 
bronchodilating, vasodilating, birth control, antihypertensive, anticoagulant, 
antispasmodic, fertility-enhancing and combinations thereof.  The formulation is 
claimed to be administered via the parenteral route which is selected from the 
group consisting of subcutaneous, intramuscular, intraorbital, intracapsular, 
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intraspinal, intrastemal and intravenous and within a plant.  In the case of a tree, a 
fungicide could be administered by injecting the formulation to fill a hole in the 
tree.   
 
Although, the patent by Bunt et al. (2003) gives a broad description of what the 
ISGM system may incorporate, i.e., a suspension of any hydrophilic polymer in 
any non-aqueous solvent, no rational investigation has been conducted on the best 
mix of excipients to use in such an ISGM system.  There are some obvious 
challenges and issues regarding the pharmaceutical formulation of this ISGM 
system.  The ISGM system is described as a non-aqueous system, for which there 
is limited information in the literature and consequently extensive research is 
needed to find the ideal excipients to use so that the ISGM system could be 
formed as a physically stable suspension.  In the case of aqueous suspensions, 
stabilisation might be achieved by adding hydrophilic polymers which thicken or 
gel in the presence of water.  This could obviously not be done in the ISGM 
system under development in this study, as the system is based on a non-aqueous 
solvent.  The difference lies in the fact that the hydrophilic polymer (which is 
added to the system) can only be suspended in the non-aqueous solvent and will 
only gel when the system comes into contact with aqueous fluids after injection 
into the body.  The use of non-aqueous solvents thus becomes challenging in that 
the hydrophilic polymer must be also maintained in suspension without settling so 
that an acceptable time of dispersion stability is realised after shaking the ISGM 
system immediately prior to its injection into a living organism.  To guarantee 
such a degree of dispersion stability, a further component modifying the non-
aqueous solvent density or viscosity would thus be required. As a further 
complication, reactions may occur at the (subcutaneous or intramuscular) 
injection site due to unpredicted lack of biocompatibility between the non-
aqueous solvent and living tissue.   There is the possibility of allergic reactions 
and irritations.  
 
Consequently, the initial thrust of the research described in this thesis was aimed 
at formulating the ISGM system to find the ideal combination of components to 
use for achieving a practical realisation of the claims set out in Bunt et al.’s 
(2003) patent. This required a cursory biocompatibility assessment of the 
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excipients and a sedimentation analysis of the possible hydrophilic polymers to 
add to a range of candidate non-aqueous solvents.  This led to an ideal 
combination of a hydrophilic polymer and a non-aqueous solvent which 
comprised a working system.  The decision was made to assess the stability and 
drug delivery capability of the system using propranolol as a model drug.  
 
The structure of this thesis is as follows: 
Chapter 2 reviews the background and theory of some commonly used injection 
methods as well as the current state of technology in this area.  Chapter 3 is the 
methodology section which outlines the experimental procedures followed in this 
study for achieving the aims set out in Chapter 1.  The detailed discussion on the 
rationale of the studies undertaken is given in Chapter 4.  Chapter 3 has been 
divided into sections each with a brief introduction.  Section 3.1 mainly deals with 
biocompatibility of various candidate non-aqueous solvents and hydrophilic 
polymers.  The excipient candidates which did not cause any significant 
immunological response were carried forward to a screening process, described in 
Section 3.2.  The screening process involved investigating the physical stability of 
the hydrophilic polymers in non-aqueous solvents.  Modifications to the solvents 
to improve physical stability by means of density- or viscosity-inducing agents 
were also investigated.  Section 3.3 describes the characterisation of the ISGM 
system by carrying out experiments such as viscosity studies, ease of redispersion 
and water absorption studies.  The chemical stability of the hydrophilic polymer 
and the continuous phase was also assessed.  Section 3.4 describes 
characterisation of the final formulation by DSC, IR analysis and UV-Vis 
analysis.  Once the formulation had been characterised, in vitro studies were 
conducted as described in Section 3.5.  The in vitro studies involved addition of a 
drug to the ISGM system and measuring its release over time.  The effects of 
various factors on the release rate of the drug were assessed.  The stability of the 
formulation was assessed as described in Section 3.6.  The purpose of the stability 
trial, carried out under accelerated ageing conditions, was to determine how the 
quantity of the drug in the system changed over time.   
 
Chapter 4 contains the results and discussion of the experimental procedures 
described in Chapter 3.  The final chapter of the thesis, Chapter 5, begins with a 
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summary of all the findings along with recommendations for future research 
followed by a list of all the conclusions made as a result of this study. 
 
 
CHAPTER TWO 
Literature Review and Scope of this 
Project 
 
There is currently considerable research on the development of new drug delivery 
systems.  This wide interest is due to the following factors: 
 
 The possibility of product lifecycle management for successful drugs by 
using controlled release drug delivery systems.  The introduction of new 
drug entities to the market is increasingly expensive.  Time is also a factor.  
The development of a new chemical entity takes approximately 10 - 12 
years whereas a new drug delivery system only involves 3 - 4 years 
(Verma et al., 2002). 
 
 New delivery systems are required to deliver genetically engineered 
pharmaceuticals such as peptides and proteins to the site of action without 
incurring significant immunogenicity or biological inactivation. 
 
 Treatment of enzyme deficiencies and cancer therapies can be improved 
by more efficient targeting. 
 
 The therapeutic efficacy and safety of drugs which are administered by 
conventional methods (such as immediate release tablets) can be improved 
by precise spatial and temporal placement in the body.  This will reduce 
the size and number of doses (as discussed in Chapter 1). 
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Background 
 
2.1 Routes of Drug Administration: The Parenteral Route 
There are many possible routes of drug administration such as oral, rectal, 
transdermal and parenteral.  The technology developed and investigated in this 
study is designed for administration via the parenteral route.  Parenteral is derived 
from the Greek words para which means beside and enteron which means gut.  
Together these words mean something done outside of the intestine.  Therefore 
parenteral products are those administered outside of the gut / gastrointestinal tract 
(Ansel and Popovich, 1990; Li et al., 1987).   
 
The advantages of the parenteral route of drug administration are the rapid 
absorption of drugs (except for intravenous bolus and infusion administration as 
the drug is administered directly into the systemic circulation), avoidance of the 
first pass (hepatic) metabolic effect, the blood level of the drug is more 
predictable (as little is lost with intramuscular and subcutaneous injections and 
virtually none with intravenous) and consequently smaller doses can be 
administered.  The disadvantage of parenteral delivery is that once the drug is 
injected, removal is practically impossible.  In contrast, if a reaction or overdose 
occurs with other routes (such as the oral route), there is time between 
administration and drug absorption to remove the drug via induced vomiting for 
instance.   
 
There are many routes of parenteral administration such as intramuscular (IM), 
subcutaneous (SC) and intravenous (IV) (Ansel and Popovich, 1990). 
 
 
2.1a Intravenous Injections 
With intravenous injections, normally an aqueous solution is injected into the 
venous system.  The solution must not precipitate once injected into the 
circulatory system as this may produce an embolism (Aoki, 1994).  An example 
of an intravenously injected controlled release delivery system is liposomes.  
Liposomes were first discovered in the 1960’s and have been extensively studied 
for the intravenous delivery of a variety of pharmaceutical compounds (Patil and 
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Burgess, 2005).  There are currently more than 10 approved liposomal 
formulations on the market with several others in the advanced stage clinical trials 
(Crommelin and Storm, 2003).   
 
Liposomes are complex emulsion like systems in which the drug is entrapped in 
the aqueous or lipid layer (which layer depends on the physicochemical properties 
of the drug).  Liposomes are microparticles ranging in size from 0.03 to 10 µm 
containing a bilayer of phospholipids encapsulating an aqueous space.  The polar 
head of the lipids face the aqueous phase and the hydrophobic hydrocarbon chains 
adhere together in the bilayer (Ranade and Hollinger, 1996) (Figure 2.1).  In an 
aqueous environment the lipid molecules swell and self-assemble in a definitive 
and consistent orientation which is also known as a bi-layer structure. 
 
 
Figure 2.1 – The Lipid Bilayer 
Polar Head
Hydrophobic Hydrocarbon 
Chain  
 
 
 
 
 
The disadvantages of liposomal products are they are expensive to manufacture 
and have limited stability (Feng et al., 2004; Malmsten, 2006).   
 
 
2.1b Intramuscular Injections 
IM injections are made deep in the muscle (Figure 2.2).  The site of injection is 
one where the chances of hitting a nerve or blood vessel are minimal.  Drugs 
which are irritating to the SC site may be injected into muscle tissue (Ansel and 
Popovich, 1990). 
 
 
2.1c Subcutaneous Injections 
Subcutaneous injections are made into the subcutaneous layer below the skin 
(Figure 2.2).  Upon injection the drug comes into contact with blood capillaries 
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and diffuses or filters into them.  In many animals, injections are made in areas of 
loose skin and where the SC site is more easily reached, such as the back of the 
neck.  The injections are made into the space between the dermis and the 
underlying SC fat layer. 
 
 
 
 
 
 
 
 
 
 
 Figure 2.2 – Depiction of SC and IM Injections (Medlicott et al., 2004) 
 
 
 
2.1d Preferred Injection Methods in Veterinary Drug Delivery 
The IM and SC routes are the main routes of drug administration.   The preferred 
route of administration depends on the animal and condition to be treated.  The 
SC site is preferred in meat producing animals to minimise commercial losses due 
to injection site reactions and any drug residue that may be present in the muscle.  
If high doses of drug are administered then a withholding period is required when 
the tissue concentration exceeds the residue limit.  Such problems can be avoided 
by injecting into the ear of an animal.  This will reduce the drug residue in the 
muscle (for meat producing animals) (Brown, 2000). 
 
The IM route may be more appropriate than the subcutaneous route for 
companion animals (for example cats and dogs) where the risk of slow release of 
drug into the muscle, tissue residue and some local tissue damage is not as 
important (compared to meat producing animals). 
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Different injection sites may give a difference in drug absorption rate.  These 
differences will be due to factors such as tissue composition and flow rate and 
abundance of blood and lymphatic supplies. 
 
The drug absorption rate tends to be faster at the IM site as the muscle is better 
perfused with blood than the SC layer. 
 
 
 
2.2 Drug Release Mechanisms in Controlled Release Devices 
With the exception of mechanical pumps controlled release devices use polymers 
in the rate control mechanism (Heller, 1987).  Such devices can be classified into 
the following categories (Heller, 1987; Rathbone et al., 2000; Ranade and 
Hollinger, 1996): 
 
 Diffusion controlled devices 
 Solvent controlled devices 
 Chemically controlled devices  
 
 
2.2a Diffusion Controlled Devices 
There are two types of diffusion controlled systems – matrix devices and reservoir 
devices.  With matrix devices, the drug is either dissolved or dispersed in the 
polymer.  The drug is released from the matrix by diffusion.  Reservoir systems 
consist of a drug core which can be in powdered or liquid form.  The drug core is 
surrounded by a non-biodegradable polymeric material which the drug slowly 
diffuses through.  Because the polymer is non-biodegradable, the device must be 
removed from the body after all the drug has been released.  The other 
disadvantage of reservoir systems is that if the reservoir membrane was to rupture 
then a large amount of drug could be released into the bloodstream.   
 
Polymeric membranes can be either dense or porous.  The membrane properties 
(as well as the properties of the drug) control the rate of release from such a 
system.  In systems incorporating dense membranes, the drug particles entrapped 
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within the reservoir system dissolve from the solid state into the medium (which 
the drug is suspended in) and then diffuse through the medium to the polymer 
membrane.  Once the drug molecules have partitioned into the polymer 
membrane, the drug then diffuses through to the outer surface of the membrane.  
The drug then partitions into the fluid surrounding the delivery device.  The rate 
of drug release will depend on the solubility of the drug in the polymer and the 
thickness of the membrane (Rathbone et al., 2000).  In the case where the 
membrane is porous, the drug will diffuse through the fluid filled pores, rather 
than the polymer itself due to favouring the path of least resistance.  In such a 
system the release rate can be manipulated by altering the thickness of the 
membrane or by altering the size and number of pores in the membrane.  
 
 
2.2b Solvent Controlled Devices 
Solvent controlled release devices are a result of solvent penetration.  There are 
two types of solvent controlled systems – osmotic and swelling (Heller 1987; 
Ranade and Hollinger, 1996). 
 
Osmotic controlled systems involve an external fluid containing a low 
concentration of drug moving across a semi-permeable membrane into a region 
within the device containing a high concentration of drug.  The increased volume 
in the osmotic compartment forces the drug out through a small orifice. 
 
In swelling controlled systems, a polymer which can hold a large volume of water 
is employed.  When the device is placed in an aqueous environment water 
penetrates the matrix and the polymer consequently swells.  As a result of the 
polymer swelling, chain relaxation takes place and the drug is able to diffuse 
through. 
 
 
2.2c Chemically Controlled Devices 
Chemically controlled devices can also be divided into two classes – “pendant-
chain” systems or biodegradable (also known as bioerodible) systems.  
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In pendant-chain systems, a drug molecule is chemically linked to a polymer 
backbone.  The drug is either linked directly or via a spacer-group to the polymer 
and drug release occurs by chemical hydrolysis or enzymatic cleavage in the 
presence of biological fluids and enzymes in the body. 
 
Bioerodible systems are designed to have a drug which is dispersed throughout 
the polymer.  As the polymer degrades, the drug diffuses out.  The major 
advantages of such systems are that the device does not have to be removed after 
release and the drug does not have to be water soluble. 
 
 
 
 
Current State of the Art in Injectable Technologies 
 
2.3 Types of Controlled Release Drug Delivery Systems 
The technology being researched in this thesis is intended for use in veterinary 
drug delivery.  There are various controlled release drug delivery systems 
currently used in the veterinary industry.  These include delivery systems such as 
injections, subcutaneous implants and microspheres (Rothen-Weinhold et al., 
2000; Okumu and Cleland, 2003; Medlicott et al., 2004; Burgess and Hickey, 
2005; Freiberg and Zhu, 2004).   
 
 
2.3a Injections  
Injections are the most common dosage form used in animals.  Indeed, one of the 
highest selling animal products is an injectable suspension called Posilac®.  
Posilac® is administered once every 14 days to increase milk production in dairy 
cows (Medlicott et al., 2004).  The popularity of injections as a dosage form arises 
because they offer several advantages to the farmer or veterinarian.  These 
advantages include: 
 
 Cheap formulations. 
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 Ease of administration of a drug to a large number of animals (for IM and 
SC). 
 Means of rapid administration of a drug to a large number of animals. 
 Animals are not needle shy. 
 No need for removal of the delivery system after administration. 
 The blood level of the drug is more predictable (as little is lost with 
intramuscular and subcutaneous injections and virtually none with 
intravenous) and consequently smaller doses can be administered. 
 
Despite the popularity of injectable use within the animal health industry these 
types of dosage forms do have inherent disadvantages.  These disadvantages 
include: 
 
 Once the drug is injected, removal is practically impossible (Okumu and 
Cleland, 2003).  If a reaction or overdose occurred with other routes such 
as the oral route, there is time between administration and drug absorption 
to remove the drug where vomiting can be induced.   
 Different injection sites may give a difference in drug absorption rate.  
These differences will be due to factors such as tissue composition and 
flow rate and abundance of blood and lymphatic supplies. 
 Injections have inherent problems associated with them; the shape, size 
and nature of the depot depends on the formulation composition, volume 
injected, the system’s rheological properties, relative dispersal rates of 
formulation components and the forces due to tissue movement and 
muscle contraction (Medlicott et al., 2004). 
 
However, the biggest problem associated with controlled release from an 
injectable drug delivery system is that the duration of action is short.  Typically a 
controlled release injectable does not deliver a drug for longer than 7 days.  Some 
may reach 14 days (e.g., Posilac®).  However, many clinical conditions require 
much longer delivery periods than this.  To date this problem has been overcome 
by the formulation of implants.   
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2.3b Subcutaneous Implants 
The administration of implants involves the use of large gauge needles or surgical 
procedures.  Consequently due to the invasive nature of administering an implant, 
a prolonged drug release of more than 3 months is preferred.  The advantage of 
implants is they operate for long periods of time when implanted and are reported 
to provide a better control of release than injectable systems (Okumu and Cleland, 
2003).  Implants can also be removed unlike injections where once the drug has 
been injected, removal is practically impossible.  Subcutaneous implants are 
typically placed into the subcutaneous tissue in the ear of animals since this is a 
non-edible tissue of the animal.   
 
Examples of commercial implant delivery devices are given below. 
 
SYNCRO-MATE-B®  
Subcutaneous implants for the ear are used to deliver sufficient quantities of 
progestagens.  The progestagens are incorporated in either hydron or silicone 
polymers (Rathbone et al., 1998).  The SYNCRO-MATE-B® is an example of a 
commercially available ear implant for cattle. 
 
The DUROS® Implant  
The DUROS® implant is a titanium alloy cylinder which is capped at one end by a 
semipermeable membrane and an exit port at the other end (Figure 2.3).  The 
cylinder contains an osmotic engine and a piston and a drug formulation.  The 
delivery of the drug is based on osmotic principles.  The implant’s membrane is 
permeable to water but not the osmotic solutes in the osmotic engine.  Water 
diffuses into the cylinder due to the osmotic gradient which exists between the 
osmotic engine and the extra-cellular fluid.  As a result of water entering the 
cylinder, the osmotic engine swells which displaces the piston reducing the 
volume of the compartment containing the drug formulation.  Consequently the 
drug is delivered through the exit port at a controlled rate (as long as an osmotic 
gradient exists). 
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Figure 2.3 – The DUROS Implant (Wright et al., 2003) 
 
 
 
 
 
 
 
 
 
Ovuplant™ 
Ovuplant™ is used to stimulate ovulation within 48 hours in oestrous mares 
(Rathbone et al., 2000).  Ovuplant™ is a small biocompatible subcutaneous 
implant which works by augmenting the gonadotrophin releasing hormone which 
in turn increases the levels of two reproductive hormones (follicle stimulating 
hormone and leutinising hormone).  The implant is inserted under the skin of the 
mare using a syringe-like applicator.  The duration of action is short (2-3 days) 
and once the drug has been released, the implant is subsequently absorbed. 
 
 
The systems described above are all examples of subcutaneous implants.  
However there are disadvantages with implants such as (Okumu and Cleland, 
2003; Ranade and Hollinger, 1996): 
 
 The implants have a fixed size and drug dose.  Consequently application 
of this technology in the treatment of diseases where the drug dosing is 
based on weight or body surface area will be difficult. 
 Administration involves large needles or surgical procedures. 
 The implants are only useful for potent drugs. 
 
As with injections, there are limitations with implants.  Therefore it would be 
ideal to have a controlled release formulation that was easy to administer yet 
formed a depot from which drug can slowly diffuse that lasts for many weeks.  
Such a delivery system would offer the advantages of an injection (namely ease of 
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administration), yet also the major advantage of an implant (prolonged delivery 
times). 
 
In recent times in both the human and veterinary health industries, researchers 
have been exploring the possibility of developing delivery systems that meet this 
aim.  Two major research directions have been followed.  These are microspheres 
and in situ forming gels. 
 
 
 
2.4 Microspheres 
Research has been conducted in developing biodegradable polymer microspheres 
for drug delivery (Freiberg and Zhu, 2004).  The advantage of microspheres is that 
they can be injected or ingested.  Drug release from the microsphere is achieved 
by the drug leaching from the polymer or by degradation of the polymer matrix. 
 
Microspheres are approximately 1 – 1000 µm in size.  Drugs can be incorporated 
within the microsphere as an encapsulated core (microcapsule) or dispersed 
through out the microsphere (Burgess and Hickey, 2005). 
 
Examples of products using microspheres as a delivery system are given below. 
 
ProLease® 
The ProLease® system was designed to deliver fragile biomolecules.  The 
ProLease® system involves encapsulation technology.  Therapeutic proteins are 
frequently administered by the parenteral route due to their low oral 
bioavailability and short in vivo half lives (Johnson and Herbert, 2003).  Therefore 
such molecules are encapsulated in injectable biodegradable matrices which also 
provide a sustained release.  The encapsulation process involves many steps such 
as production of lyophilised protein powder and extracting microspheres.  It is 
essential to maintain the integrity and stability of the protein during the 
encapsulation process.  Prior to delivery, the microsphere powder is dispersed in 
an aqueous viscous diluent.  Upon injection, the encapsulated drug is released by a 
mechanism which depends on dissolution of the drug, diffusion of the drug out of 
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the microsphere and hydrolysis and weight loss of the polymer which creates 
pores for continuous release of the drug from the microsphere matrix (Johnson 
and Herbert, 2003). 
 
SMARTShot B12™  
SMARTShot B12™ was the first commercially available micro-particle based 
veterinarian product.  This product continuously releases vitamin B12 for over 
200 days (Rathbone and Martinez, 2002; Medlicott et al., 2004; Matschke et al., 
2002). 
 
ProHeart®6  
ProHeart®6 is a product used for protection against heartworm disease in dogs.  
The product is administered subcutaneously and provides release for 6 months 
(Rathbone and Martinez, 2002; Medlicott et al., 2004). 
 
P+®
P+® (formerly called Lutamete Plus) is used in cyclic and late transitional phase 
non-cyclic mares (Blanchard et al., 1992; Jasko et al., 1993; Burns et al., 1990).  
P+® comprises of biodegradable microspheres containing estradiol and 
progesterone (Figure 2.4).  The preparation is administered intramuscularly.  The 
product was developed to release its load and then suddenly cease delivery 
resulting in a drop in progesterone levels.   
 
Figure 2.4 – The Product P+® Comprising of Microspheres 
Containing Estradiol and Progesterone (Rathbone et al., 2000) 
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Ivermectin  
A biodegradable microsphere preparation containing ivermectin has also been 
developed.  The product provides prolonged release of ivermectin for control of 
livestock pests such as cattle ticks and horn flies (Miller, 2000; Medlicott et al., 
2004). 
 
 
Despite the fact that microspheres are easy to administer via a syringe, have 
effective carrier characteristics and afford prolonged release of drug, they suffer 
from a drawback which is that the very large surface area that is created by the 
thousands of microscopic particles results in a very large burst effect.  Also, they 
have a limited drug loading capacity (Matschke et al., 2002). 
 
The other disadvantage of microspheres is their short residence time at the 
absorption site.  The residence time can be increased by coupling bioadhesion 
characteristics to microspheres.  Such systems are referred to as bioadhesive 
microspheres.  Bioadhesion is defined as the attachment of a synthetic or 
biological macromolecule to a biological tissue (Vasir et al., 2003).  Bioadhesive 
microspheres either consist entirely of a bioadhesive polymer or have an outer 
coating of the bioadhesive polymer (Mathiowitz et al., 2001). 
 
Because of the expense of manufacturing microspheres (due to emulsification, 
solvent handling and lyophilisation), in situ forming technologies have been 
developed as an alternative for the veterinary field (Dunn et al., 1994; Matschke et 
al., 2002). 
 
 
2.5 In Situ Forming Gels 
The in situ forming gel systems are designed such that they are fluid prior to 
injection.  Once injected, the formulation responds to a change in the environment 
to give a high viscosity or solid depot at the injection site.  The changes which can 
be affected to result in gelation or depot formation are temperature, loss of organic 
solvent by diffusion or hydration with water at the injection site.  This type of 
injectable system is highly relevant to the present research.  
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Hydrogels are considered to be polymeric materials which are able to absorb more 
than 20% of its weight of water while maintaining a distinct 3-dimensional 
structure (Gupta et al., 2002).  Hydrogels are also referred to as intelligent gels or 
smart hydrogels (Dagani, 1997).  The smartness or intelligence is so given 
because the hydrogels can perceive the prevailing stimuli and respond by 
changing their physical or chemical behaviour which results in a controlled 
release of the entrapped drug (Gupta et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 Figure 2.5 – Comparison of a Gel and a Hydrogel (Gupta et al., 2002) 
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Hydrogels and gels are similar chemically but are physically distinct (Figure 2.5).  
The difference between hydrogels and gels is that hydrogels can absorb large 
amounts of water and swell maintaining their 3-dimensional structure (Vasir et al., 
2003; Jeong et al., 2002).  In contrast gels are polymeric networks already swollen 
to equilibrium.  The addition of further water results in dilution.  Some gels are 
rigid enough to maintain their structure under a small amount of stress. However 
beyond this, gel fluidity is observed as well as a loss of polymer structure.  The 
ability of the hydrogel to swell is due to the inherent cross-linking.  Conventional 
gels may have small levels of cross-linking but this is reversible due to the weak 
physical forces. 
 
A hydrogel can swell in response to many stimuli such as pH, ionic strength and 
temperature (Zhang et al., 2005).  Hydrogels which respond to changes in pH are 
made up of polymeric backbones with ionic pendant groups.  In an aqueous media 
at a certain pH and ionic strength the pendant groups (these groups are either 
acidic or basic) will ionise and develop fixed charges on the polymer network 
(Brannon-Peppas and Peppas, 1991; Tanaka, 1979; Peppas et al., 2000; Skouri et 
al., 1995).  These fixed charges will generate electrostatic repulsion and the 
uptake of the solvent into the network is increased (Figure 2.6).  
 
Hydrogels containing acidic pendant groups such as carboxylic groups ionise 
when the pH of the environment is higher than the pKa of the ionisable group.  As 
the system’s pH increases, the number of charges increases resulting in increased 
electrostatic repulsion between the negatively charged groups.  Consequently the 
hydrophilicity of the network is increased giving greater swelling ratios. In 
contrast, hydrogels containing basic pendant groups such as amines will ionise 
when the pH of the environment is below the pKb of the ionisable group.  
Therefore at low pH, ionisation increases giving increased electrostatic repulsion 
which increases the hydrophilicity of the network thus resulting in greater 
swelling ratios (Peppas et al., 2000). 
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Figure 2.6 – Hydrogel Formation as a Result of a Change in pH (Gupta et al., 2002) 
Hydrogel formation can also occur due to a change in ionic strength.  When gellan 
gum is dispersed in an aqueous solution, it undergoes a liquid-gel transition at 
increased ionic strengths (Baeyens et al., 2000; Cohen et al., 1997).  Divalent ions 
have been shown to be more effective in promoting sol-gel transitions than mono-
valent ions (Baeyens et al., 2000). 
Alginate with a high glucuronic acid content forms a 3-dimensional ionotropic 
hydrogel matrix.  This hydrogel formation is generally by the preferential 
interaction with the calcium ions resulting in the formation of inhomogeneous 
gels.  Properties such as mechanical strength and porosity of the hydrogel depend 
on factors such as the type of ionic cross-linker (bi- or poly-valent cations) and 
concentration and viscosity of the initial alginate solution (Cohen et al., 1997). 
 
Gel formation as a result of a change in temperature is known as a thermosensitive 
hydrogel.  There are two types of thermosensitive hydrogels – positive and 
negative.  Negative thermosensitive gels have a lower critical solution 
temperature.  Beyond the lower critical solution temperature, hydrogen bonding 
between the polymer and water becomes unfavourable (compared to polymer-
polymer and water-water interactions).  Consequently there is an abrupt transition 
as the solvated macromolecule dehydrates and changes into a structure which is 
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more hydrophobic (Schild, 1992; Hoffman, 1997; Ruel-Gariepy and Leroux, 
2004). 
 
Positive thermosensitive gels have an upper critical solution temperature.  Below 
this temperature, the hydrogel will contract. 
 
Another means of gel formation is solvent-removal precipitation.  This system 
consists of a water insoluble polymer dissolved in a water miscible solvent.  When 
the formulation is injected into an aqueous environment, the solvent diffuses into 
the aqueous environment and water diffuses into the polymer matrix.  The 
polymer, being water insoluble precipitates upon contact with water resulting in a 
solid polymeric implant (Hatefi and Amsden, 2002; Packhaeuser et al., 2004).   
 
The release mechanisms from systems such as hydrogels are either diffusion 
controlled, solvent controlled or chemically controlled.  These mechanisms were 
discussed earlier in Section 2.2.  The most widely applicable mechanism to 
hydrogels is diffusion controlled.  Swelling controlled release occurs when the 
drug diffusion is faster than polymer swelling.  Chemically controlled release 
describes release which is determined by reactions that occur within the delivery 
matrix.  Examples of such reactions include cleavage of polymer chains by 
hydrolytic or enzymatic degradation, reversible or irreversible reactions between 
the polymer network and drug and surface or bulk erosion (Lin and Metters, 
2006). 
 
The mechanism of gelling in the ISGM system investigated in this study involves 
hydration with water from the injection site.  Polymers which swell by responding 
to the presence of water are not classed as “intelligent materials” unlike the cases 
discussed above where gel formation is a result of responding to stimuli such as 
pH and temperature (Colombo et al., 2000). 
 
Upon injection of the formulation into the body, a steep water gradient is formed 
between the formulation and water interface.  Consequently, as a result of this 
steep water gradient, water diffuses into the formulation.  At the same time, the 
vehicle suspending the polymer diffuses out into the body. 
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The diffusion of water into the formulation, results in the hydrophilic polymer 
swelling.  As a result of water absorption by the individual polymer chains (which 
were originally in an unperturbed state) the polymer chains end-to-end distance 
and radius of gyration expand to a new solvated state.  This is due to the lowering 
of the transition temperature of the polymer (Colombo et al., 2000).   
 
When the polymer matrix is exposed to water there are 3 distinct zones formed 
(Figure 2.7).   
 
Zone 3 
Zone 2 
Zone 1 
Figure 2.7 – The Three Zones Which Are Formed When a 
Polymer Matrix is Exposed to Water (Conti et al., 2007) 
 
 
 
 
 
 
 
 
 
 
Zone 1 represents the polymer which is still in a glassy state as water has not 
penetrated this region.  The mobility for the macromolecules is low and leads to a 
low diffusion rate of water in this region.  Zones 2 and 3 represent the polymer 
being in a rubbery state.  The mobility of the polymer chains in these regions is 
higher than that of those in zone 1.  Consequently as a result of increased 
mobility, the diffusion rate of water is higher (Gao and Fagerness, 1995).  Drug 
dissolution will occur at the boundary between solid and dissolved drug where 
solid drug is found in zone 2 and dissolved drug in zone 3.  The rate of 
movements of each boundary (for each zone) will depend on factors such as 
polymer hydration, swelling and dissolution behaviour (Ju et al., 1995).   
 
On a molecular level, drug release is determined by water penetration, polymer 
swelling, drug dissolution, drug diffusion and matrix erosion.  These factors 
depend on the interaction between water, polymer, matrix content and drug.  Drug 
diffusion in the system occurs once water has penetrated into the matrix leading to 
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polymer swelling and drug dissolution.  The diffusion of water into the system 
decreases the polymer’s glass transition temperature to the experimental 
temperature resulting in the glassy polymer transforming into a rubbery phase.  
The enhanced mobility of the polymer chains favours transport of water and 
therefore also the dissolved drug (Jamzad et al., 2005). 
 
Therefore swelling leads to changes in the polymer and drug concentration as well 
as increasing dimensions of the system.  The viscous gel which is formed acts as a 
barrier to drug release thus slowing the release of the drug (Rathbone et al., 2000).  
When the drug comes into contact with the water, the (hydrophilic) drug dissolves 
and diffuses out of the injected depot.  The diffusion of the drug is a result of the 
concentration gradient of the drug. 
 
As water continues to diffuse into the system the gel becomes progressively 
hydrated.  Once sufficient water has accumulated into the depot, the polymer 
chains disentangle, detach from the gelled matrix and then dissolve (Lee and 
Peppas, 1987; Narasimhan and Peppas, 1997; Colombo et al., 2000; Kavanagh 
and Corrigan, 2004) (Figure 2.8).  The time for break down will depend on the 
chain length and degree of substitution of the polymer. 
 
 
 
 
 
 
 
 
 
 
(a) (b) (c) 
Figure 2.8 - Diagram Indicating the Successive Stages of Polymer Disentanglement. 
(a) System of Entangled Chains, (b) A Chain Disentangling from the System and (c) 
A Completely Disentangled Chain (Narasimhan and Peppas, 1997). 
 
 
In the case where poorly water soluble drugs are used, drug release is by erosion 
of the matrix (Skoug et al., 1993; Tahara et al., 1995). 
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In recent years several systems have been investigated for both human and animal 
application and such examples are given below.  
 
2.5a The Atrigel® System 
The Atrigel® system consists of a biodegradable polymer dissolved in an 
appropriate solvent.  Injection of the formulation results in the formation of a solid 
implant upon contact with water.  The drug becomes entrapped in the solid 
polymer matrix.  The drug is then released slowly over time as the polymer 
biodegrades (Dunn et al., 1990; Rathbone and Martinez, 2002). 
 
Eligard®  
Eligard® is a delivery system based on the Atrigel® technology and delivers 
leuprolide acetate for the treatment of prostate cancer.  Eligard® consists of a 
biodegradable polymer dissolved in NMP.  The formulation is then mixed with 
leuprolide and injected subcutaneously to form a solid depot at the site of injection 
(Dunn, 2003; Berges, 2005). 
 
Deoxyrobe® 
Deoxyrobe® is another example of an Atrigel® system (Dunn, 2003).  Deoxyrobe® 
delivers doxycycline for the treatment of periodontal disease in companion 
animals. 
 
 
2.5b The Alzamer® System 
The Alzamer® depot technology consists of formulated drug particles, a solvent of 
low water miscibility and a biodegradable polymer.  The polymer is dissolved in 
the solvent.  Upon injection of the formulation, the depot comes into contact with 
the water in the physiological environment which causes the gel to undergo phase 
inversion resulting in a 2-phase gel implant being formed (Wright et al., 2003).  
The drug is released by diffusion.  During the latter stages of release, the polymer 
biodegrades promoting drug release. 
 
To date this technology has not been applied to veterinary application. 
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2.5c The SABER System 
SAIB (Sucrose Acetate Isobutyrate) is a food additive (Reynolds and Chappel, 
1988) used as an alternative to brominated vegetable oil in soft drinks.  The high 
hydrophobicity and high viscosity properties of SAIB (Rathbone and Martinez, 
2002) may be used to provide sustained drug delivery.  The high viscosity SAIB 
is formulated as a low viscosity liquid which is achieved by mixing specific 
solvents (such as ethanol and propylene carbonate (Matschke et al., 2002)).  The 
drug is then dispersed or dissolved in the SAIB/solvent mixture (Figure 2.9).  If 
the solvent is water soluble the solvent will diffuse out when injected leaving a 
viscous depot containing the SAIB and drug.  The use of a hydrophobic solvent 
results in a less viscous depot with slower diffusion of the solvent (Tipton, 2003).   
SAIB is less expensive to manufacture than other technologies such as implants 
and microspheres with PLGA (Section 2.5f).  SAIB does not require expensive 
polymers, only small amounts of solvents (approximately between 15 and 35%) 
are needed and they have a short and easy method of manufacturing (Matschke et 
al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.9 – The SABER Delivery System
 
.  The SAIB, additive and solvent are 
added together to give the SABER delivery system.  The drug is then added to 
 and the formulation is then injected into the body (DURECT the SABER system
 Corporation, 2006). 
 
An example of a technology using SAIB, is a delivery system which provides 
prolonged release of deslorelin.  Deslorelin is a potent gonadotropin-releasing 
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hormone (GnRH) analogue used to induce ovulation at precise and predictable 
times in swine and mares prior to artificial insemination (Rothen-Weinhold et al.,  
2000). 
 
 
2.5d Pluronic® 127 
Pluronic® 127 (also known as Poloxamer 407) is a non-ionic triblock co-polymer 
consisting of polyoxyethylene and polyoxypropylene units (Moore et al., 2000).  
In an aqueous environment at room temperature, Pluronic® 127 exists as a liquid.  
However at 37°C it is able to transform into a reversible semi-solid gel (above a 
critical concentration of 20%) (Wang and Johnston, 1991; Mortensen and 
Pedersen, 1993). 
 
A system similar to the Pluronic® 127 is the pH-sensitive polymeric hydrogel 
which is a polymer complex of polyacrylic acid, polymethacrylic acid and 
polyethylene glycol.  The complex is barely soluble at pH’s below 5.7.  However 
addition of 50% ethanol as a co-solvent results in a fluid formulation which can be 
injected.  Upon injection, the ethanol diffuses out of the formulation into the body 
and at the same time water diffuses into the formulation resulting in the sol-to-gel 
transition.  However the use of such a large amount of ethanol is not desirable due 
to its local intolerability (Joshi et al., 1998). 
 
Although this approach appears to hold promise as a delivery technology, to date 
no veterinary system has been developed. 
 
 
2.5e Glycerol Monoleate 
Glycerol monoleate is an unsaturated monoglyceride classed as a water insoluble 
amphiphilic lipid (Matschke et al., 2002).  In the presence of water, glycerol 
monoleate forms liquid crystals.  (Engstrom, 1990).  The phase transformation of 
glycerol monoleate depends on the water content in the matrix.  If the water 
content is only 0 – 5% (w/w), a reversible micellar phase is formed.  In 5 – 20% 
w/w water content, a lamellar phase is observed.  In the presence of excess water 
(35% w/w) cubic phase viscous gels are formed (Hyde et al., 1984).  The cubic 
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phase gel has a 3-dimensional network of curved lipid bilayers which are 
separated by a network of congruent water channels.  The formation of cubic 
phase gels depends on the lipid concentration, water content and the temperature 
(Ganguly and Dash, 2004; Shah and Paradkar, 2005; Matschke et al., 2002)  
 
 
2.5f PLA/PLGA Polymers 
PLA/PLGA (poly-lactide-acid / poly(lactic-co-glycolic) acid) are synthetic 
polymers which are used in controlled release drug delivery systems.  These 
polymers are made up of non-toxic monomers (glycolic and lactic acid) 
(Matschke et al., 2002).  The benefits of using such polymers include their 
degradation products where hydrolytic degradation gives lactic and glycolic acid 
which are then subsequently metabolised to form water and carbon dioxide (Tice 
and Crossar, 1984; Lewis, 1990).  Also the degradation time can vary from 1 
month to several years.  The time period is altered by changing parameters such as 
molecular weight and proportion of glycolic/lactic acid content ratio. 
 
The PLA/PLGA polymers are dissolved in an organic solvent.  The drug is either 
dispersed or dissolved in the solvent system.  Upon injection, the solvent diffuses 
into the body leaving a semi-solid implant which is formed by precipitation of the 
polymer in an aqueous environment. 
 
To date no veterinary system has been developed using this technology. 
 
The patent awarded to Bunt et al. (2003) describes a formulation for parenteral 
administration to a subject.  The formulation described comprises at least one 
water miscible solvent, at least one gelling agent and at least one active agent.  
The gelling agent is in particulate form and suspended in the solvent.  Examples 
of water miscible solvents which may be used in the formulation include 
propylene glycol, polyethylene glycol 400 and ethanol.  Examples of hydrophilic 
gelling agents which may be used in the formulation include hydroxypropyl 
methylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol and polyvinyl 
pyrrolidone.  Such materials are preferred due to their pharmaceutical and 
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physiological acceptability and ability to form gels of desirable viscosity for use 
in such depot formation. 
 
According to the patent, it is understood that administration of the formulation 
into the subject results in the solvent dispersing naturally into the subject fluids.  
The solvent being water miscible easily dissolves into such environments without 
leaving harmful residue levels.  A water miscible solvent is a liquid which is 
capable of being dissolved in or mixing with water.  This is essential as the water 
miscible solvent will not linger in the subject and therefore will not cause possible 
side effects.  Water miscible solvents are often less aggressive than other non-
aqueous solvents and therefore more physiologically acceptable.  Upon dispersal 
of the solvent, the gelling agent particles coagulate to form a depot from which the 
active agent is released.  
 
The patent also states that the suspension will remain largely stable (biologically, 
chemically and physically) when stored.  Settling can occur but simple shaking of 
the formulation by means such as shaking by hand, will re-establish the desired 
particulate suspension. 
 
This technology has clear advantages where a standard injection syringe can be 
used to administer the formulation.  As a result of the natural depot forming 
characteristics of the formulation, the formulation can be administered to areas of 
a subject not easily reached using methods such as oral administration and 
insertion into a cavity or surgery. 
 
However, though the patent describes an idea for a novel technology, there are 
deficiencies.  The formulation uses water miscible solvents which the patents 
states are often less aggressive than other non-aqueous solvents and therefore 
more physiologically acceptable.  However, there are various reports of uses of 
such solvents and contradictions in the literature regarding their biocompatibility.  
Therefore there is a need to assess the biocompatibility of such excipients.  A 
possible major limitation of the technology may be the use of non-aqueous 
solvents which may present biocompatibility issues.   
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The patent describes the ISGM system as remaining largely stable and therefore 
the physical stability of the suspension needs to be assessed.  Though the patent 
states that settling can occur, it is essential that if the hydrophilic polymer was to 
settle, the hydrophilic polymer does not form a hard compact mass which may be 
difficult or impossible to redisperse.  The patent describes the formulation as one 
which can be easily redispersed by means such as shaking by hand.  Therefore the 
ISGM system must be a physically stable suspension that can be easily 
redispersed if settling was to occur. 
 
In addition though the concept of the technology described in the patent is sound, 
the feasibility of the technology has yet to be assessed where the ISGM system is 
incorporated with a drug to determine if the drug release rate is retarded upon 
formation of a gelled depot. 
 
 
 
2.6 The Scope of the Current Study 
The above literature review and description of commercial veterinary drug 
delivery products led to the identification of a gap in the existing research 
literature.  Clearly, there is a need for an injectable drug delivery system that 
allows long-term predictable release of drugs.  Such a system requires 
characteristics where the formulation is liquid prior to injection and gels upon 
contact with water to form a depot much like a semi-solid implant.   
 
While Bunt et al’s (2003) patent in principle describes such a technology, it lacks 
sufficient practical demonstration of a viable system.  Furthermore, there has been 
no systematic study of the components that would make a suitable formulation, 
nor any methodology to develop such a system.  Therefore the current study was 
devised to address these deficiencies. 
 
There are many types of controlled release delivery systems currently available on 
the market as discussed above.  However, there are many disadvantages 
associated with these delivery systems for the veterinary area.  With subcutaneous 
implants, large gauge needles or surgical procedures are required.  Microspheres 
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are easy to administer, but they are very expensive to manufacture and are not 
economically viable for the veterinary industry.  There is a need to have an easily 
deliverable controlled release system for the veterinary field.   
 
Injectables are the ideal form of drug delivery as animals are not needle shy, the 
amount of drug administered is known and it is cheap and easy to administer.  
However, a problem with injections is that the duration of action is short.  
Implants have the advantage of long delivery times, but administration is 
disadvantageous as previously discussed in this section.  Therefore a technology 
which has the combined advantages of being injectable (without serious side 
issues) and at the same time providing a drug-loaded slow release implant would 
be ideal.  Such a technology would be easy to administer and at the same time 
form the semi-solid “depot” (the terminology denoting the “implant”) thus 
achieving longer release times.  This type of technology is (as previously 
described) broadly classifiable as being in the area of in situ forming gels.  The 
current technologies available in this area have the gelling agent dissolved in the 
actual solvent.  Once administered, the solvent carrier disperses into the subject, 
leaving the gel implant material behind (after it has reacted with aqueous fluids 
and gelled).  A major issue with this technology as it stands is that the solvents 
employed in these methods have needed to be aggressive in order to dissolve the 
gelling agent.  Such solvents include dimethyl sulphoxide which is used due to its 
advantageous physical properties of high solubilising capability, low viscosity and 
water-miscibility.   However the use of dimethyl sulphoxide is controversial due 
to its side effects such as local dose-related toxic effects on the vessel and pig 
brain tissue and systemic effects such as cardiovascular toxicity (Mottu et al., 
2000).  Therefore the use of such solvents poses a problem in that they may be 
potentially toxic in vivo and cause further illness or ailments.  
 
Consequently, there is a gap in this area of knowledge and a potential to develop a 
beneficial technology in the veterinary field with application to other areas if 
successful.  
 
The ISGM technology developed in this study is different from conventional in 
situ gelling systems in that the gelling agent is suspended in a non-aqueous 
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solvent as opposed to being dissolved as in current systems.  Consequently, the 
use of aggressive solvents such as dimethyl sulphoxide are not required as the 
gelling agent is merely suspended in the non-aqueous solvent and will react with 
aqueous bodily fluids to gel, with the non-aqueous solvent diffusing away from 
the injection site without leaving harmful solvent residue levels.   
 
A product which has a hydrophilic gelling agent suspended in a non-aqueous 
solvent has the potential to deliver a drug via the preferred route of injection and 
at the same time give longer release times (similar to that of an implant), without 
having to use aggressive solvents so would be highly beneficial.  The use of non-
aqueous solvents is not without its problems however.  Aqueous vehicles are 
usually less irritating than non-aqueous vehicles.  In the case of water or 
physiological saline, injection into the intramuscular tissue results in little or no 
tissue reaction (Baggot and Brown, 1998).  A suitably innocuous non-aqueous 
solvent must be chosen as negative side effects may occur, including possible 
precipitation, pain, damage, inflammation and haemolysis upon injection (Gad et 
al., 2006, Rasmussen and Svendsen, 1976; Blom and Rasmussen, 1976).  
Irritation can give local inflammation, pain and tissue damage.  Tissue damage is 
the reversible or irreversible change in the anatomy, biochemistry or physiology at 
the injection site as a result of introducing a formulation (Gad, 2000).    Hence any 
non-aqueous solvents used in such an injectable technology must be non-
irritating, non-toxic (in the amounts administered) and non-sensitising (Spiegel 
and Noseworthy, 1963; Ansel and Popovich, 1990).   
 
There are many examples of non-aqueous solvents which can be used in a 
formulation such as fixed oils, ethanol, propylene glycol, glycerin and ethyl 
carbonate.   Fixed oils (mainly mixtures of esters of unsaturated fatty acids which 
are fluid at 20°C) have been used as vehicles in parenteral formulations.  
Examples of fixed oils include peanut oil, sesame oil and corn oil.  The toxicity of 
vegetable oil is relatively low.  However, some patients have exhibited allergic 
reactions to vegetable oil.  Fixed oils can also cause local tissue reactions such as 
cysts (Spiegel and Noseworthy, 1963) and rancidity may be an issue.  
Consequently the use of vegetable oil requires a label to indicate the specific oil 
included.   
 34
There is some controversy regarding the use of glycerin in parenteral 
formulations, as administration of glycerin to animals resulted in hemoglobinurea, 
hypotension, central nervous disturbances and weight loss (Spiegel and 
Noseworthy, 1963).  Subcutaneous injection of ethanol is known to cause pain 
followed by anaesthesia.   
 
As described in the examples above, there are issues regarding the use of non-
aqueous solvents.  Consequently there is a need to assess the biocompatibility of 
non-aqueous solvents. There are a number of vehicles available which meet the 
chemical and physical requirements of pharmaceutical formulation.  However, 
there will be differences in species and routes of administration specific to the 
tolerances of these vehicles (Gad et al., 2006).   
 
Assessment of Biocompatibility 
It is important to have some means of assessing the irritation potential of solvents.  
This amounts to a need to assess the biocompatibility of the possible non-aqueous 
solvents to use in the formulation.  There are many types of biocompatibility tests 
which can be conducted to determine the nature and extent of any immunological 
response such as the Draize eye test (Lambert et al., 1993; Balls et al., 1995; 
Cormier et al., 1996), the low volume eye test (Cormier et al., 1996; Lambert et 
al., 1993; Calvin, 1992; Bruner et al., 1992) and the HET-CAM test (Luepke and 
Kemper, 1986; Dannhardt et al., 1996; Balls et al., 1995; Dahl, 1999; Schlage et 
al., 1999).  The HET-CAM test is described as a cross-over between in vitro and 
in vivo testing (Luepke and Kemper, 1986) and has the advantage that the CAM 
has the ability to simulate the pharmocokinetic profile of the substance tested 
which is not the case with an in vitro assay (Dannhardt et al., 1996).  The HET-
CAM test is suggested to be more sensitive than the Draize eye test.  In addition, 
the HET-CAM is also advantageous in regard to the cost (it is less expensive) and 
does not involve the use of laboratory animals (Dahl, 1999).  The HET-CAM test 
was thus chosen in this study to assess the biocompatibility of the possible 
excipients to use in the formulation (see Section 4.1b). 
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Consideration of a Model Drug for Use in the Studies 
The testing of a new injectable in situ gelling technology is not complete without 
tests involving a model drug. The feasibility of the technology in acting as an in 
situ gelling system with controlled release characteristics is assessed herein using 
the model drug propranolol.  Propranolol is a hydrophilic, non-selective, beta-
adrenergic blocking agent that has been used in the treatment of hypertension, 
angina pectoris, tachycardia and many other cardiovascular disorders (Taylan et 
al., 1996; Thevis et al., 2001; Farooqi and Aboul-Enein, 1996). It is chemically 
known as 1-isopropylamino-3-(1-napthyloxy)-2-propanol (Figure 2.10) (Farooqi 
and Aboul-Enein, 1996) and its use in dog and cat veterinary medicine is well 
established and documented (Walker et al., 1997).  The drug has a melting point 
of 162 – 165 °C and UV-Vis absorption maxima at 214 and 290 nm when 
dissolved in water. 
 
Figure 2.10 – Molecular Structure of Propranolol (Thevis et al., 2001) 
 
 
 
 
 
 
 
In a veterinary application, propranolol has been used in combination with 
phenobarbitone as a possible means of treating anxiety in dogs (Walker et al., 
1997).  Upon oral administration, propranolol undergoes extensive and highly 
variable hepatic first pass metabolism (Guyot and Fawaz, 2000).  The propranolol 
is completely absorbed from the gastrointestinal tract where less than 5% is 
recovered in the faeces (Namedo and Jain, 2002).  As a result of the metabolism, 
the oral bioavailability is low i.e. 30% (Riddel et al., 1987).  The variability of 
propranolol plasma concentration is as much as 10 - 20 fold.  There are alternative 
forms of administering propranolol.  IV (intravenous) delivery is available for 
acute administration.  Transdermal delivery is also possible and has the advantage 
that the propranolol is not subjected to the hepatic first pass metabolism.  
However the problem with transdermal delivery is that propranolol has a poor 
ability to permeate the skin in sufficient quantities to maintain the therapeutic 
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levels.  The skin has a horny outer layer known as the stratum corneum.  The 
inability of propranolol to penetrate this skin barrier will be due to the low 
partitioning through the lipid matrix of the stratum corneum.  Factors other than 
lipophilicty may also affect the permeability of propranolol through the skin such 
as skin protein binding and first pass metabolism in the skin. 
 
Hence using propranolol in the current research for developing a novel injectable 
in situ gel forming technology is not only useful in its capacity as a model water 
soluble drug but could also provide an alternative route for delivering propranolol 
without considering a wholly transdermal route  
 
Modelling  
Modelling of the release data was carried out using the Higuchi and power law 
relationships.  Though modelling in this study cannot be used to assess in vivo 
drug release behaviour (as there were restrictions imposed on the in vitro drug 
release system), modelling was used as comparative tool to assess the effect of 
various parameters.  Complications such as swelling of the matrix, erosion of the 
polymer and irregular geometries of gel depots make mechanistic descriptions of 
the release difficult (as described in Section 4.5c).  The Higuchi and power law 
relationships were used to model the release data as a means of comparing the 
effect of various parameters on the release rate.   
 
Stability 
The stability of the drug in the formulation was assessed by quantifying the 
amount of drug in the formulation over a period of 4 weeks under accelerated 
ageing conditions.  In the case of the delivery of propranolol, the technology 
would likely be packaged as a two-component system where the dry powder is 
packaged separately along with the liquid for use at the time of reconstitution.  
Consequently a 4-week period was chosen to conduct the accelerated ageing 
stability study as this was considered to be a sufficient period of time to assess the 
stability of the formulation from a practical, commercial viewpoint. 
 
CHAPTER THREE 
Methodology 
 
 
Throughout this research, reference will be made to the terms “the in situ gelling 
matrix (ISGM) system” and “the final formulation” (also referred to as the final 
product).  The ISGM system comprises a dispersed phase and a continuous phase.  
The dispersed phase consists of a hydrophilic polymer that is suspended as solid 
particles in a continuous phase.  The continuous phase consists mainly of a non-
aqueous solvent but which may also include a density-inducing agent or viscosity-
inducing agent dissolved in the solvent.  Figure 3.1 is a schematic representation 
of an ISGM system.  
 
Continuous Phase (+/- viscosity / density 
inducing agent) 
Dispersed Phase 
Figure 3.1 - Diagrammatic Representation of an ISGM System 
 
 
 
 
 
 
 
“The final formulation” is defined as a system comprising the drug (in the case of 
this study, propranolol was chosen) present as a homogeneously dispersed 
saturated solution throughout the ISGM system (Figure 3.2).   
 
 
Saturated Solution of Drug 
Figure 3.2 - Diagrammatic Representation of the Final Formulation 
 
 
 
 
 
 
 
 38
3.1 Structure, Properties and Biocompatibility of the 
Hydrophilic Polymers and Non-Aqueous Solvents Used in the 
Study 
An investigation into the structure and properties of the hydrophilic polymers and 
the non-aqueous solvents was carried out.  In order to determine which excipients 
to use for the ISGM system a biocompatibility study was conducted on the 
various hydrophilic polymers and non-aqueous solvents to ensure the excipients 
would not cause an adverse immunological response.   
 
3.1a Structure and Properties  
The structure and properties of the hydrophilic polymers and non-aqueous 
solvents used in the studies were compiled from literature sources and are listed in 
Tables 4.1 and 4.2 (Section 4.1a). 
 
 
3.1b Biocompatibility  
Biocompatibility studies were performed on all hydrophilic polymers (Table 3.1) 
and non-aqueous solvents (Table 3.2) investigated in this study using the HET-
CAM (Hen’s Egg Test – Chorioallantoic Membrane) test.   
 
Table 3.1 - Polymers Investigated in this Study 
 Polymer 
Xanthan Gum (Jungbunzlauer GmbH, Switzerland) 
Sodium Carboxymethylcellulose (Sodium CMC) ( BDH, UK) 
Sodium Alginate ( BDH, UK) 
Polyvinyl Pyrrolidone (PVP) (BDH, England) 
Hydroxypropylmethylcellulose (HPMC) (Shin-Etsu Chemical Co. 
Ltd, Japan) 
Polyethylene Oxide (PEO) N12 (Dow Chemical Company, USA) 
Polyethylene Oxide (PEO) N10 (Dow Chemical Company, USA) 
Polyethylene Oxide (PEO) 303 (Dow Chemical Company , USA) 
Polycarbophil (PCP) ( Goodrich BF, England) 
Polyvinylalcohol (PVA) (Sigma, USA) 
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Table 3.2 - Solvents Investigated in this Study 
Solvent 
Propylene Glycol (PG) (Sigma, USA) 
Polyethylene Glycol 400 (PEG 400) 
(Sigma, USA) 
Glycerin (Pronalys, Australia) 
Alcohol (Ethanol) (Scharlau Chemie, 
Spain) 
N-Methylpyrrolidone (NMP) (BDH, 
England) 
 
 
Fertilised hen cobb eggs were obtained from Bromley Park Hatcheries Ltd., 
Tuakau, New Zealand.  The eggs at the hatchery were stored in a cold room to 
ensure embryo development did not commence.  Embryo development only starts 
at higher temperatures of approximately 37°C, and therefore the eggs were able to 
be transported and stored in the lab at room temperature (20°C).  When fertilised 
hen eggs are produced, there is a maximum time period of 1 week upon within 
which embryo growth can proceed (Bromley Park Hatcheries Ltd., 2003).  
Beyond this time period, the success rate of chicken embryos developing in the 
fertilised eggs markedly decreases.  It was thus critical to adhere to this time 
period in the HET-CAM studies. 
 
The eggs were placed in an incubator (Contherm Stability Oven, Contherm, UK) 
(recorded as day 0) where the temperature was maintained at 36°C and the 
humidity at 60%.  The humidity was controlled by placing a large tray of water at 
the bottom of the oven.  The temperature and humidity of the oven were 
monitored using a digital thermometer/hygrometer (Tecpel, Taiwan).  The eggs 
were rotated (mimicking the hen which turns eggs every hour whilst she lays on 
them) 180 degrees each day until day 3 to prevent the growing embryo from 
sticking to the side of the egg shell membrane.  On day 3, the eggs were carefully 
cracked open into a growing chamber (i.e., a cylindrical plastic holder that was 
specifically designed for this application – Figure 3.3a).  A polyethylene film, 
such as Gladwrap®, was placed on top and pushed down to ensure there was 
sufficient space for the egg contents to fall into and to be held in place using a 
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circular sleeve (Figure 3.3b).  The excess polyethylene film hanging below the 
circular sleeve was trimmed short to ensure minimum weeping out of the albumin 
(the egg white) from the plastic holder. 
 
 
 10.5 cm 
 
 
 
 
 
 
 
 
 
Figure 3.3a – The Chamber and Circular Sleeve Used to Incubate the Chicken Embryo 
7.
9 
cm
  8.2 cm 
2.0 cm 
 
 
 
 
 
 
 
 
 
Circular Sleeve 
Chamber
Gladwrap 
Figure 3.3b – The Final Appearance of the Assembled Chamber 
The cracking process is important as the yolk and CAM must remain intact.  Eggs 
with broken yolks or a damaged CAM had to be discarded as there was very little 
chance of the embryo surviving in such a case.  Prior to cracking, the eggs were 
sprayed with 70% isopropanol as a sterilisation measure, as once the egg was 
cracked open, the embryo would no longer have the natural protection of the shell 
to prevent exposure to bacteria.  The cracking technique used consisted of tapping 
the egg against the edge of the bench to produce a single crack.  Immediately 
after, the shell was opened along the crack and the egg contents dropped into the 
chamber.  Non-viable (eggs with a broken yolk) or non-fertilised eggs (where the 
heart and blood vessels were not observable) were discarded.  The chambers 
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containing the chicken embryos were then covered with a petri dish and placed in 
an incubator for 10 days.  The actual HET-CAM test was performed on day 10 
(the 10th day of incubation) by applying the materials to be tested onto the embryo 
and assessing their irritancy potential.   
 
Different methodologies were used to apply the test materials depending on 
whether they were non-aqueous solvents or solid polymers.  In the case of the 
non-aqueous solvents 300 µL of the test solvent was pipetted gently onto the 
CAM and the reaction of the blood vessels to the solvent was noted at pre-
determined times (30 seconds, 2 minutes and 5 minutes) over a 5 minute period 
(this followed the method described by Schlage et al. 1999).  In the case where the 
test material was a solid polymer, several different methods were adopted which 
were variations of the method described by Schlage et al. (1999).  The first 
variation of the method was the so-called endpoint assessment method where 
sufficient (3-4 milligrams) solid polymer was sprinkled onto the CAM and 
carefully washed off with physiological saline after 30 seconds of exposure, and 
the time for any haemorrhage, hyperaemia and coagulation events to occur was 
observed over a 5 minute period.  In another method,  3-4 milligrams of the solid 
polymer was sprinkled onto the CAM for a total exposure time of 5 minutes and 
then washed off (with physiological saline) to assess if any reaction had occurred.  
In yet another method, the solid polymer was dissolved in water and 300 µL was 
pipetted gently onto the CAM and left in contact with the CAM for 5 minutes.  
The reaction of the blood vessels was noted at fixed times (30 seconds, 2 minutes 
and 5 minutes) over a 5 minute period (this followed the method described by 
Schlage et al. 1999).   
 
At the end of any exposure period, assessment of the irritancy potential of the 
material was carried out by observing the reaction at three fixed time points (0.5, 
2.0 and 5.0 minutes).  The time for the first appearance of any irritancy was 
recorded and allocated the score as shown in Table 3.3 (Schlage et al., 1999).   
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Table 3.3 - Scoring System for Irritancy Potential 
Time (minutes) 
Irritancy 
0.5 2.0 5.0 
Hyperaemia 5 3 1 
Haemorrhage 7 5 3 
Coagulation 9 7 5 
 
 
The scores allocated for each individual irritancy were totalled to give a 
cumulative score where 21 was the maximum possible total score.  Generally, the 
score is high if irritancy is experienced in a small time-frame.  The highest 
cumulative score of 21 is only possible if hyperaemia, haemorrhage and 
coagulation all occur within 30 seconds of applying the test substance which 
would indicate an extremely adverse reaction of the HET-CAM to the test 
substance, i.e. 5 (hyperaemia) + 7 (haemorrhage) + 9 (coagulation) = 21.   
 
Table 3.4 shows how the cumulative score was used to define the severity of the 
reaction.  
 
Table 3.4 – Severity of Reaction  
Cumulative Score Severity of Reaction 
0.0 - 0.9 Practically None 
1.0 - 4.9 Slight 
5.0 - 8.9 Moderate 
9.0 - 21.0 Strong 
 
 
All tests were carried out in quadruplicate and three positive controls and one 
negative control were employed for each test.  The positive controls were sodium 
dodecyl sulphate (Sigma, USA), ethanol and sodium hydroxide (Sigma, USA) 
which gave severely irritant reactions of lysis (disappearance of vessels), 
haemorrhage and coagulation, respectively.  Although lysis was not included in 
the scoring system by Schlage et al. (1999), other authors have observed the 
 43
phenomenon of lysis (Dahl, 1999; Wilson and Steck, 2000) and consequently 
lysis was included in this study as a control.  The negative control employed in 
this study was water which produced zero change in the HET-CAM upon 
application.  Results are summarised in Chapter 4 (Section 4.1b). 
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3.2 Formulation and Manufacture of the ISGM System 
 
Those excipients not found by the HET-CAM tests to cause any severe 
immunological response were carried forward to the screening process.  The 
screening process involved investigating the physical stability of the hydrophilic 
polymers in the non-aqueous solvents.   
 
3.2a Sedimentation Behaviour of Hydrophilic Polymers in Non-Aqueous 
Solvents 
The sedimentation behaviour of each hydrophilic polymer (see Table 3.5 for 
details) in pure non-aqueous solvent systems (Table 3.6) was determined in 6 mL 
glass vials (flat bottomed) (Samco Glass, Australia).  An adhesive paper ruler was 
attached to the side of each vial and was used to measure the sediment height 
during the experiment.  The paper ruler was constructed on computer.  The printed 
paper ruler was checked against an actual plastic ruler to ensure the scale was 
accurate.  The same ruler was used for each vial (numerous copies were printed 
onto adhesive paper) ensuring differences in readings did not occur between the 
different vials.   
 
In preparing samples for sedimentation analysis, each test polymer was sieved to 
give particle sizes of less than 100 μm.  0.4 g of the test polymer was then added 
to the vial followed by 3.6 g of the pure non-aqueous solvent (10% w/w polymer 
concentration).  Lids of the vials were tightly closed to prevent moisture entry as 
any exposure of the gelling agent to moisture will result in the system gelling 
which must be avoided, as a prematurely gelled ISGM system will be difficult or 
impossible to inject.  The polymer was then homogeneously distributed 
throughout the solvent by means of a vortex mixer (Chiltern, Model MT17V, UK) 
for 2 minutes at the maximum speed setting of 8.  The extent of homogeneity was 
observed by eye, ensuring no polymer remained “caked” on the bottom of the 
glass vial.   
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Table 3.5 - Polymers Investigated in these Studies 
 
 
P1Polymers investigated in the pure solvent study 
Polymer 
Xanthan Gum1,2,4
Sodium Carboxymethylcellulose (Na CMC)1,2,4
Sodium Alginate1,2
Polyvinyl Pyrrolidone (PVP)1
Hydroxypropylmethylcellulose (HPMC)1,2,4
Polyethylene Oxide (PEO) N121,2
Polyethylene Oxide (PEO) N101,2
Polyethylene Oxide (PEO) 3031,2,4
Polycarbophil (PCP)1,3
Polyvinylalcohol (PVA)1
2Polymers investigated in glycerin modified continuous phase study 
3Polymers investigated in polycarbophil modified continuous phase study  
4Polymer used as viscosity inducing agent 
 
 
 
 
Table 3.6 - Solvents Investigated in these Studies 
Solvent 
Propylene Glycol (PG)1,3
Polyethylene Glycol 400 (PEG 400)1,3
Glycerin2
Ethanol1,3
 
1Solvents investigated in pure solvent and glycerin modified  
continuous phase study. 
2Solvent used to induce density/viscosity changes  
in the continuous phase. 
3Solvents investigated in polycarbophil modified  
continuous phase study. 
 
 
Upon uniform dispersion (in the vials) of the test polymer the vials were placed on 
shelves with a black background and the sedimentation process was observed and 
recorded by taking photographs (with a Canon MVX150i Digital Camera).  The 
sedimentation process was monitored until the polymer had completely settled to 
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the bottom of the vial.  Sedimentation profiles (Section 4.2a) for each 
polymer/solvent system were subsequently collated from the photographs.   
 
 
3.2b Effect of Glycerin on the Sedimentation Rate of Hydrophilic Polymers 
The effect of viscosity and density of the continuous phase on the sedimentation 
rate of each of the dispersed hydrophilic polymers (Table 3.5) was determined by 
the addition of glycerin to each of the non-aqueous solvents listed in Table 3.6. 
Glycerin was used as a density modifier for the continuous phase as out of the 
vehicles which were deemed biocompatible (Section 4.1a), glycerin had the 
greatest density of 1.258 g mL-1 (Table 4.2).  Table 3.7 shows the percentage 
composition of the resultant binary solvent systems investigated in the study.  
 
Table 3.7 - Binary Solvent Systems Composition 
Solvent:Glycerin Ratios (%)* 
0:100 10:90 30:70 50:50 70:30 90:10 100:0 
*Each binary solvent system composition was prepared by weight by weight additions of the 
respective solvents.   
 
 
Sedimentation behaviour was determined in 6 mL glass vials as described in 
Section 3.2a.  0.4 g of the test polymer was then added to the vial followed by 3.6 
g of the binary solvent system (10% w/w polymer concentration).  Lids of the 
vials were (as in the earlier experiments) tightly closed to prevent moisture entry 
and premature gelling of the hydrophilic gelling agent. 
 
The state of homogenisation of the dispersion and sedimentation behaviour of the 
hydrophilic polymer was observed and then evaluated as described earlier in 
Section 3.2a.   
 
The experimental errors for these procedures were calculated as the relative 
standard deviation in the percentage sedimentation height of the replicates, (where 
each experiment was carried out in duplicate). 
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3.2c Determination of the Potential Use of Polycarbophil as a Viscosity 
Inducing Agent in Non-Aqueous Solvents 
Polycarbophil was one viscosity inducing agent of interest chosen for this study. 
Hence a preliminary qualitative evaluation of the use of polycarbophil as a 
viscosity inducing agent was conducted in which polycarbophil in various 
concentrations (0.50, 1.00 and 1.25% w/w) was added to propylene glycol by 
simple addition then shaken vigorously by hand for 1 minute.  These preparations 
were then examined by eye by inverting the container and noting the flow 
characteristics (i.e. to check for evidence of viscosity increases in the solvent by 
the polycarbophil).  It must be stated that the visual assessment of the viscosity of 
the continuous phase was merely for preliminary evaluation purposes.  A viscosity 
analysis on the effect of polycarbophil concentration on the continuous phase 
viscosity was carried out as described in Section 3.2f.   
 
 
3.2d Manufacturing Methods for Incorporating the Viscosity Inducing Agent 
into the Non-Aqueous Solvent 
Various manufacturing methods were investigated to arrive at the optimum 
method for uniformly dispersing the viscosity inducing agent (polycarbophil) 
throughout the non-aqueous solvent.  Propylene glycol was used as the non-
aqueous solvent throughout this particular investigation.  After identifying the 
best method for manufacturing the continuous phase, the other candidate non-
aqueous solvents (ethanol and polyethylene glycol 400) were then investigated. 
 
i. Magnetic Stirrer 
The initial manufacturing process involved the use of a magnetic stirrer 
(Speedsafe, Hanna, UK).  A known amount (50 g) of propylene glycol was placed 
into a 150 mL glass beaker at room temperature.  The non-aqueous solvent was 
stirred rapidly using an 8 mm diameter x 30 mm length Teflon coated magnetic 
stirrer.  0.5% w/w polycarbophil was added slowly to the propylene glycol (over a 
period of 5 minutes) and stirring was continued until the experiment was 
terminated (after 30 minutes).   
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ii. Overhead Stirrer 
In this method, 50 g of the non-aqueous solvent propylene glycol was placed into 
a 150 mL glass beaker at room temperature and stirred using an overhead stirrer 
(Heidolf, Model RZR1, Germany).  The non-aqueous solvent was stirred from 
above using a three blade overhead stirrer at 2000 RPM.  0.5% w/w polycarbophil 
was added slowly (over a period of 5 minutes) to the propylene glycol and stirring 
was continued until the experiment was terminated (30 minutes).    
 
iii. Overhead Stirrer Plus Heating 
A known amount of propylene glycol (50 g) was placed into a 150 mL glass 
beaker.  0.5% w/w polycarbophil was added to the propylene glycol and mixed as 
described in Section 3.2d ii.  After 30 minutes of stirring (at 2000 RPM), the 
mixture was placed on a heating mantle (IEC, Australia) and heated to 
temperatures of approximately 80°C while still being stirred by the overhead 
stirrer for a further 30 minutes.  
 
iv. Overhead Stirrer Followed By Placing on a Roller at 40°C 
A known amount of propylene glycol (50 g) was placed into a 150 mL glass 
beaker.  0.5% w/w polycarbophil was added to the propylene glycol and mixed as 
described in Section 3.2d ii.  After 30 minutes of stirring (2000 RPM), the mixture 
was placed on a custom made roller in a 40°C heated room (the temperature was 
maintained by a thermostat).  The room temperature was monitored by a digital 
thermometer (Tecpel, Taiwan).  The mixture was rotated on the roller at 50 RPM 
for 14 days.  No further manipulation of the mixture was conducted during this 
time.   
 
v. Mortar and Pestle 
A small amount of non-aqueous solvent (10 g) was placed in the pestle, followed 
by the addition of a known amount of polycarbophil (0.25 g – which would give 
an ultimate concentration of 0.5 % w/w).  This was mixed using the mortar until a 
thick gel formed.  The remaining solvent (40 g) was then added slowly in 10 even 
amounts over a period of 2 hours with continued mixing.  During this period the 
solvent/polymer mixture was left to stand intermittently for 5 minutes to allow the 
gel to thicken.   At intervals, a small amount (0.5 mL) of the dispersion was 
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removed (using a plastic disposable pipette) and analysed for the presence of 
globules (refer to Section 4.5d v for a definition of what a globule observed in this 
study is).  The presence of globules was assessed by tipping the glass vial onto its 
side.  The thickness of the liquid layer becomes thin and globules of undissolved 
polymer can be observed if they exist. 
 
vi. Mortar and Pestle Followed By Placing on a Roller at 40°C  
The resultant mixture obtained when using the mortar and pestle technique 
(described in Section 3.2d v) was placed on a roller in a 40°C room.  The mixture 
was left on the roller (rotating at 50 RPM) for 14 days.   At intervals (every 24 
hours), a small amount of the dispersion was removed and analysed for presence 
of globules (Section 3.2d v). 
 
Control experiments investigated the amount of water uptake of the mixture 
during the mixing process by simple weighing (Sartorious 4-figure balance, 
Germany) at intervals of 20 minutes.  The analysis was conducted in duplicate. 
 
vii. Silverson® Homogeniser 
A Silverson® L4RT (Silverson®, England) high speed homogeniser (Figure 3.4) 
was used to incorporate the polycarbophil into propylene glycol at speeds of 2000 
RPM (low speed setting) 5000 RPM (medium speed setting) and 8000 RPM (high 
speed setting). 
 
 
 
Figure 3.4 – The Silverson® Homogeniser 
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Figure 3.5a – The General 
Purpose Disintegrating Head 
Figure 3.5b – The Square 
Hole High Shear Screen Head 
 
 
 
 
 
 
 
 
Two types of heads (Figures 3.5a and 3.5b) were used in the mixing process - the 
general purpose disintegrating head and the square hole high shear screen head.   
 
To mix the polycarbophil into the propylene glycol, the appropriate head of the 
Silverson® high speed homogeniser mixer was placed into the non-aqueous 
solvent (90 g in a 150 mL plastic vessel) and the mixer turned on to a speed of 
8000 RPM.  The high speed mixing capability allowed a greater amount of the 
continuous phase to be manufactured (i.e. 90 g compared to 50 g in the previous 
methods (Section 3.2d i – 3.2d vi) due to its greater stirring efficiencies which 
would allow a greater batch to be manufactured at one time.  Though the volume 
was different the overall concentration of the polycarbophil was still the same at 
0.5% w/w).  The plastic vessel was submerged into an ice bath to prevent 
unwanted temperature increases of the propylene glycol.  The polycarbophil 
(0.5% w/w) was added by continuously sprinkling small quantities from above 
over a period of 10 minutes.  The polycarbophil was added in small amounts at a 
time to ensure the polymer was drawn into the workhead preventing clumping.  
The mixture was stirred for a period of up to 2 hours.  At time points of 5, 10, 15, 
20, 25, 60 and 120 minutes the mixing process was interrupted long enough to 
withdraw a small amount of the mixture which was analysed for the presence of 
globules (as outlined in Section 3.2d v). 
 
viii. Ultra Turrax® 
The Ultra Turrax® (T18 basic, IKA Works INC, USA) (Figures 3.6a and 3.6b) is 
similar to the Silverson homogeniser (in that it is a high speed homogeniser) but 
can operate at much higher speeds. 
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To mix the polycarbophil and the propylene glycol using the Ultra Turrax®, the 
probe was placed into the propylene glycol (90 g added into a 150 g plastic vessel) 
and the Ultra Turrax® turned on to a speed of 18000 RPM.   The polycarbophil 
(0.5% w/w) was added by continuously sprinkling small quantities from above 
over a period of 2-3 minutes.  The mixture was then stirred for a period of up to 1 
hour and 45 minutes (which was found to be sufficient time to remove any 
globules which may have formed).  At intervals of 20 minutes the mixing process 
was interrupted long enough to withdraw a small amount of the mixture which 
was analysed for the presence of globules. 
 
 
 
 
 
Figure 3.6a – The Ultra Turrax®  T18 Basic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.6b – The Ultra Turrax® Probe 
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3.2e Characterisation of Potentially Useful Continuous Phases 
Following the outcomes of previous sections (discussed more in depth in Chapter 
4 – Section 4.2e), continuous phases involving the particular non-aqueous 
solvents propylene glycol and polyethylene glycol 400 were prepared. These were 
manufactured according to the method outlined in Section 3.2d viii. where 0.5% 
(w/w) polycarbophil was added to 90 mL of each non-aqueous solvent.  
  
i. Appearance of Continuous Phase 
The appearance of each continuous phase manufactured in Section 3.2e was 
assessed by observing the colour, clarity and the presence of any globules every 
24 hours over a period of 4 weeks.  The experiment was carried out in duplicate. 
 
ii. Physical Stability 
The physical stability of each continuous phase was monitored for 4 weeks.  Glass 
vials containing 7 mL of each of the 2 possible continuous phases were set aside 
against a black background at room temperature.  The sedimentation process was 
observed and recorded by taking photographs (Canon MVX150i Digital Camera) 
every 48 hours over a period of 4 weeks.  The experiment was carried out in 
duplicate. 
 
 
3.2f Determination of the Effect of Polycarbophil Concentrations on 
Viscosity of the Continuous Phase (Polycarbophil Plus Propylene Glycol) 
The effect of the viscosity inducing agent on the viscosity of the continuous phase 
was investigated by conducting viscosity measurements.  Viscosity studies were 
conducted using a S10 vibro-viscometer (A&D, Japan).  The viscometer has two 
sensor plates which vibrate like a tuning fork maintaining a constant frequency 
and amplitude.  The viscometer measures the current which is varied to keep the 
constant vibration according to the viscosity change during the measurement.  The 
sensor plates vibrate at 30 Hz at an amplitude of about 0.4 mm. 
 
The viscometer was calibrated using glycerin standards (which were tightly sealed 
to prevent moisture entry and stored in a desiccator) having known viscosities of 
104 and 500 mPa.s (Brookfield, USA).  The sensitivity and robustness of the 
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viscometer was determined by varying conditions such as temperature and volume 
of sample. 
 
The effect of sample volume was assessed by measuring the viscosity of the 104 
mPa.s glycerin standard using volumes of 9, 9.2, 9.4, 9.6, 9.8, 10.0, 10.2, 10.4, 
10.6, 10.8 and 11 mL (where 10 mL was the required sample volume).  A pipette 
was used to measure the desired volumes.  The effect of filling the sample cup 
with solution using the 10 mL line (etched on the sample cup) compared to using 
a 10 mL pipette was also assessed.  Experiments were conducted in triplicate. 
 
The effect of temperature was determined by altering the temperature of the water 
bath from 24.6 to 25.6°C in increments of 0.1°C.  Experiments were conducted in 
triplicate. 
  
Upon developing and validating the method, viscosity readings were taken.  The 
test solution was poured into the sample cup until the bottom meniscus was in line 
with the 10 mL mark.  The sensor plates must be placed in the sample at the exact 
location for each reading.  The correct position of the sensor plate for each sample 
was ensured by using a magnifying glass.  The sample was left in the water jacket 
for 30 - 45 minutes or until a constant temperature reading was obtained on the 
viscometer.  Once the sample temperature had equilibrated, a reading was taken 
every 5 seconds for 2 minutes.  
 
 
3.2g Incorporation of the Hydrophilic Polymer into the Continuous Phase 
To manufacture the ISGM system, the hydrophilic polymer was incorporated into 
the continuous phase.  This was achieved by manufacturing the continuous phase 
by using the Ultra Turrax® method described in Section 3.2d viii. and then adding 
the hydrophilic polymer by addition of the required weight (10 % w/w) to a closed 
container (glass vial - Samco Glass, Australia) (at a rate of 0.2 g s-1).  The mixture 
was mixed by hand for 2 minutes which was sufficient time for the polymer to be 
homogeneously dispersed.   
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3.2h Sedimentation Behaviour of the Hydrophilic Polymers in the 
Continuous Phase 
A physical sedimentation analysis was carried out on the ISGM systems described 
in Table 3.8 where the continuous phase was globule-free.   
 
Table 3.8 – The ISGM Systems Investigated in the Physical Stability Study 
 
 
The sedimentation behaviour was determined in 6 mL glass vials (Samco Glass, 
Australia) as previously described in Section 3.2a.  0.4 g of the test polymer was 
then added to the vial followed by 3.6 g of the continuous phase (10% w/w 
polymer concentration).  The vials were tightly closed to prevent moisture entry.  
Experiments were conducted in duplicate. 
 
Homogeneous dispersion and observation of the sedimentation behaviour of the 
hydrophilic polymer was then evaluated as described in Section 3.2a over a period 
of 4 weeks.   
 
The errors were calculated as the relative standard deviation in the percentage 
sedimentation height of the replicates, (where each experiment was carried out in 
duplicate).  
 
The effect of the amount of polycarbophil present on the ease of redispersion of 
the ISGM system was determined by manually shaking the suspension.  It must be 
stated that the visual assessment of the ease of redispersion of the continuous 
phase was merely for preliminary evaluation purposes.  (An investigation into the 
ease of redispersion of the ISGM system was conducted in Section 3.3c).  
 
The particle size of the hydrophilic polymers was determined using the Olympus 
BX60 (Olympus, Japan) optical microscope which was connected to a Nikon DS-
Continuous Phase 
Non-Aqueous Solvent Polycarbophil Concentration
Hydrophilic 
Polymer 
PG 0.50 0.67 0.84 1.00 HPMC 
PG 0.50 0.67 0.84 1.00 PEO 303 
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5Mc (Nikon, Japan) camera.  The polymer was dusted over a coverslide and 
placed under a microscope and observed at 50 x magnification.  A random area 
was chosen and photographs taken.  200 particles were selected from the 
magnified area and measured using the calibrated scale on the optical microscope.   
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3.3  Characterisation and Stability of the ISGM System 
 
The ISGM system was characterised by carrying out experiments such as 
viscosity studies, ease of redispersion and water absorption studies.  The chemical 
stability of the hydrophilic polymer and the continuous phase was also assessed. 
 
3.3a Water Absorption Studies on the ISGM System 
It is essential that water is not absorbed by the ISGM system as the water will 
cause the hydrophilic polymer to gel.  Earlier studies (Section 3.2d vi. indicated 
when the continuous phase was open to the air, the hygroscopic non-aqueous 
solvent absorbed water leading to an increase in weight). 
 
The extent of water absorption was monitored by placing 7 mL of the ISGM 
system contained in a glass vial (Samco, Australia) in a controlled environment 
which consisted of a humidity controlled oven, where the humidity was set to 
60% and the temperature to 25°C.  Over 7 weeks the vials were removed and 
weighed to determine the amount of water absorbed.   
 
Variations of the ISGM system were also investigated to determine what effect 
the constituents had on the water intake.  Each experiment involved altering one 
variable at a time.  The HPMC concentration in the ISGM system was varied 
(Table 3.9) from 10% to 5 and 25% (keeping the polycarbophil concentration the 
same).  The effect of the concentration of polycarbophil was also investigated by 
altering the concentration from 0.67% to 0.5, 0.84 and 1% (while keeping the 
HPMC concentration the same) (Table 3.9).  All tests were conducted in triplicate. 
 
Three sealed vials containing the ISGM system were also placed on the bench at 
room temperature in sealed vials to determine whether water absorption still 
occurred. 
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Table 3.9 – Tested Variations of the ISGM System 
HPMC % (while keeping the 
PCP concentration the same) 
PCP % (while keeping the HPMC 
concentration the same) 
0 0.00 
5 0.50 
10 0.67 
20 0.84 
- 1.00 
 
 
 
3.3b Chemical Stability  
i. Hydrophilic Polymer (HPMC) 
The stability of the hydrophilic polymer (HPMC) was monitored by SEC (size 
exclusion chromatography) based on previously reported methods (Crowley et al., 
2002; Vijayalakshmi et al., 2005; Wittgren et al., 2005; Liu et al., 2004).   An 
Amersham Bioscience HPLC instrument with a T-Load 16/60 Sephacryl S500 HR 
(Pharmacia LKB Biotechnology AB, Sweden) column was used.  The column had 
a volume of 120 mL and a mean particle size of 47 µm.  The column bed 
consisted of a cross-linked copolymer of allyl dextran and N,N-
methylenebisacrylamide.  PBS (phosphate buffered saline) (Sigma, USA) buffer 
(pH 6.74) was used as the mobile phase at a flow rate of 1 mL min
-1
.  The buffer 
was prepared by dissolving PBS tablets in Millipore ultra pure water (Millipore 
Company, 0.22 µm Millipore filter).  The mobile phase was degassed using 
helium sparging (BOC) and filtered (0.2 µm pore size) (Nalgene Filtration 
Products, Nalge Nunc International, USA).  A 0.1% (w/w) sample of HPMC was 
injected into the HPLC.  The spectrum was monitored using a RI (refractive 
index) detector (Pharmacia LKB Biotechnology AB, Sweden). 
 
SEC analysis was repeated on the Waters HPLC using the ultrahydrogel 1000 
column (7.8 1D mm x 30 cm).  A ultrahydrogel guard column (6 x 40 mm) was 
used to protect the column.  20 µL of 0.1% (w/w) HPMC was injected using a 
syringe (Hamilton, USA) into the system.  0.05% (w/w) sodium azide (Sigma, 
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USA) (antibacterial agent) was used as the mobile phase at a flow rate of 0.9 mL 
min-1.   
 
To verify the detected peak was due to HPMC, the concentration of HPMC was 
halved to 0.05% and was injected into the HPLC system to determine if the 
detected peak would respond accordingly.  The analysis was repeated 6 times to 
ensure results were reproducible. 
 
To determine what effect a degraded sample of HPMC may have on the 
chromatogram, a sample of HPMC treated with 0.1 mol L
-1
 HCl (Scharlau, Spain) 
was also analysed.  Treatment with HCl would result in acid hydrolysis of HPMC 
and any changes in the resulting chromatogram were noted. 
 
Three samples of 10% (w/w) HPMC suspended in propylene glycol were 
prepared.  An aliquot from each sample was taken, diluted with water, and 
injected into the HPLC.  The prepared samples of HPMC dispersed in propylene 
glycol were then stored in a room maintained at 40°C / 75% relative humidity.  
Samples were then taken at time points of 3, 6 and 9 months to analyse the 
stability of HPMC.  Analysis was carried out in triplicate. 
 
To determine the molecular weight of HPMC, standards of dextran were run.  The 
following molecular weight standards were used: 4 400, 50 000, 70 000, 110 000,         
401 300 and 2 000 000. 
  
 
ii. Continuous Phase 
The stability of the continuous phase (the polycarbophil and the propylene glycol) 
could not be monitored by changes in molecular weight as polycarbophil has a 
very broad molecular weight range (Chen, 2000).  Consequently the stability of 
the polymer was monitored by changes in viscosity (Chen, 2000).  Viscosity 
readings were conducted using a SV 10 vibro-viscometer as outlined in Section 
3.2f.  The continuous phase was stored at room temperature (20°C) and the 
viscosity was measured over time at periods of 0, 3, 6 and 9 months.  
Measurements were conducted in triplicate. 
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3.3c Ease of Redispersion of the ISGM System 
Twelve sealed glass vials containing 6 g of the ISGM system were stored in a 
cupboard in the dark at room temperature.  3 vials were removed each week for 
four weeks to assess the redispersibility of the ISGM system over time where the 
average of the 3 vials was taken.  Redispersion was conducted by placing the vial 
in a rotary evaporator at 30 RPM.  Cotton wool was placed alongside the vial to 
prevent the vial from breaking and to ensure the vial rotated end to end.  The 
rotation was carried out for a total of five minutes and the extent of redispersion 
was observed (by measuring the height of the sediment which had not 
redispersed) every 30 seconds during the 5 minute period. 
 
 
3.3d Appearance of the ISGM System after Administration into an Aqueous 
Environment 
i. In Vitro Appearance of the ISGM System after Administration into an 
Aqueous Environment  
A cellulose medium was prepared by addition of 3% (w/w) HPMC to a solution 
comprising of 50:50 water:ethanol.  A cellulose medium was used as it formed a 
gel of suitable viscosity to allow injection of the formulation.  The solution was 
stirred at 2000 RPM for 20 minutes using an overhead stirrer (Heidolf, Model 
RZR1, Germany).  The ISGM system, with the inclusion of a blue dye, was 
injected (at a rate of 0.4 g s-1) into the cellulose medium.  A photograph of the 
gelled ISGM system was taken using a Canon MVX150i digital camera.  This 
experiment was conducted at room temperature (20°C). 
 
ii. In Situ Appearance of the ISGM after Administration into an Excised Calf 
Ear  
The ISGM system was injected into the ear of a dead calf (20°C) using a 22 gauge 
needle to observe whether the injected suspension would gel in the aqueous 
environment of the tissues.  The ear was used as the site of injection due to the 
ease of visualisation and excision.  The purpose of this study was to determine 
whether the ISGM system would function as anticipated i.e. to determine whether 
the injected suspension would gel as a result of water from the surrounding tissue 
diffusing into the depot. 
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iii. In Vivo Appearance of the ISGM System after Administration into a Rat  
The ISGM system was also injected into a rat.  Ethics approval was gained from 
the Ruakura Animal Ethics Committee.  The area posterior to the scapulae was 
shaved and swabbed with 70% ethyl alcohol.  0.5 mL of the ISGM system was 
injected using a 22 gauge needle.  The rat was killed by CO2 administration and 
then dissected to observe the appearance of the depot. 
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3.4 Formulation and Characterisation of the Final Product 
 
The final formulation (which was the ideal mix of components containing the 
drug) for the ISGM system was characterised by carrying out experiments such as 
DSC (differential scanning calorimetry) studies, IR analysis and UV-Vis analysis.  
DSC studies were conducted to assess whether any potential incompatibilities 
existed between the drug and the excipients of the formulation and the DSC 
findings were then examined further by IR analysis.  
 
3.4a Incorporation of the Drug into the ISGM System 
To manufacture the final product, the drug (propranolol HCl (Sigma, USA)) was 
incorporated into the continuous phase.  This was achieved by adding the required 
amount of drug to the continuous phase (manufactured using the Ultra Turrax® as 
described in Section 3.2d viii.) in a closed container and then mixing by shaking 
for 1 minute.  The drug was weighed by difference to ensure the amount of drug 
transferred was known.  Once the drug was incorporated, the hydrophilic polymer 
(10% w/w) was added and mixed by shaking for 2 minutes to ensure a 
homogeneously dispersed suspension.  The properties of the drug are given in 
Section 4.4a. 
 
 
3.4b Differential Scanning Calorimetry (DSC) Analysis 
DSC (using a DSC 6, Perkin-Elmer, USA) studies were carried out to determine 
whether any potential interactions occur between the excipient and drug and hence 
whether any potential incompatibilities existed.  The pure drug, the excipient 
alone and a 1:1 sample of excipient:drug were analysed.  A 1:1 ratio was selected 
to maximise the likelihood of any interactions (Mura et al., 1998).  The sample to 
be analysed was placed in an aluminium pan and spread out to ensure even 
coverage on the pan.  An aluminium lid was placed on top and crimped using the 
DSC crimper.  A crimped empty aluminium pan and lid was used as the reference.  
Handling of the pans was carried out using a pair of tweezers. The sample and 
reference were placed in the DSC instrument and a heating experiment conducted 
under the following conditions: 
Temperature range: 25 – 250 °C 
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Heating Rate:  10 °C min-1 
 
 
3.4c Infra-Red (IR) Analysis 
All FTIR spectra were acquired at 4 cm-1 resolution using a Digilab FTS-40 
(Digilab FTS-40 Fourier Transform IR spectrometer, Massachusetts, USA) 
Fourier Transform infrared spectrometer which employed KBr optics and Win-IR 
version 4.14 Software (Galactic Industries Corporation, Massachusetts, USA).  
The KBr disc method was utilised to prepare solid samples for analysis.  The 
drug, propranolol was added to dried KBr in a mortar and pestle in the 
approximate ratio of 1:5 and mixed to obtain a homogeneous mixture.  The 
mixture was ground for 2 minutes.  A sufficient amount (1-2 milligrams) of the 
mixture was placed in a holder between two metal discs and transferred to a 
hydraulic press to give a hard clear white disc.  The resulting disc was then placed 
carefully (to avoid cracking or breaking of the disc) in a holder which was then 
positioned in the sample compartment of the infrared spectrometer.  Absorbance 
spectra were acquired by ratioing sample single beam spectra against a spectrum 
of air (i.e. an empty sample compartment).  Absorbance FTIR spectra were then 
baseline corrected to achieve a flat baseline.  The following settings were used for 
all spectra: 
 4 cm-1 resolution 
 400 – 4000 cm-1 wavelength range 
 Speed setting of 5 kHz for the DTGS (deuterated triglycine sulphate) detector 
 Open aperture 
 
 
3.4d   Electrospray Mass Spectrometry (ESMS) Analysis  
All ESMS analyses were conducted on an LCMS LCQ Advantage (Thermal 
Finnigan, USA) using the mass spectrometry function only.  ESMS was used as a 
means of characterising the drug as well as determining whether drug was present 
in stability studies (Section 3.6).  The spectra were collected under the following 
conditions:  
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 Vapour temperature 450ºC  
 Sheath gas flow 80 mL min-1  
 Discharge current 5 µA  
 Discharge potential of 4.38 kV.   
 
An electrospray ionisation mode was used to collect the spectra.  Mass spectra 
were acquired in the positive ion mode (Upthagrove et al., 1999).  Each spectrum 
was the average of 20 scans. 
 
 
3.4e Ultra-Violet (UV) Analysis 
All UV analyses were conducted on a Cary 1 UV spectrophotometer (Cary, USA).  
Samples of propylene glycol, polycarbophil, HPMC and propranolol were 
analysed using quartz 10 mm cells (Starna Ltd., England).  Samples were scanned 
over the wavelength range of 200 – 400 nm at a speed of 600 nm min-1. 
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3.5 Drug Release Studies on the Final Product 
 
Once the formulation was characterised (Section 3.3 and 3.4), in vitro studies 
were conducted.  The in vitro drug release studies were carried out to assess the 
feasibility of the formulation.  The in vitro studies involved addition of a drug to 
the ISGM system and measuring its release over time.  The effects of various 
factors such as the concentration of the hydrophilic gelling agent on the release 
rate of the drug were assessed.  The release data was then modelled using the 
Higuchi equation and the power law relationships to compare the effects of 
parameters such as the concentration of the gelling agent on the drug release rate. 
 
 
3.5a Drug Release Studies Conducted on the Hanson Dissolution Apparatus 
Drug release studies were conducted on the final formulation (Section 4.2h) which 
consisted of a hydrophilic gelling agent HPMC and the chosen model drug 
propranolol in the continuous phase (comprising of the non-aqueous solvent 
propylene glycol and the viscosity inducing agent polycarbophil).  2 g of the 
formulation was drawn out with a 10 mL syringe and injected into the dissolution 
test medium.  The formulation was injected at rate of 0.4 g s-1 each time as 
differing rates produced depots of differing surface area. 
 
Dissolution studies were performed on a calibrated dissolution apparatus (Hanson 
Dissolution Apparatus, SR8Plus, USA).  The dissolution test medium (water) was 
maintained at 37.0 ± 0.5°C.  To each of the six vessels in the dissolution 
apparatus, 500 mL of dissolution test medium was added.  The paddle blade was 
incorporated as the stirrer for each of the six vessels.  A paddle was placed 25 mm 
from the bottom of each vessel as described in the protocol in the United States 
Pharmacopoeia (USP, 1994) method and set to a speed of 50 RPM.  Upon 
injection into the vessel, the HPMC gelled giving a very viscous dissolution test 
medium posing problems of drawing adequate volumes using the narrow bore 
auto sampler.  As a result samples were taken manually with a 2.5 mL pipette.  
The samples were collected and analysed by UV (Unicam, Helios Gamma, 
England) absorbance at 290 nm to determine the drug level.   
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i. Mode of Formulation Introduction to the Hanson Dissolution Apparatus 
Initial release assessment studies were conducted using the USP Apparatus 2 
(Paddle).  The formulation was introduced into the vessel in one of two ways.  
The first method involved injecting the formulation from above the vessel in order 
to observe the effect of a dispersed injection.  The second method involved 
injecting the formulation at the bottom of the vessel (after the addition of the 
dissolution test medium) thus forming an intact “bulb” (the second method of 
introducing the formulation was executed in a style that was anticipated to be the 
case in vivo).  The run was conducted using 6 vessels.   
 
ii. Effect of the Hydrophilic Gelling Agent 
The effect of omitting the hydrophilic gelling agent HPMC from the formulation 
was also investigated.  The trivial observation expected from this was obviously 
instant release of propranolol given there was no polymer to entrap the drug and 
retard its release rate.  All formulations were introduced to the dissolution test 
medium by injection via a syringe onto the bottom of each of the 6 vessels. 
 
iii. Basket Method (USP Apparatus I) 
This experiment involved using a rotating basket instead of a paddle.  The 
formulation was injected into the basket while it was held stationary in the 
dissolution test medium.  After injection, the basket was rotated at 50 RPM for 
each of the 6 vessels. 
 
iv. Reproducibility of Release Trials Conducted on the Hanson Dissolution 
Apparatus 
The experiment was run in 6 vessels simultaneously and on 3 different days to 
assess the intra and inter-day reproducibility of the method. 
 
 
3.5b  In Vitro Drug Release Studies Conducted on the Modified Dissolution 
Apparatus 
A different means of carrying out drug release was required where the injected 
formulation (i.e the final product) was not exposed to the stirrer and the surface 
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area of the depot remained fixed.  A novel system was developed to overcome 
these issues.  A coagulating flocculating simulator (Boltac Ltd., New Zealand), 
capable of holding 6 vessels, was utilised as a mixing station.  Each vessel 
(Perspex) was modified to allow space for a lid (Perspex) and a glass tube to be 
placed on top (Figure 3.7a).  The use of the glass tube ensured the surface area of 
the depot exposed to the dissolution test medium remained fixed (as the injected 
formulation covered the whole area) and that it was no longer subjected to the 
stirrer.    The glass tube was covered with a dialysis membrane (membra-cel, MW 
cut-off 14 000) held in place with an o-ring (see Figure 3.7b).  The dialysis 
membrane was wide enough to cover the whole glass tube and the molecular 
weight cut-off value ensured the gelling agent could not diffuse through into the 
dissolution test medium.  The dialysis membrane was hydrated prior to use and 
wrapped over the tube carefully to prevent breakage of the membrane and to 
ensure creases or folds did not form which would alter the surface area. 
 
 
 
 
Figure 3.7a – Illustration of the Vessel in the Modified Dissolution 
Apparatus used to Conduct Drug Release Studies 
Stirrer 
Sampling  
Port 
Glass tube 
Formulation injected 
here 
Release assessment 
media 
 
 
 
 
 
 
 
 
 
 
Figure 3.7b – The Glass Tube Held in the Vessel of the 
Modified Dissolution Apparatus  
o-ring 
Glass tube 
Dialysis 
membrane
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A drug concentration of 0.8% (w/w) was used in the ISGM system.  The UV 
spectrum of propranolol had absorption maxima at 214 and 290 nm (Section 
4.4e).  Many researchers have reported using 290 nm for monitoring the drug to 
ensure minimal interference from any other UV absorbing material that may be 
present (Guyot and Fawaz, 2000; Namdeo and Jain, 2002; Taylan et al., 1996; 
Huang et al., 2004).  However with this study a dialysis membrane was used 
which prevented the polymers from diffusing into the dissolution test medium 
(this was verified as described in Section 4.5).  The molecular weight cut-off for 
the dialysis membrane is 14 000, therefore only the drug and propylene glycol 
will be able to diffuse out.  Propylene glycol and HPMC have no UV absorption 
peaks in the region of interest however polycarbophil does (Section 4.4e) but 
because it is retained within the glass tube, the 214 nm wavelength was able to be 
used to monitor the drug concentration without interference.  This was verified by 
monitoring the absorbance values at 214 nm of the dissolution test medium using 
a formulation without drug to ensure absorbance did not change with time (so 
indicating the polymer was not diffusing through the dialysis membrane and into 
the solution contributing to the absorbance).  Even though the analytical 
wavelength of 214 nm is in a region where selectivity and specificity may be 
comprised, the UV absorbance did not register any change over time and therefore 
drug levels were able to be monitored at 214 nm with confidence.  The advantage 
of utilising 214 nm was that the molar absorptivity coefficient of this UV 
absorption peak for propranolol was higher than for the other propranolol-
associated absorbance at 290 nm. This hence allowed lower concentrations of 
drug to be detected in the dissolution test medium. 
 
The majority of experiments were conducted using a stirring rate of 100 RPM 
using 500 mL of water (the dissolution test medium) with the glass tube placed at 
a fixed position of 1 cm from the lid of the vessel.  A stirring rate of 100 RPM 
was chosen as it was the ideal speed to ensure the drug concentration at the release 
interface was zero at a faster rate.  Speeds greater than 100 RPM resulted in an 
agitated dissolution test medium.  The 1 cm position ensured the o-ring was 
located above the water preventing water from leaking into the glass tube. 
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Unless otherwise stated the final formulation was analysed in the in vitro trials i.e. 
a uniformly dispersed suspension (assessed by sight) of 10% (w/w) HPMC 
(hydrophilic gelling agent) and 0.8% (w/w) propranolol (the model drug) in the 
continuous phase comprising of propylene glycol (the non-aqueous solvent) and 
0.67% (w/w) polycarbophil (viscosity inducing agent).   
 
The following trials detailed in 3.5b i to 3.5b x were conducted to determine 
whether these parameters had an effect on the drug release behaviour. 
 
i. Reproducibility of Release Trials Conducted on the Modified Dissolution 
Apparatus 
Initial trials involved determining whether the method was reproducible.  The 
experiment was run using 6 vessels and repeated on 3 different days to ascertain 
the intra- and inter-day reproducibility.  Reproducibility studies were undertaken 
to ensure results were reproducible so that any differences which may occur will 
not be due to inter- or intra-run variations. 
 
2 g of the formulation was drawn into a syringe and then injected into the glass 
tube (closed off at the end by the dialysis membrane).  After injection, stirring was 
commenced at 100 RPM. 
 
ii. Effect of the Hydrophilic Gelling Agent 
A run was conducted where the formulation did not contain the hydrophilic 
gelling agent.  This was to determine whether the absence of the gelling agent in 
the formulation would result in an altered release profile.  The absence of the 
gelling agent should obviously give full release at a faster rate than with the 
gelling agent.  The formulation was injected into each of the 6 glass tubes.  The 
stirrer was maintained at 100 RPM. 
 
iii. Effect of Volume of Water in Tube 
Water was added to the glass tube prior to addition of the formulation.  Upon 
injecting the formulation into the glass tube, the formulation gelled.  The 
experiment was conducted to determine whether premature gelling of the 
formulation prior to release had an effect on the drug release rate.  0, 0.5 and 2.5 
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mL of water was added via syringe for each run.  Each run consisted of 6 samples.  
The stirrer was maintained at 100 RPM. 
 
iv. Effect of Tube Height 
The height at which the glass tube was placed in the vessel of the modified 
dissolution apparatus was altered from 1.0 cm (measured from the lid of the 
vessel) to 0.7 cm to determine whether the distance between the stirrer and the 
diffusion site (end of the glass tube) had an effect on the drug release rate.  6 
samples were analysed and the stirrer was maintained at a speed of 100 RPM. 
 
v. Stirring Rate 
The effect of the stirring rate on the release profile was investigated.  The stirring 
rate was altered from 100 RPM to 50 and 150 RPM.  Each trial involved 6 
samples. 
 
vi. Effect of pH of Dissolution Test Medium 
The effect of altering the pH of the dissolution test medium was investigated as 
the pH of the system can affect the extent of drug release (as discussed in Section 
4.5b vi.).  A dissolution test medium at pH 1 was prepared by simply using 0.1 
mol L
-1
 hydrochloric acid in place of the water.  Dissolution test medium adjusted 
to  pH 4.5 were prepared by the use of a solution which was 0.05 mol L
-1
 in 
sodium dihydrogen phosphate (May & Baker, Australia) to which 0.1 mol L
-1
 
sodium hydroxide was added dropwise to bring the solution to pH 4.5. 
 
Each trial comprised 6 samples.  The stirrer was maintained at 100 RPM. 
 
vii. HPMC (Gelling Agent) Concentration 
The HPMC concentration in the formulation was altered from 10% (w/w) to 5 and 
25% (w/w) to assess the effect on the release rate of the drug.  Each run consisted 
of 6 samples and the stirrer was maintained at a speed of 100 RPM. 
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viii. Polycarbophil (Viscosity Inducing Agent) Concentration 
The concentration of polycarbophil in the formulation was altered from 0.67% 
(w/w) to 0.5 and 1% (w/w).  Each run consisted of 6 samples and the stirrer was 
maintained at 100 RPM. 
 
ix. HPMC Viscosity Grade 
A different viscosity grade of HPMC (HPMC 90SH (Shin-Etsu Chemical Co. Ltd, 
Japan) instead of HPMC 60SH was used in the formulation to determine if there 
was any influence on drug release.  6 samples were analysed and the system was 
stirred at 100 RPM. 
 
x. Different Gelling Agents 
The effect of using a gelling agent other than HPMC in the formulation was also 
studied out of scientific interest (as discussed in Section 4.5b x).  Three additional 
gelling agents from the initial screening process (Section 3.2), PEO 303, sodium 
CMC and xanthan gum were selected.  The formulation was prepared using 10% 
(w/w) of the gelling agent.  Each run consisted of 6 samples and the stirrer was 
maintained at 100 RPM. 
 
 
3.5c  Modelling of the Drug Release Data 
Modelling of the drug release data obtained from the experiments described in 
Section 3.5b was attempted using the Higuchi and the power law relationships as 
discussed in Section 4.5c.  Modelling was used as a means of comparing the effect 
of various parameters on the release rate.  Microsoft Excel software (Microsoft 
Corporation, 2002) was used to conduct the modelling studies.   
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3.6 Stability Assessment of the Final Product 
 
The stability of the final formulation was assessed visually and by using an 
HPLC-based protocol.  The purpose of the stability trial, carried out under 
accelerated conditions, was to determine how the quantity of the drug changed 
over time (refer to Section 4.6 for a discussion on the need for stability studies).   
 
3.6a Drug Stability 
i. Method Development 
The stability of the drug was monitored using a Nova-Pak C18 column (8 x 100 
mm) (Waters, USA) for reasons as discussed in Section 4.6a i.  The column was 
held in a RCM (radial compression module) 8 x 10 module (Waters, USA).  The 
module was used to apply and maintain radial compression along the 
circumference of the flexible Radial-Pak® cartridge.  The pressure moulded the 
cartridge wall around the column packing decreasing the interstitial spaces within 
the column bed.  Consequently the more homogeneous packed bed structure 
resulted in increased cartridge efficiency and eliminated the formation of voids.  
Methanol was injected into the column holder to maintain the pressure at 17 MPa.  
The mobile phase (USP, 1994) was prepared by dissolving 1 g of sodium dodecyl 
sulphate in 36 mL of 0.15 mol L
-1
 phosphoric acid (Merck, Germany) in a glass 
vessel.  To this glass vessel,   180 mL of HPLC grade methanol (Scharlau, Spain) 
and HPLC grade acetonitrile (Burdick and Jackson, USA) in addition to 104 mL 
of water were added to produce a final volume of 500 mL.  The mobile phase was 
filtered (0.2 µm) (Nalgene Filtration Products, Nalge Nunc International, USA).  
The flow rate of the mobile phase was maintained at 1 mL min-1.  A guard column 
was used to protect the column (Nova-Pak, 4 μm, 60 Å, C18 Guard-Pak Insert).  
20 µL of the sample was injected into the HPLC using a Hamilton syringe 
(Hamilton, USA).  The Waters 996 PDA (Photo Diode Array) detector (Waters, 
USA) was able to scan wavelengths from 200 - 410 nm.  The PDA detector was 
used as propranolol has a UV chromophore thus allowing UV to be used as a 
mode of detection.   
 
A diode array detector is made up of many photosensitive diodes adjacently 
placed and insulated from each other in the form of a multilayer sandwich.  The 
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output from each diode is scanned, stored and processed by the computer.  The 
diode array detector monitors the light which has passed through a liquid sensor 
cell.  The light source such as a deuterium or xenon lamp is focussed by an 
achromatic lens through the sample cell and the light is dispersed by a holographic 
grating onto the surface of the diode array.  Each diode will receive light of a 
slightly different wavelength (Beesley et al., 2001). 
 
The output from any diode can be selected to give a chromatogram using the 
wavelength which fell on that particular diode.  The advantage of using this 
detector is that analysis can be carried out simultaneously on a range of 
wavelengths. 
  
The process of method development involved assessment of parameters such as 
the linearity of measured peak areas, the influence of forced drug degradation on 
specificity and robustness in the solvent composition used in the protocol. 
 
Linearity and Calibration 
The linearity of the method assesses the ability within a concentration range to 
obtain results which are proportional to the peak area (International Conference on 
Harmonisation, 2005; Center for Drug Evaluation and Research, 2000).  Pure drug 
standards were prepared by dissolving propranolol in methanol to give 
concentrations of 0.25, 1, 5, 10, 15 and 20 mg mL-1.  20 µL of each standard was 
injected into the HPLC.  The peak area measured for the propranolol drug samples 
were plotted against the concentration of propranolol in the standards to obtain a 
calibration curve.  The data was analysed to determine whether a linear 
relationship existed between the peak area and concentration over the expected 
range of concentrations that would arise in analyses of actual samples.    
 
Forced Drug Degradation Study 
This study was conducted to investigate the specificity of the HPLC method, i.e. 
its ability of detecting the analyte in the presence of other components such as 
degradants from the propranolol (Rao et al., 2005). 
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Forced degradation of propranolol was carried out by subjecting a 10`mg mL-1 
starting concentration of propranolol to the following extreme conditions for 24 
hours (except for the heat degradation experiment which was carried out for only 
1 hour): 
 
 For the alkali-induced degradation, addition of 1 mol L-1 NaOH to the 10 
mg mL-1 propranolol solution in a glass vial to give effectively a 
concentration of 5 mg mL-1 (propranolol).  
 
 For the acid-induced degradation, addition of 1 mol L-1 HCl was added to 
10 mg mL-1 propranolol solution in a glass vial to give a concentration of 5 
mg mL-1 (propranolol). 
 
 For oxidatively induced degradation, addition of 3% H2O2 was added to 10 
mg mL-1 propranolol solution in a glass vial to give a concentration of 5 
mg mL-1 (propranolol).  
 
 For thermally induced degradation, 0.2 g of propranolol was heated in a 
contherm stability oven for one hour at 105 °C. 
 
 For photoinduced degradation, a 5 mg mL-1 solution of propranolol in 
water was placed in front of a UV light source at 254 nm for 24 hours 
(Uwai et al., 2005).  The broad distribution range of wavelengths on either 
side of the wavelength source centred at 254 nm most likely would have 
intensities included at 214 and 290 nm (the absorption maxima for 
propranolol).  A 5 mg mL-1 solution of propranolol in water subjected to 
open light for 3 months was also analysed. 
 
Robustness 
The robustness of the method towards solvent composition variables in the HPLC 
protocol was determined by changing the following components in the mobile 
phase used: 
 
 Acetonitrile concentration from 36% to 66% 
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 Methanol concentration from 36% to 66% 
 Phosphoric acid concentration from 0.15 mol L-1 to 0.30 mol L-1 
  
ii. The Final Method 
The final procedure decided upon for conducting a drug stability study (as a result 
of conducting the method development study) is given in Table 3.10. 
 
Table 3.10 – HPLC Method for the Analysis of Propranolol 
Parameter Description 
Column Nova-Pak C18 column (8 x 100 mm) 
Guard 
Column Nova-Pak, 4 μm, 60 Å, C18 Guard-Pak Insert 
Mobile 
Phase 
The mobile phase (USP, 1994) was prepared by dissolving 1 g 
of sodium dodecyl sulphate in 36 mL of 0.15 mol L
-1
 
phosphoric acid (Merck, Germany) in a glass vessel.  To this 
glass vessel,   180 mL of HPLC grade methanol (Scharlau, 
Spain) and HPLC grade acetonitrile (Burdick and Jackson, 
USA) as well as 104 mL of water were added to give a final 
volume of 500 mL. 
Flow Rate 1 mL min-1
Temperature The temperature was not varied during the method development as the column was not heated.   
Injection 
Volume 20 µL 
Detector PDA 200 – 410 nm 
 
 
iii. Method Validation 
Method validation was conducted by assessing the linearity, accuracy, precision, 
limit of quantitation, limit of detection, robustness and specificity.  The object of 
method validation was to demonstrate that the method was suitable for its 
intended purpose (International Conference on Harmonisation, 2005; Center for 
Drug Evaluation and Research, 2000).  
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Linearity 
Pure drug standards were prepared by dissolving propranolol in methanol to give 
concentrations of 0.25, 1, 5, 10, 15 and 20 mg mL-1.  20 µL of each standard was 
injected into the HPLC.  The data was analysed to determine whether a linear 
relationship existed between the peak area and concentration over the expected 
range of concentrations in the analysis.   
 
Accuracy 
The accuracy of the method shows the closeness of agreement between the 
reference value and the experimentally determined value on the instrumentation 
used following the decided protocol (International Conference on Harmonisation, 
2005; Center for Drug Evaluation and Research, 2000).  To assess the accuracy of 
the method,  3 samples of  2 mg mL-1, 3 samples of 9 mg mL-1 and 3 samples of 
17 mg mL-1 propranolol dissolved in methanol were passed through the column to 
determine whether the concentrations from the calibration curve matched the 
actual concentration of the prepared samples. 
 
Precision 
Precision can be determined on 3 levels – repeatability, intermediate precision and 
reproducibility.  Repeatability assesses the precision of the method over a short 
period of time under the same operating conditions.  It can also be referred to as 
intra-assay precision.  Intermediate precision expresses the precision under 
conditions such as different days of analysis or different equipment.  These are 
conducted in the same laboratory.  Reproducibility is the measure of precision in 
different laboratories (International Conference on Harmonisation, 2005; Center 
for Drug Evaluation and Research, 2000).   
 
In this study the repeatability and intermediate precision were assessed.  In terms 
of repeatability, the %RSD (relative standard deviation) was calculated using 6 
individual samples of pure drug with a concentration of 0.5 mg mL-1 and 6 
individual samples of pure drug with a concentration of 5 mg mL-1.  
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The intermediate precision was assessed by preparing calibration curves for 
concentrations of propranolol of 0.25, 1, 5, 10, 15 and 20 mg mL-1 (dissolved in 
methanol) on 3 different days. 
 
Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
LOD is the lowest concentration which can be detected and LOQ is the lowest 
concentration which can be quantitatively determined (International Conference 
on Harmonisation, 2005).  The LOD and LOQ were calculated in Section 4.6 
(Chapter 4).  To verify the theoretically derived value calculated from these 
equations, a 0.040 and 0.060 mg mL-1 sample of propranolol dissolved in 
methanol was passed through the column to determine if these concentrations 
could be detected. 
 
iv. Extraction of the Drug from the Formulation 
Initially extraction of the drug from the formulation was assessed using the size 
exclusion KS-803 sugar column (300 x 8 mm) (Phenomenex, USA).  The 
formulation was diluted with water in the ratio 1:5 (formulation:water).  This 
dilution was sufficient to ensure the formulation was no longer viscous as a result 
of addition of water.  20 μL of sample was injected into the HPLC (Waters, USA) 
via a Hamilton (Hamilton, USA) syringe using a mobile phase of water at a flow 
rate of 1 mL min-1.  The column was heated to a temperature of 30°C.  The 
Waters 2410 RI (refractive index) detector (Waters, USA) and  Waters 996 PDA 
detector were both used to detect the drug.   
 
Intra-sample variation (for 4 samples) and variation in retention time for differing 
concentrations of propranolol (0.5, 1, 5, 10, 15 and 20 mg mL-1) were also 
assessed using the above described procedure with the KS-803 column. 
 
Due to the issues involving the use of the KS-803 column (see Section 4.6a iv in 
Chapter 4 for a discussion of these) drug extraction from the formulation was 
attempted using the Nova-Pak C18 column (8 x 100 mm).   
 
Extraction of the drug from the final product was conducted by diluting the final 
product in a ratio of 4:1 (methanol:final product).  However, diluting the final 
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product with methanol resulted in the HPMC precipitating out.  Consequently the 
vessel containing the methanol diluted final product was centrifuged (Heraeus, 
Sepatech, Germany) at 4000 RPM for 5 minutes to collect the HPMC.  20 µL of 
the supernatant was then injected into the HPLC. 
 
The efficiency of the drug extraction process from the final product was 
determined by addition of methanol to a formulation with a known concentration 
of drug (5 mg mL-1).  20 μL of the supernatant (containing the dissolved drug) 
was passed through the HPLC.  The peak area obtained was used to determine the 
concentration of propranolol in the supernatant using the calibration curve.  The 
concentration interpolated from the calibration curve was compared to the known 
concentration to ascertain the efficiency of the extraction process.  This analysis 
was conducted in triplicate.  The experiment was also repeated for a formulation 
containing only 1 mg mL-1 propranolol. 
 
v. Accelerated Stability Study of the Drug in the ISGM System 
Samples of the final product were stored in conditions of 40°C / 75% relative 
humidity for a period of 4 weeks.  The temperature of the heated room was 
maintained by a thermostat.  The temperature and humidity was monitored using a 
digital thermometer (Tecpel, Taiwan).  Each week a sample was removed, 
methanol was added to the sample (as described in Section 3.6a iv) and then 20 
μL of the supernatant was introduced to the HPLC to measure the peak areas.  The 
concentration of drug remaining in the solution prepared after this treatment was 
determined by interpolation from the calibration curve. 
 
This experiment was conducted in triplicate on each occasion.   
 
 
3.6b Appearance of the Final Product 
The appearance of the formulation subjected to accelerated conditions (40°C / 
75% relative humidity) was assessed over a period of 4 weeks.  The experiment 
was conducted in triplicate.  Each week the appearance of the formulation was 
visually assessed and the observations recorded.  The presence/absence of the 
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following features that may have appeared in the final product were assessed by 
careful observation: 
 
 Air bubbles 
 Colour 
 Caking 
 Particulate Matter 
 
The air bubbles and colour of the final product were assessed visually.  Each vial 
containing the formulation under observation was also set up such that a paper 
ruler was attached on the side (as described in the screening methodology (Section 
3.2a)).  If any caking events were to occur in the final product, the height of the 
“caked material” could then be measured using the paper ruler.  The observation 
of particulate matter may be not be feasible due to the difficulty of differentiating 
the suspended gelling agent from any particulate matter which may form. 
 
 
 
CHAPTER FOUR 
Results and Discussion 
 
The overarching goal of this research was to convert the conceptual technology 
described in Bunt et al.’s (2003) patent into a viable formulation.  In order to 
achieve this a systematic and thorough investigation had to be carried out to 
identify the key components which led to a workable system and a system of 
potential commercial value.  Chapter 3 has described the experimental details of 
this investigation which involved a cursory biocompatibility study for identifying 
possible formulation components (i.e., hydrophilic polymer and non-aqueous 
solvents) that caused the least or no irritation to tissues and also a 
screening/sedimentation study for determining how to formulate the ISGM system 
into a chemically and physically stable product.  Chapter 3 then described how the 
chosen drug, propranolol, was incorporated into the formulated ISGM system to 
give the “final formulation” consisting of drug plus ISGM system and then how 
the “final formulation” was characterised and assessed in terms of its performance 
as a drug delivery vehicle by conducting in vitro drug release experiments using 
propranolol. 
 
 
4.1 Structure, Properties and Biocompatibility of the 
Hydrophilic Polymers and Non-Aqueous Solvents Used in the 
Study 
 
4.1a Structure and Properties  
The structure and properties of the hydrophilic polymers and non-aqueous 
solvents used in this study are summarised in Tables 4.1 and 4.2. 
 
 
 
 
 80
Table 4.1 - Hydrophilic Polymer Properties 
Properties 
Polymer Structure State 
(20ºC) 
Bulk Density   
(g mL-1)  
(20ºC) 
Colour 
HPMC 
 
 
 
                                 (Wang et al., 2003) 
Powder 0.313 White 
Xanthan Gum 
 
 
 
 
 
 
 
 
 
 
 
 
(Rosalam and England; 2006) 
Powder 0.620 Brown 
PEO 303, 
N12 and N10 
 
 
 
 
 
(Berg et al., 2006) 
Powder 0.469 (303) 
0.451 (N10) 
0.496 (N12) 
White 
Polycarbophil 
 
 
 
 
 
 
 
(Noveon, 2005) 
Powder 0.174 White 
Sodium 
Alginate 
 
 
 
 
 
(Peng et al., 2006) 
Powder 0.382 Orange-
Brown 
n
CH 2
 
 
 
 
 
 
CH 2HO O H
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Properties 
Polymer Structure State 
(20ºC) 
Bulk 
Density    
(g mL-1)  
(20ºC) 
Colour 
Sodium 
CMC 
 
 
 
 
 
 
 
 
 
(Guo et al., 1998) 
Powder 0.430 White 
n
PVP 
 
 
 
 
 
 
 
Powder 0.241 White 
(Nierle, 2006) 
PVA 
 
 
 
 
(Porter, 1998) 
Powder 0.484 White 
 
 
 
Table 4.2 – Non-Aqueous Solvent Properties 
Properties Non-
Aqueous 
Solvent 
Name 
Structure Density 
(25ºC) 
Molec. 
Wt. 
State 
(20ºC) 
Colour Boiling Point 
Pharmaceutical 
Uses 
Propylene 
Glycol 
 
 
 
 
(Sengwa, 2003) 
1.04 
76.09 Liquid Colourless 188°C    
Used as a 
humectant 
Solvent in many 
oral, injectable 
and topical 
formulations 
(Smolinske et al., 
1987) 
 
PEG 400 
 
 
 
(Nandi et al., 2003) 
1.12 
400 Liquid Colourless 250°C 
Ointment Bases 
Suppository Bases 
Capsules           
Tablet Binders 
(Hermansky et al., 
1995) 
n 
O CH2 CH2HO H 
CH CH 2
N O
n 
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Properties Non-
Aqueous 
Solvent 
Name 
Structure Density 
(25ºC) 
Molec.
Wt. 
State 
(20ºC) 
Colour Boiling Point 
Pharmaceutical Uses 
Ethanol 
 
 
 
(Pilling et al., 2007) 
0.789 46.1 Liquid Colourless 79°C 
Manufacturing of 
pharmaceutical 
products 
Mouthwash          
Cough and cold 
medicines             
NMP 
 
 
 
 
(Carnerup et al., 2005) 
1.026 99.1 Liquid Colourless 202°C 
Solvent in 
pharmaceutical 
preparations (Koizumi 
et al., 2004) 
 
Excipient and 
formulation aid     1.258 92.1 Liquid Colourless 290°C Glycerin 
(Pouilloux et al., 1999) 
 
 
According to the patent awarded to Bunt et al. (2003), any or all of these materials 
could be used to produce the ISGM system.  However, formulation of the ISGM 
system requires consideration of the biocompatibility of the ingredients with the 
tissues with which they will come into contact since the introduction of a 
xenobiotic to a body may elicit an immunological response.  Consequently, the 
materials and their degradation products (if any) used in attempts to formulate a 
stable product needed to be proven safe (Fournier et al., 2003).  Therefore 
biocompatibility studies were conducted to determine the nature and extent of the 
immunological response to the materials listed in Tables 4.1 and 4.2.   
 
 
4.1b Biocompatibility 
Biocompatibility has been described as “the ability of a material to perform with 
an appropriate host response in a specific application” (Williams, 1987).  There 
are many types of biocompatibility tests that can be conducted to determine the 
nature and extent of any immunological response such as the Draize eye test 
(Lambert et al., 1993; Balls et al., 1995; Cormier et al., 1996), the low volume 
eye test (Cormier et al., 1996; Lambert et al., 1993; Calvin, 1992; Bruner et al., 
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1992) and the HET-CAM test (Luepke and Kemper, 1986; Dannhardt et al., 1996; 
Balls et al., 1995; Dahl, 1999; Schlage et al., 1999).   
 
The HET-CAM test (hen’s egg test – chorioallantoic membrane) is often used as a 
quasi-in vitro test to assess the irritation potential of the substance to be tested.  
The CAM or chorioallantoic membrane is a highly vascularised membrane which 
surrounds the developing chick embryo.  The HET-CAM test is described as a 
cross between in vitro and in vivo testing (Luepke and Kemper, 1986) and has the 
advantage that the CAM has the ability to simulate the pharmacokinetic profile of 
the substance tested which is not the case with in vitro assay techniques 
(Dannhardt et al., 1996).  The HET-CAM test is seen as a more humane 
alternative to the Draize eye test for assessment of irritation, where the effects on 
the blood vessels of the CAM are comparable to the irritation caused in the eye by 
the same test substance (Balls et al., 1995).  It has even been suggested that the 
HET-CAM test is more sensitive than the Draize eye test as the CAM (HET-CAM 
test) is thinner than the mucous membrane of the eye (Draize eye test).  In 
addition, the HET-CAM is less expensive as well as the advantage of its complete 
lack of involvement of the use of live laboratory animals (Dahl, 1999). 
 
After application of the test substance to the CAM, the specifically categorised 
irritant reactions such as haemorrhage, coagulation and lysis must be observed for.  
Haemorrhage refers to bleeding of the CAM vessels and this can either be 
punctuate (i.e. manifesting multiple bleeding points) or diffuse (i.e. bleeding 
generally over the entire CAM).  A lysis event refers to damage in endothelial 
vessel structure leading to disappearance or “whitening” (due to blood loss) of 
these vessels in the CAM.  A coagulation event indicates blood clotting which can 
be either intra-vascular or extra-vascular. In the case of intra-vascular coagulation, 
the blood flow in the vessels will decrease and eventually stop as a result of 
thrombosis, resulting in “tree” branches and increased vessel diameter. For extra-
vascular coagulation, in contrast, precipitation of CAM proteins is the cause as it 
leads to increased opacity with the membrane becoming completely white so that 
the CAM takes on a mesh-like porous appearance.  A hyperaemia event is 
characterised by the swelling of small blood vessels resulting in an increased 
blood flow.  
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The biocompatibility studies performed in this research were conducted on each 
of the possible formulation candidates listed in Tables 3.1 and 3.2 using the HET-
CAM test.  The following presents the results of this study together with a 
discussion. 
 
The ideal approach for direct comparison of all materials tested is obviously to 
conduct all HET-CAM experiments at the same time.  In this study, however, the 
volume of the incubation oven limited the realisation of this ideal as the attempted 
incubation of as many as  60 eggs in this small oven cavity resulted in a low 25% 
success rate of embryo development  due to overcrowding-induced contamination.  
This thus necessitated the execution of multiple experiments or ‘tests’ to assess 
each of the polymers and solvents used in the studies.  Each experimental run 
hence involved incubating only 20 eggs at a time.  Because these experiments had 
to be carried out on numerous occasions, it was necessary to employ positive and 
negative controls (refer to Section 3.1b for details of the controls) in each 
experimental run.  The use of 20 eggs in each experimental run resulted in a 
success rate of embryo development of approximately 70%.  The chance of cross 
contamination was successfully minimised by using an approach of spraying and 
washing all holders and sleeves with 70% isopropyl alcohol between runs. 
 
Figures 4.1a - 4.1d illustrate the observations given by the HET-CAM test in the 
case of application of the non-aqueous solvent NMP.  When applied to the CAM 
over a period of 5 minutes, the blood vessels in the CAM go initially from the 
time zero appearance of being discrete and intact (Figure 4.1a) to the appearance 
shown in Fig. 4.1b where haemorrhaging and hyperaemia occurs after only a 30 
second contact time.  Exposure to the NMP for longer times is observed to cause 
coagulation of the blood (Figure 4.1c) which progressively gets worse with 
continued exposure (Figure 4.1d). 
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Figure 4.1a – CAM Appearance at Time Zero 
Before Addition of NMP
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1b – CAM Appearance at 30 Seconds 
After Addition of NMP  
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Figure 4.1c – CAM Appearance at 2 Minutes 
After Addition of NMP
Figure 4.1d – CAM Appearance at 5 Minutes after 
Addition of NMP
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These reactions were observed to occur to differing degrees with the different 
materials tested in this HET-CAM study.  The irritancy and severity of reaction 
potential for each material assessed is shown in Table 4.3 (see Section 3.1b in 
Chapter 3 for criteria on how scores were assigned). 
 
Table 4.3 - Irritancy Potential of Each Test Material in the HET-CAM Tests for Non-Aqueous 
Solvents and Polymers Under Consideration 
Test Material Average Score Irritancy Potential 
NMP 18.5 Strong 
Ethanol 12 Strong 
PEG 400 5 Moderate 
Glycerin 5 Moderate 
Non-Aqueous 
Solvent 
Propylene glycol 3.5 Slight 
PEO 303 0 Practically None 
PEO N10 0 Practically None 
PEO N12 0 Practically None 
Polycarbophil 0 Practically None 
PVP 0 Practically None 
Sodium Alginate 0 Practically None 
Sodium CMC 0 Practically None 
HPMC 0 Practically None 
PVA 0 Practically None 
Polymer*
Xanthan Gum 0 Practically None 
*Results were the same regardless of which application technique was adopted. 
 
From Table 4.3 it can be seen that of all the non-aqueous solvents tested, ethanol 
and NMP gave strong reactions according to the scoring system reported by 
Schlage et al. (1999).  In contrast, glycerin and PEG 400 produced moderate 
effects.  Propylene glycol produced a very weak effect.  None of the solid 
polymers used elicited any immunological response of note (Table 4.3).   
 
Biocompatibility studies from previous work on similar materials were located for 
comparison although it should be noted that the literature-sourced 
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biocompatibility studies of the tested materials did not use the HET-CAM test.  
Al-Shamkhani et al. (1991) evaluated the biocompatibility of xanthan gum and 
found that it showed good haemocompatibility.  Xanthan gum was also tested for 
toxicity in the stomachs of rats and mice where it was found that toxic effects did 
not occur despite the administration of an extremely high dose which caused an  
actual obstruction of the gastrointestinal tract in the animals tested (Diao et al., 
1990).  Smyth et al. (1970) found larger doses (oral dosage form) of high 
molecular weight PEO (approximately 4 000 000) had no immediate detectable 
effect.  However 90 days after administration minor kidney and liver effects in the 
rat were noted.  (A discussion on the clearance of a high molecular weight 
polymer is given in Section 4.3d).  A study on alginates revealed that the 
compounds did not accumulate in any major organs.  However, some evidence of 
in vivo degradation has been reported (Al-Shamkhani et al., 1991).  Sodium 
alginate is widely used in pharmaceutical formulations (Kubo et al., 2003).  Zhang 
et al. (2004) reported PVA has low toxicity and no irritation.  Rodwell et al. 
(2003) studied the effect of PVA on fertility, embryonic and growth development 
in rats.  No effect was found in the female reproductive performance, pup 
survival, growth and organ weight.  Warne and Schifko (1999) conducted a study 
on the toxicity of laundry detergents and their components on a freshwater 
cladaoceran which included sodium CMC.  Sodium CMC was found to be among 
one of the most toxic components.  However it contributed little to the overall 
toxicity of the detergent due to its low concentration in the powder.  The 
biocompatibility of HPMC has been assessed in the anterior chamber of the 
rabbit’s eye.  Ehrich et al. (1990) found no toxic effects and that the HPMC was 
well tolerated.  The Food and Drug Administration (FDA) allows the use of 
HPMC as a direct and indirect food additive (for specific uses) (Organic Materials 
Review Institute for the USDA National Organic Program, 2002).  HPMC is 
generally recognised as safe (GRAS), through scientific procedures, as an 
ingredient for use in food in general (including meat products) (Food and Drug 
Administration, 2006).  Polycarbophil is listed by the FDA as safe and effective as 
an over-the-counter bulk laxative and antidiarrheal (Food and Drug 
Administration, 1990).  Danhof (1982) reported polycarbophil use in laxatives as 
being non-toxic and did not interfere with digestion or absorption and did not 
cause gastrointestinal  irritation (at daily doses of 4-5 g in adults).  Hornof and 
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Bernkop-Schnurch (2002) used polycarbophil-cysteine conjugates to enhance the 
corneal permeability for ocular delivery systems.  The extent of corneal damage 
was assessed using a corneal hydration level test and it was found corneal tissues 
were not damaged.  Higa et al., (1999) conducted a biocompatibility study for 
PVP wound dressings.  Their study showed no cell toxicity.   
 
The results of the HET-CAM study carried out in this investigation found the 
polymers did not elicit an immunological response.  The majority of the polymers 
in the literature are described as being relatively biocompatible.  Based on the 
result of the HET-CAM study (which in most cases was in agreement with the 
literature), none of the hydrophilic polymers investigated were eliminated.   
 
In contrast to the hydrophilic polymers which did not cause irritation in the HET-
CAM test, the non-aqueous solvents produced an immunological response ranging 
from slight to severe.  The literature-sourced findings gave various results.  The 
effect of PEG 400 on rats was monitored (Hermansky et al. 1995) over a 13 week 
period.  A modest decrease in food consumption and body weight in rats which 
were administered mid (2.5 mL kg-1 day-1) and high level doses of PEG 400 (5 
mL kg-1 day-1), was noted.  This was attributed to the presence of relatively large 
amounts of PEG 400 in the intestinal tract (which would have had an increased 
“satiety” effect in the rats) and not a result of direct toxicity effect from the PEG 
400 (Hermansky et al. 1995).  In a study by Montaguti et al. (1994), the acute 
intravenous toxicity of certain solvents including PEG 400 on mice was 
investigated.  The mice were given doses of PEG 400 ranging from 2 – 8 mL kg-1.  
While the lowest dose of 2 mL kg-1 was found to be safe, the highest dose of 8 mL 
kg-1 resulted in approximately half the mice dying.  Montaguti’s study also 
reported that PEG 400 resulted in a body weight decrease in one of the mice 
strains.  However, despite the observation of these apparently adverse effects, they 
still conclude by recommending the use of PEG 400 as a solvent.  As a general 
rule, polyethylene glycols such as PEG 400 are considered inert and of low 
toxicity (Chadwick et al., 1977; Klugmann et al., 1984; Swinyard and Pathak, 
1980).  This claim has been verified in several species including humans 
(Chadwick et al., 1977; Principe, 1968, Shaffer et al., 1950; Smyth et al., 1955).  
Cutaneous injection of PEG 400 for 13 weeks at 2.5 mg kg-1 was well tolerated.  
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Increasing the residence time from 13 weeks to 104 weeks was still well tolerated 
(Gad et al., 2006).  Subcutaneous injection of PEG 400 (up to 10 mL – 10 times 
the human dose) caused no permanent damage.  The reactions observed were 
blanching of the skin and scab formation in 48 hours.  PEG 400 did not give a 
foreign body reaction in animals.  The removal of PEG from the injection site (in 
dogs) was rapid as the PEG diffused freely into the surrounding tissue (Spiegel 
and Noseworthy, 1963).  PEG 400 is generally regarded as being one of the safest 
non-aqueous solvents (Gad et al., 2006).  The HET-CAM investigation carried out 
in this study has shown PEG 400 to have a moderate effect where the average 
cumulated score was found to be 5 (Table 4.3).  PEG 400 was therefore 
investigated further as a possible non-aqueous solvent for the ISGM system. 
 
Subcutaneous injection of ethanol caused pain followed by anaesthesia (Spiegel 
and Noseworthy, 1963).  Injections in or close to the nerves are made to cause 
anaesthesia to treat severe pain.  If injections of ethanol occurred near or in the 
nerves, then neuritis and nerve degeneration may occur.  Cutaneous 
administration of ethanol into the mouse for 13 weeks was well tolerated for a 
70% solution (100 μL/animal/day) (Gad et al., 2006).  Wali and Hayter (1987) 
investigated the pharmacological and toxic side effects of ethanol in rats.  They 
found that low concentrations of ethanol had no toxic side effects but high 
concentrations of ethanol resulted in toxic side effects in all the tissues studied 
especially the liver and the lung.  This was further supported by Joshi et al. (1998) 
who reported the use of high concentrations of ethanol in sustained release 
injectables was a drawback due to local intolerance.  This was in agreement with 
the findings of the HET-CAM test where ethanol had a cumulative score of 12, 
indicating a severe immunological response.  The toxicity of ethanol will 
therefore depend on its concentration.  As the ISGM technology being developed 
in this study is a non-aqueous system, water diluted forms of ethanol cannot be 
used.  Though the HET-CAM test found ethanol to have a severe effect, ethanol 
was still investigated as a possible non-aqueous solvent as the extent of reaction in 
the HET-CAM test was lower than that of NMP (12 compared to 18.5 for NMP).  
If ethanol is considered as one of the final possible non-aqueous solvents to use in 
the ISGM system, its biocompatibility results will be considered before choosing 
the ideal non-aqueous solvent. 
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Guchok (1986) found administration of glycerin during an early postnatal period 
was not very toxic to rats.  Subcutaneous injection of glycerin into the rat and 
mouse at a dose of 10 mg kg-1 was well tolerated (Gad et al., 2006).  Glycerin has 
low toxicity in oral formulations as no deleterious effects were observed in 
humans dosed with 110 g of glycerin per day for 50 days.  There is, however, 
some controversy regarding the use of glycerin in parenteral formulations as 
administration of glycerin to animals resulted in hemoglobinurea, hypotension, 
central nervous disturbances and weight loss (Spiegel and Noseworthy, 1963).  
Sloviter found no such toxic effects of glycerin administered intravenously to both 
humans and mice and attributed the previously observed toxicities to the osmotic 
disturbances caused by injecting high concentrations of glycerin (Sloviter et al., 
1957; Sloviter, 1958).  Parenteral administration of large doses of glycerin can 
affect the central nervous system resulting in effects such as paralytic symptoms.  
The blood corpuscles were found to be laked which is thought to be due to the 
osmotic effect.  Glycerin was found to remain at the injection site unabsorbed and 
in high concentrations and it was thought the corpuscles were laked during their 
passage through this area (Spiegel and Noseworthy, 1963).  In this investigation 
the cumulative score for glycerin was 5 (Table 4.3) which represents a moderate 
irritation potential.  Though the literature indicates some issues in the use of 
glycerin as a non-aqueous solvent, glycerin was still investigated as a possible 
non-aqueous solvent as the HET-CAM test resulted in only a moderate irritation 
potential.  
 
The European regulatory authorities (The European Agency for the Evaluation of 
Medical Products, EMEA) have critically judged the use of NMP in parenteral 
pharmaceutical technologies.  NMP is regarded as a Class 2 solvent (Matschke et 
al., 2002).  Class 2 solvents have significant toxicity such as neurotoxicity, non-
genotoxic carcinogenicity or birth defects (International Conference on 
Harmonisation, 2000).  Despite this NMP still seems to be used in several 
delivery systems.  Injectable implants containing only NMP as a solvent were 
tested in Rhesus monkeys (Royals et al., 1999).  Results showed only a mild local 
tissue response and inflammatory effects such as swelling, redness or irritation 
were not observed.  However NMP is not permitted for use in dogs and cats due 
to observed pain reaction during application followed by local inflammatory 
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effects (Matschke et al., 2002).  Such results question the safety of NMP as a 
solvent for parenteral products.  The findings of the literature correlated with the 
findings of this investigation where NMP was found to cause a severe 
immunological response.  The cumulative score of NMP in the HET-CAM test 
was calculated to be 18.5 (Table 4.3) out of a maximum 21 thus indicating the 
severity of the reaction.  Consequently NMP was removed as a possible solvent 
choice for the ISGM system. 
 
Propylene glycol is the most common organic solvent used in commercially 
available formulations (Gad et al., 2006).  Propylene glycol has been considered 
as safe to use in commercial formulations of foods, drugs and cosmetics (Center 
for the Evaluation of Risks to Human Reproduction, 2004).  Propylene glycol is 
FDA approved in the use of food, tobacco and pharmaceutical products as an inert 
ingredient (Food and Drug Administration, 1982).  In the pharmaceutical industry 
propylene glycol is used as a glycogenic in ruminants, co-solvents for drugs, 
stabiliser for vitamins and ointments for medical applications (Center for the 
Evaluation of Risks to Human Reproduction, 2004). 
 
Propylene glycol is GRAS in the direct addition to foods.  Such substances are 
also permitted as packaging materials provided the substances are used in amounts 
not to exceed that required to accomplish their intended physical or technical 
effects (Food and Drug Administration, 1982).  Propylene glycol is also used as a 
humectant in pet food products.  However it is not used in cat food.  Propylene 
glycol causes a red blood cell disorder in cats called Heinz disorder (Dzanis, 
2001).  Consequently propylene glycol was removed from cat food products by 
the FDA in 1996 (Food and Drug Administration, 1996).  Subcutaneous 
administration of propylene glycol into rats for 4 weeks was well tolerated 
(dosage of 2.5 mL/kg).  Cutaneous administration of propylene glycol into a 
minipig for 26 weeks at the same dose was also well tolerated (Gad et al., 2006).  
The intramuscular minimum fatal dose of propylene glycol for rats and rabbits 
were 14.7 and 9.7 g kg-1 respectively.  Mice are more sensitive to propylene 
glycol and consequently have a lower tolerance.  The HET-CAM investigation 
found propylene glycol to have a slight irritation potential with a cumulative score 
of only 3.5 (Table 4.3).  According to the HET-CAM test, propylene glycol was 
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the most biocompatible of the non-aqueous solvents and therefore would be the 
ideal solvent to use for the ISGM system based on these results. 
 
This discussion includes aspects of systemic toxicology of formulation 
components.  The object of this review was to determine what effect and whether 
there are any implications of using the materials considered for the ISGM system.  
Consequently one can gain an understanding of the issues, if any, involved with 
the material to be used.  Correlation of the literature findings and those in this 
research using the HET-CAM methods suggest that all the materials thus far 
investigated in the study (with the exception of NMP) could be used in the final 
formulation as they should be safe for injection into animals.   A review of the 
literature showed there was some controversy over the use of NMP.  The findings 
from this study showed NMP caused a severe immunological response and was 
consequently removed as a possible non-aqueous solvent choice for the 
technology.  Furthermore as mentioned earlier in this section, Matschke et al. 
(2002) reported the use of NMP is not allowable for cats or dogs due to observed 
pain reaction during application followed by local inflammatory effects.  
Consequently the delivery of propranolol to dogs using the ISGM technology 
developed in this study would not be able to use NMP as a non-aqueous solvent. 
 
As a result of the HET-CAM study, NMP was not investigated any further as a 
possible non-aqueous solvent due to the severe reaction observed in the HET-
CAM test.  Ethanol also produced a strong immunological response in the HET-
CAM test and there is some debate in the literature on the use of ethanol.  As 
mentioned earlier in this section Joshi et al. (1998) reported the use of high 
concentrations of ethanol in sustained release injectables was a drawback due to 
local intolerance.  In contrast, cutaneous administration of ethanol into the mouse 
for 13 weeks was well tolerated (100 μL/animal/day) (Gad et al., 2006), but, this 
was for a concentration of 70% ethanol.  As the technology being developed in 
this study is a non-aqueous system, water diluted forms of ethanol cannot be used.  
Ethanol was still investigated as a possible non-aqueous solvent as the extent of 
reaction in the HET-CAM test was lower than that of NMP (12 compared to 18.5 
for NMP).  Therefore, if ethanol is considered as one of the final possible non-
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aqueous solvents to use in the technology, its biocompatibility results will be 
considered before choosing the ideal non-aqueous solvent. 
 
The next stage of this investigation involved analysing the sedimentation 
behaviour of the hydrophilic polymers (PVP, PVA, HPMC, PEO 303, PEO N12, 
PEO N10, xanthan gum, polycarbophil, sodium CMC and sodium alginate)  in the 
non-aqueous solvents (ethanol, glycerin, PEG 400 and propylene glycol).  
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4.2 Formulation and Manufacture of the ISGM System 
 
4.2a Sedimentation Behaviour of Hydrophilic Polymers in Non-Aqueous 
Solvents 
The polymers, PVP and PVA dissolved completely in all the test solvents 
investigated in this study (see Section 3.2a in Chapter 3) giving clear solutions.  In 
terms of our working definition for our ISGM system, this is undesirable as the 
hydrophilic gelling agent needs to exist in a suspended state in the non-aqueous 
solvent as described in Section 2.6. 
 
When polycarbophil was added to all the test solvents, it exhibited a very different 
behaviour in that much of the powder that was added to the non-aqueous solvent 
clumped in the medium and the polymer appeared to become partially gel 
forming. 
 
The remaining hydrophilic polymers (HPMC, PEO 303, PEO N12, PEO N10, 
xanthan gum, sodium CMC, and sodium alginate), which were initially 
homogeneously dispersed as discrete particles throughout the pure non-aqueous 
solvents, were observed to sediment to the bottom of the vials very rapidly (within 
60 minutes they had completely settled).  In one solvent (ethanol), the polymers 
sedimented rapidly within a few minutes.  Upon standing, the sedimented 
particles were observed to compact or “cake” into a compact mass that was not 
easily redispersed by shaking.  This phenomenon has been commonly observed 
(Burgess, 2005; Mysels, 1959; Shaw, 1970; Cartensen, 1995). 
 
All suspensions are susceptible to some kind of physical instability such as 
sedimentation of the particulate matter over time by gravity so leading to a non-
uniformly distributed system (Burgess, 2005; Yoshida et al., 2004). Not only 
sedimentation but also “creaming” processes can occur where the dispersed 
particulate matter can rise to the top. Creaming occurs when the density of the 
particles is less than the density of the solvent while sedimentation occurs when 
the density of the particles is higher than the density of the solvent (Burgess, 
2005).   
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Flocculation events occur when aggregates or more appropriately “flocs” build up 
from particles which come together due to weak attractions between them.  
Redispersion of the flocs should result in no changes to the particle size or size 
distribution as one is simply breaking up loosely held masses of particles (i.e. no 
discrete growth of a particle diameter has occurred).  Therefore in flocculated 
suspensions, the particles are loosely held together by electrostatic forces and the 
suspension will exist as a loosely packed network of particles (Burgess, 2005; 
Ansel and Popovich, 1990).  As a result, caking of the sediment is not expected to 
occur so that the system should be easy to redisperse by relatively non-aggressive 
methods. 
 
The velocity, v, of sedimentation for a uniform collection of spherical particles 
can be predicted by Stokes Law (Burgess, 2005; Ansel and Popovich, 1990): 
 
 
v =                                                                                      (4.1) 
d g2 1 2( )ρ ρ
η
−
18 0
 
where v  =  the sedimentation velocity 
 d  =  the diameter of the suspended particles 
 ρ1 =  the density of the suspended particles 
 ρ2 =  the density of the medium 
 g   =  the acceleration of gravity 
 ηo =  the viscosity of the external phase  
 
When a suspension settles rapidly v, the sedimentation velocity, is relatively large.  
As shown in the equation above (Equation 4.1), v is directly proportional to Δρ 
(the difference in density between the solid and liquid i.e. ρ1 - ρ2 ) and inversely 
proportional to the viscosity of the suspending liquid.  Therefore to decrease v, Δρ 
needs to be reduced or the viscosity of the suspending liquid has to be increased.  
To reduce the difference in density between the solid and liquid (i.e. reduce Δρ) 
the density of the liquid is manipulated by addition of solvents such as sucrose, 
sorbitol, and glycerin to make the liquid medium more dense.  Alternatively the 
viscosity can be increased (as viscosity is inversely proportional to v as mentioned 
above) by addition of a viscosity inducing agent.  This is the basic underlying 
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principle for improving the dispersion properties of the ISGM system in this 
study. 
 
At this stage of the screening study, the decision was made not to consider the 
following polymers for any further development work (in their role as the 
dispersed gelling polymer) of the ISGM system: 
 
1.  PVA and PVP as these polymers clearly dissolved in each of the solvents, and 
the criteria for the ISGM system under study demand that they be suspended as 
particles. 
 
2. Polycarbophil since this gelled when incorporated into each of the non-aqueous 
solvents.  (Though polycarbophil was not investigated further as a dispersed 
gelling agent, the polymer was considered as a viscosity inducing agent in Section 
4.2c). 
 
 
4.2b Effect of Glycerin on Sedimentation Rate of Hydrophilic Polymers 
Glycerin was one candidate used to manipulate the viscosity and density of the 
continuous phase.  Density as shown in the Stokes Law (Equation 4.1) is 
indirectly related to the viscosity.  Glycerin alters the density of the continuous 
phase by reducing the difference in density between the solid and liquid (i.e. 
reduce Δρ) making the liquid medium more dense (and more viscous).  This has 
the effect of reducing the sedimentation velocity of the suspended particulate 
matter.   
 
Figures 4.2 – 4.4 show the sedimentation profiles for the polymer sodium CMC in 
the different non-aqueous solvents investigated in the study (PEG 400, propylene 
glycol and ethanol) each containing varying amounts of glycerin in the continuous 
phase.  The graphs for all the remaining polymers showed similar trends and are 
documented in the appendix (A1 – A18). 
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Figure 4.2 - Comparison of Sedimentation Profiles for Sodium 
CMC at each Glycerin Concentration in Alcohol (n=2) 
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Figure 4.3 – Comparison of Sedimentation Profiles for Sodium 
CMC at each Glycerin Concentration in PEG 400 (n=2) 
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Figure 4.4 – Comparison of Sedimentation Profiles for Sodium 
CMC at each Glycerin Concentration in Propylene Glycol (n=2) 
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The experimental errors for these procedures were calculated as the relative 
standard deviation in the percentage sedimentation height of the replicates (where 
each experiment was carried out in duplicate). 
Figures 4.2 – 4.4 show that for sodium CMC (10% w/w) in each of the non-
aqueous phases that were investigated (PEG 400, propylene glycol and alcohol), 
as the glycerin concentration in the medium increased, the rate of sedimentation of 
the polymer decreased.  In all cases the pure non-aqueous solvent containing 
sodium CMC exhibited the fastest rate of sedimentation and 100% glycerin 
resulted in the slowest rate of sedimentation of the polymer particles.  The effect 
is plainly ascribable therefore to the addition of glycerin to the non-aqueous 
solvent which increases the solution density and viscosity and hence decreases the 
sedimentation rate. 
 
Figures 4.2 – 4.4 show that the sodium CMC reached a final sedimentation height 
of 20 - 30%.  This was observed for all the other polymers except HPMC which 
exhibited a much higher sedimentation height of approximately 65% in all solvent 
systems (Refer to A1 – A3 in the Appendix).  HPMC had the smallest bulk 
density of the investigated hydrophilic polymers (Table 4.1).  The smaller the bulk 
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density, the greater the inter-spatial voids between the particles (as explained in 
Section 4.2h) Therefore the greater sediment height observed for the HPMC 
system can be attributed to the larger inter-spatial voids between the particles.  
 
PEO N12, PEO N10 and PEO 303 exhibited similar sedimentation behaviour 
(Appendix A4 – A12).  Therefore there was no need to continue investigating all 
three PEOs.  PEO N10 and PEO N12 were therefore eliminated from the 
screening process.  In addition sodium alginate was also removed from the 
screening process.  Sodium alginate was available as a powder that had a wide 
ranging particle size (from large particles to very fine ones).  All the polymers 
were sieved to give a particle size of less than 100 µm.  However, despite this, 
there was still a range of particle sizes (an analysis of the polymer particle sizes 
was conducted on the polymers at a later stage of the analysis as discussed in 
Section 4.2h).  Consequently, when the polymer was dispersed throughout the 
non-aqueous solvent the larger particles sedimented quickly.  According to 
Stoke’s Law (Equation 4.1), the larger the particle diameter the faster the velocity 
of sedimentation.  Consequently, the very fine particles, which will have a smaller 
diameter, will have a slower sedimentation velocity and therefore remain 
suspended longer producing a very diffuse layer.  The diffuse layer caused 
difficulties in determining the sediment height.  This was compounded by the 
orange-brown colour of the polymer.  Consequently sodium alginate was removed 
as a possible gelling agent. 
 
The above study has shown that the use of glycerin to stabilise a suspension (i.e., 
retard sedimentation of the polymer particles) was only partially successful and 
required the use of a high concentration of glycerin to achieve the desired effect.  
A complication noted in the systems investigated was that although the polymer 
remained dispersed for longer in the solvent when high concentrations of glycerin 
were incorporated into the non-aqueous solvent, most of the continuous phases 
(i.e. non-aqueous solvent plus glycerin) were observed to gel over time.  This was 
postulated to be due to the absorption of atmospheric moisture by virtue of the 
hygroscopic nature of the glycerin which was sufficient to initiate the gelation of 
the continuous phase.  This postulation was supported by the observation that 
gelling was only observed in the systems containing high concentrations of 
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glycerin (50 - 100% (w/w) glycerin).  The occurrence of this gelling phenomenon 
was obviously not desirable from a practical point of view as the ISGM system 
involves being injected as a relatively lower viscosity liquid containing dispersed 
particles and the occurrence of gelling may result in a preparation that is too thick 
to be injected using conventional administration techniques such as hypodermic 
syringes.   
 
An interesting observation made during this part of the study was that, as 
mentioned earlier in this section, the sedimentation height of HPMC was greater 
than the other polymers.  This suggested that HPMC may be a more favourable 
polymer to use compared to the other hydrophilic polymers as the greater 
sedimentation height should lead to a decreased chance of caking  (as it is 
perceived to be more greatly dispersed).  Ideally a sedimented suspension should 
be able to be redispersed with minimum effort as caking (due to the close 
proximity of the sedimented particles) of the particles may bring about permanent 
coalescence. This would be favourable from a storage point and a “shelf life” 
point of view as often a common situation is that pharmaceuticals when 
manufactured are not necessarily used immediately. These sedimentation 
observations with respect to the HPMC (A1-A3 in the Appendix) thus suggested 
that formulations containing this polymer would be easier to redisperse than the 
others and this was the general observation made in this work. 
 
The next step in the formulation development involved addition of a solid 
polymer as a viscosity inducing agent to modify the viscosity of the vehicle in 
order to retard the sedimentation rate of the polymer particles. 
 
At this stage of the study it was decided the following polymers would not be 
studied further as a result of the observations made during these studies:  
 
1. PEO N12 and PEO N10 were eliminated as screening three different types of 
PEO was deemed unnecessary because the sedimentation profiles of each of the 
three different molecular weight PEO polymers were similar. 
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2.  Sodium alginate produced a very diffuse layer which caused difficulties in 
determining the sediment height.  This was compounded by the orange-brown 
colour of the polymer. 
 
 
4.2c Determination of the Potential Use of Polycarbophil as a Viscosity 
Inducing Agent in Non-Aqueous Solvents 
In contrast to the formulation of suspensions in which the continuous phase is 
aqueous based (Ansel and Popovich, 1990; Cuna et al., 2000) the formulation for 
suspensions in which the continuous phase comprises a non-aqueous solvent is 
much less documented in the literature.  Studies on the formulation of aqueous 
suspensions and the delay of sedimentation studies by added excipients are 
numerous in the literature.  However, although polycarbophil was eliminated in 
Section 4.2a as a potentially useful hydrophilic polymer for inclusion in the ISGM 
system (since it partially gelled in each of the solvents tested), the fortuitous 
observation that it underwent this reaction to form a colloidal gel in each of the 
non-aqueous solvents tested was recognised as being a potentially valuable 
attribute to the system under development.  Polycarbophil was therefore 
investigated from the point of view of its use as a viscosity-inducing agent in the 
non-aqueous solvents being considered in this study. 
 
A preliminary (and qualitative) evaluation of polycarbophil as a viscosity 
inducing agent was thus carried out and involved manufacture by simple addition 
and manual shaking of various concentrations of polycarbophil (0.50, 1.00 and 
1.25% w/w) in the non-aqueous solvent, propylene glycol.  These preparations 
were visually examined for their ability to flow (a more quantitative viscosity 
analysis on the effect of polycarbophil concentration on the continuous phase 
viscosity is discussed in Section 4.2f).  As expected, the flow properties of these 
dispersions did change as a function of polycarbophil concentration which 
confirmed the viscosity inducing role of the polycarbophil.  Hence this component 
could be used in this role to retard the sedimentation of suspended particles.  One 
problem that was observed during manufacturing was that not all the 
polycarbophil was dissolving in the non-aqueous solvent.  Incomplete dissolution 
of the polycarbophil from sample to sample can pose problems in terms of 
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varying concentrations.  It was important that the concentration of this component 
in the non-aqueous solvent be accurately known for quantitative evaluation of its 
viscosity inducing effect.  Complete dissolution would also be vital in any mass 
manufacture of this as it is essential to make a material with a consistent 
composition.  
 
Therefore numerous manufacturing methods were investigated in order to achieve 
the complete dissolution of the polycarbophil in the ISGM system so that its 
property of being a viscosity inducing agent could be exploited for physically 
stabilising the polymer dispersion (either HPMC, PEO 303, sodium CMC or 
xanthan gum). 
 
 
4.2d Manufacturing Methods Investigated for Incorporating the 
Polycarbophil Viscosity Inducing Agent into the Non-Aqueous Solvent 
 
i. Magnetic Stirrer 
The first manufacturing process investigated involved stirring the solvent using a 
simple magnetic “flea”.  This method proved to be ineffectual as the 
polycarbophil did not mix into the non-aqueous solvent and clumps of 
polycarbophil were observed on the surface of the non-aqueous solvent and 
remained there despite the long mixing times (see Section 3.2d i).  It was 
concluded that a faster, more vigorous stirring method was required as the 
polycarbophil was not being adequately mixed into the non-aqueous solvent.  
 
ii. Overhead Stirrer 
The overhead stirrer (three blade overhead stirrer at 2000 RPM) was considered a 
faster stirring method than the magnetic stirrer.  It was observed that upon 
addition to the non-aqueous solvent, the polycarbophil was drawn into the vortex 
created by the agitation of the overhead stirrer paddle.  This observation 
contrasted to the magnetic stirrer where the polycarbophil was not drawn into a 
vortex.  Despite this improvement in the mixing method, the polycarbophil though 
no longer sitting in clumps on the solvent surface, did manifest itself as white 
clumps of polymer within the solvent.   
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iii. Overhead Stirrer Plus Heating 
Since it is commonly known that increasing temperature aids dispersion of most 
materials, raising the temperature of the mixing solution was investigated in 
combination with the overhead stirrer.  The suspension was thus heated to a 
temperature of 80°C whilst stirring, but observations of the resultant mixture 
revealed that this led to little improvement as clumps of polymer were still 
observed in the final mixture. 
 
iv. Overhead Stirrer Followed by Placing on a Roller at 40°C 
Noveon (2002) claimed that polymers such as polyacrylic acid (for example 
polycarbophil) take a long time to disperse throughout a non-aqueous solvent.  
The results of this study support this view, that complete dispersion of 
polycarbophil in propylene glycol would require a lengthy mixing process if a 
simple mixing apparatus is used.  It was obvious that mixing beyond that 
subjected by the overhead stirrer needed to be carried out.  Therefore further 
investigations involved placing a suspension obtained from previous mixing 
(using an overhead stirrer) onto a roller in a hot room maintained at 40°C (by a 
thermostat as described in Section 3.2d iv).  The roller was used to continuously 
stir the suspension in an attempt to increase dispersion of and hence help dissolve 
the polycarbophil in the propylene glycol.  Initial results had suggested that this 
helped but only to the extent that fewer and smaller sized clumps of unsolvated 
polycarbophil were observed in the propylene glycol.  
 
Noveon (2002) reported clumps of particles may form and the surface of these 
clumps solvate to form a layer, leaving a dry interior.  In the methods used to date 
in this study (magnetic stirrer, overhead stirrer, overhead stirrer plus heating and 
overhead stirrer followed by placing on a roller at 40°C) the formation of the 
polycarbophil clumps may be due to the agglomeration of particles that were only 
wetted on the outside without adequate penetration of solvent to solvate the 
presumably dry interior of the clumps.  The mixing time required to remove these 
globules will thus be dictated by the slow diffusion of the solvent through the 
solvated layer to the dry interior.  If we were to rely on this mechanism of 
solvation whilst using the present “gentle” methods of stirring, the time to achieve 
this penetration would be impractically long.  Noveon (2002) suggested that 
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outright prevention of the clumping process will reduce the mixing time required 
to effect complete solution of the polymer in the solvent of choice, hence the 
mixing methodology was altered with this aim in mind. 
 
v. Mortar and Pestle 
This mixing method involved the use of a mortar and pestle to give a more 
intimate contact between the solvent and the solid particles (see Section 3.2d v). 
Propylene glycol and polycarbophil were ground for 2 hours continuously (except 
where the solvent/polymer mixture was left to stand intermittently for 5 minutes 
to allow the gel to thicken).  The results from this suggested that the clumping of 
particles was overcome, but then a new phenomenon was noted.  The 
phenomenon had been reported previously (Charles Ross and Son Company, 
2005; Noveon, 1993) and is referred to as “fish-eyes”.  This is where the formed 
dispersion looks to the naked eye as being homogeneous and complete, however 
when the containing vessel is tipped onto its side, and the thickness of the liquid 
layer becomes thin on the glass, semi-transparent globules of undissolved polymer 
(hence the “fish eyes” appearance)  can be seen (Figures 4.5a and 4.5b). 
 
Figure 4.5a – Vial Containing the Prepared Continuous 
Phase (Against a Red Background) 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.5b – Vial Tilted to its Side Revealing the Existence of 
Globules or “Fish Eyes” (Against a Red Background) 
Globules or “fish eyes” 
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The fish eyes can also be detected using UV-Vis spectrophotometry as these will 
cause scattering of light in the same way as a turbid solution would.  Alternatively 
a viscosity analysis of the continuous phase can be conducted.  If fish eyes were 
present, the viscosity of the continuous phase will be affected to some extent.  
However, visual observation (as used in this study) is still an effective means of 
confirming the presence of fish eyes, as the undissolved polymer on the side of the 
tilted glass tube is very easy to see with the naked eye. 
 
vi. Mortar and Pestle followed by Roller in 40°C Room 
In a similar vein to the overhead stirrer/roller method, the polycarbophil and 
propylene glycol were ground together and the resulting polymer solvent mixture 
was placed on a roller in a 40°C hot room (see Section 3.2d vi in Chapter 3).   
This procedure merely served to decrease the size of the polycarbophil globules 
but not make them disappear from the medium.  In addition, during the 
preparation of the gels by the mortar and pestle method, a change of weight was 
noted as shown in Table 4.4.  The change in weight was attributed to the 
absorption of water by the solvent during the manufacturing process which was 
conducted in open air.  Both the solvents and the polycarbophil are inherently 
hygroscopic substances and given the manufacturing process was conducted over 
a lengthy period of time, water absorption from the atmosphere occurred 
(consequently an investigation into the extent of water absorption by the ISGM 
technology was undertaken as described in Section 4.3a).  It was concluded from 
this part of the study that a faster method of making the gels was required that 
minimised water absorption from the air. 
 
Table 4.4 – Weight Increase During Manufacture of Continuous Phase Due to Water Absorption 
Sample Solvent (g) PCP (g) Total Wt. (g) Actual Wt. (g) Wt. Increase (g) 
1 50.000 0.025 50.025 51.600 1.575 
2 50.051 0.025 50.076 51.595 1.519 
 
 
As was noted earlier, Noveon (2002) suggested that preventing clumping will 
reduce the mixing time required and recommended the use of a high speed mixing 
tool.  The mortar and pestle, though providing a better degree of admixing of the 
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non-aqueous solvent and the polycarbophil, caused the emergence of the “fish 
eye/globule” phenomenon.  It was important to eliminate these globules, 
therefore, the next method investigated used an even more aggressive mixing 
approach (i.e. Silverson® homogeniser) which involved stronger (and faster) 
mechanical dispersion with cutting of the polycarbophil particles.  It was also 
envisaged that this would destroy the globules and by virtue of the faster mixing 
regimen decrease mixing time and prevent/minimise water absorption from the 
air. 
 
vii. Silverson® Homogeniser  
The Silverson® homogeniser operates by rotating the rotor blades (within the 
workhead of the homogeniser) at high speeds causing a powerful suction action 
which draws the dispersion into the centre of the workhead.  Inside the workhead 
the solvent/polymer dispersion is furthermore subjected to a milling action 
followed by an intense hydraulic shear as the materials are forced out through the 
slots of the head.  Once expelled, the materials are projected radially towards the 
sides of the mixing vessel and fresh material is drawn into the workhead to 
maintain the mixing cycle.  
 
Initial work on the Silverson® homogeniser (high speed dispersion tool) involved 
determining which head to use for the dispersing process.  The general purpose 
disintegrating head is used in preparation of gels and suspensions.  The square 
hole high shear screen head can be used to prepare emulsions and fine colloidal 
suspensions (see Figures 3.4, 3.5a and 3.5b) 
 
Table 4.5 - Comparison of Different Heads Utilised in Manufacturing Process 
Head Speed 
(RPM) General Purpose Disintegrating Head Square Hole High Shear Screen 
2 000 Large clumps of polycarbophil Globules present 
5 000 Clumps remain Fewer globules than above  
8 000 Fewer clumps but globules were present Even fewer globules than above 
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As shown in Table 4.5 the square hole high shear screen was more effective at 
preventing globule formation than the general purpose disintegrating head (where 
the presence for globules was assessed visually).  The general purpose 
disintegrating head had fewer and less sharp perforations, therefore it was harder 
to break down the polycarbophil.  The square hole high shear screen, which has 
the ability to rapidly reduce the size of granular solids, did not lead to clump 
formation as the many sharp perforations broke down the polycarbophil granules.  
It was also apparent that the higher speeds utilised were more effective than the 
other mixing methods investigated thus far (Section 4.2d i – 4.2d vi).  
Consequently subsequent work was conducted using the square hole high shear 
screen head. 
 
As indicated in the following table (Table 4.6) mixing for 2 hours decreased the 
amount of globules present.  Longer time periods were not investigated as such 
time periods caused an increase in weight due to absorption of water (as with the 
mortar and pestle mixing method). 
 
Table 4.6 - Observations from an Extended Study at Various Stirring Speeds Using the Square 
Hole High Shear Screen on the Silverson® Homogensier 
Stirring Speed (RPM) 
Time (mins) 
2 000 5 000 8 000 
5 Globules present Globules present Globules present 
10 Same as above Same as above Same as above 
15 Same as above Globules present but smaller 
in size 
Globules present but smaller in 
size 
20 Same as above Same as above Same as above 
25 Smaller number of 
globules present. 
Smaller number of globules 
present. 
Smaller number of globules 
present. 
60 Less globules present. Less globules present. Mixing not conducted due to a 
high increase in temperature. 
120 Less globules present. Very little globules present. Mixing not conducted due to a 
high increase in temperature. 
 
 
The introduction of the polymer to the solvent was the vital stage in the mixing 
process as it is desirable to disperse the polycarbophil rapidly before the semi-
solvated and difficult-to-disperse clumps or globules can form.  Unfortunately as 
shown in Table 4.6 above, the polymer was still not satisfactorily dissolved in the 
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non-aqueous solvent even at the much higher mixing speed as globules still 
remained despite the use of this more mechanically aggressive stirring regimen.  
The next step was thus to advance to even more aggressive stirring methods which 
required the use of another dispersing tool, i.e. the Ultra Turrax®. 
 
viii. Ultra Turrax®
The Ultra Turrax® operates similarly to the Silverson® but is capable of much 
faster speeds than the Silverson® (see Section 3.2d vii and 3.2d viii).  Unlike the 
Silverson® homogeniser, an ice bath was not required as the temperature increase 
during the mixing operation was not significant.  Preliminary investigations 
revealed that the method of introduction of the polymer to the solvent was critical 
as the polymer needed to be sprinkled into the small vortex which appeared during 
mixing.  This ensured the polymer was instantly drawn into the dispersion tool 
and hence dispersed rapidly.   
 
The use of the Ultra Turrax® thus gave a manufacturing process that resulted in 
fast and effective dispersion of the polycarbophil into the propylene glycol and 
produced a continuous phase with no polymer floating on the surface and most 
importantly no globules (or “fish-eyes”) present.  This was an important 
development in the steps to obtaining a workable ISGM system.  
 
 
4.2e Characterisation of Potentially Useful Continuous Phases 
Several continuous phases were now able to be manufactured using the Ultra 
Turrax® manufacturing method and then characterised.  During the manufacture 
of the ethanol-based continuous phases it was found that this solvent was not a 
suitable non-aqueous solvent as the polycarbophil did not dissolve to form a gel 
but remained in permanent suspension.  Not using ethanol any further also 
avoided potential biocompatibility issues that were highlighted in the HET-CAM 
studies as discussed in Section 4.1b.  This left only two possible solvents to 
consider further i.e., propylene glycol and PEG 400. 
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i. Appearance of the Continuous Phase 
Table 4.7 summarises information on the colour, clarity and presence of any 
globules for each of the continuous phase manufactured in propylene glycol and 
PEG 400.  It was noted that after manufacturing the solvent/polycarbophil system, 
the PEG 400 system appeared turbid whereas the propylene glycol system was 
transparent.  As a result of this observation a physical sedimentation study was 
carried out on each solvent/polycarbophil system to assess whether each system 
was stable over a 4 week period (see Figures 4.6 and 4.7).   
 
Table 4.7 - Appearance of Continuous Phase After Manufacture on the Ultra Turrax®
Observations 
Continuous Phase 
Colour Clarity Globules 
Propylene glycol 
and 0.5% w/w 
polycarbophil 
Globules were 
not observed Colourless Transparent 
PEG 400 and 0.5% 
w/w polycarbophil White Turbid 
Globules were 
not observed 
 
 
ii. Physical Stability 
The propylene glycol/polycarbophil continuous phase was physically stable as no 
particulate matter was ever observable (Figure 4.6) over the 4 week period.  
Hence the continuous phase exhibited no sedimentation indicating that the 
polycarbophil had effectively dissolved in the propylene glycol.  
 
 
Figure 4.6 – 0.5% Polycarbophil in Propylene Glycol.  Time is Shown in Hours. 
0 264 456 696 888 
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In contrast the turbid PEG 400 system appeared to sediment over time (Figure 
4.7) indicating the polycarbophil had produced a suspension that was not 
physically stable.  This indicated that although the Ultra Turrax® had thoroughly 
dispersed the polycarbophil in the PEG 400, it had not dissolved in this solvent to 
produce a transparent continuous phase as had happened in the case of the 
propylene glycol. 
 
 
0 264 456 696 888 
Figure 4.7 – 0.5% Polycarbophil in PEG 400.  Time is Shown in Hours. 
 
 
 
 
 
 
 
 
 
To confirm whether or not heating of the PEG 400/polycarbophil system would 
clear the turbidity by facilitating the dissolution of the polycarbophil, mixing with 
an Ultra Turrax® followed by mechanical stirring at 70°C (using an overhead 
stirrer) for 30 minutes (following a procedure reported by Bonacucina et al. 
(2004) as described in Section 3.2e ii) was attempted.  This did not clear the 
turbidity to produce a homogeneous transparent system.  Consequently PEG 400 
was eliminated as a possible solvent choice for the continuous phase. 
 
At this stage of the research, only one non-aqueous solvent had been identified as 
being potentially useful in the ISGM system (i.e., propylene glycol).  This was 
based on the fact that the hydrophilic polymer that was to be added to make the 
ISGM system had to be physically stable in the continuous phase.  The research 
has shown (Section 4.2 c) that to achieve this polycarbophil needed to be added as 
a viscosity inducing agent.  Propylene glycol proved to be the only non-aqueous 
solvent that gave a physically stable system (i.e., propylene glycol and the 
viscosity inducing agent polycarbophil) as the polycarbophil dissolved in the 
propylene glycol.  The solubility of the polycarbophil in propylene glycol was 
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greater than the 1% (w/w) investigated in this study.  Greater concentrations of 
polycarbophil in propylene glycol were not investigated as concentrations greater 
than 1% (w/w) produced a solvent system which was very viscous and difficult to 
inject.  
 
The biocompatibility study (Section 4.1b) showed that neat propylene glycol 
solvent gave low scores in the HET-CAM test so indicating minor reactions.  As 
mentioned earlier (Section 4.1b) many of the reported toxicity studies involve the 
non-aqueous solvent in a diluted form and this is not representative of a practical 
situation when the non-aqueous solvents may be used in an undiluted form.  
Propylene glycol has been used in formulations in an undiluted form such as the 
propylene glycol based formulation of lorazepam (Ativan) which is administered 
intramuscularly (Strickley, 2004).  Therefore propylene glycol was chosen as the 
non-aqueous solvent to use in the ISGM system as the biocompatibility and the 
physical stability results showed propylene glycol to be the most practical solvent 
to use. 
 
The next stage of this research will involve a quantitative investigation of the 
effect of the concentration of the viscosity inducing agent (polycarbophil) on the 
viscosity of the vehicle (propylene glycol). 
 
 
4.2f Determination of the Effect of Polycarbophil Concentrations on 
Viscosity of the Continuous Phase (Polycarbophil Plus Propylene Glycol) 
The viscosity of the propylene glycol/polycarbophil continuous phase and the 
effect of the polycarbophil concentration were determined by using a S10 vibro-
viscometer.  Details of these measurements are described in Section 3.2f in 
Chapter 3.  The concentrations investigated are given in Table 4.8.   
 
 
Table 4.8 - Polycarbophil Concentrations (%) Used in the Continuous Phase 
Solvent Polycarbophil Concentration (%) 
Propylene 
Glycol 0.50 0.67 0.84 1.00 
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Prior to assessing the viscosity of the samples on the viscometer, a standard 
operating procedure had to be developed (see Appendix).  The viscometer was 
very sensitive to changes in measurement conditions and therefore it was 
important to ensure readings were determined in the same manner from sample to 
sample and from day to day. 
 
Temperature, as expected, had a dramatic effect on the viscosity.  Therefore 
viscosity measurements were conducted at a fixed temperature of 25 + 0.4°C.  
Within this range viscosity readings on the samples were stable. 
 
The amount of liquid in the sample volume cup (10 mL) had to be kept constant to 
within small tolerance (+ 2%).  Any large variation in sample volume (i.e., by 1 
mL) resulted in a 5% difference in the readings taken on identical samples. 
 
The most critical parameter in which to obtain reproducible results was the level 
of the sensor plates.  The sensor plates must be placed in the sample at the same 
position for each reading (this was achieved using a magnifying glass as described 
in Section 3.2f).  If the sensor plate was lowered so the top portion of the halfway 
point was in line with the solvent level, a variation of 8 - 9% in the viscosity was 
observed compared to when the sensor plate was lowered to the bottom portion of 
the halfway point as shown in the following diagram (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
525.83 mPas 
503.97 mPas 
484.59 mPas 
Viscosity variation  
of  8 – 9%. 
Figure 4.8 – Effect of Sensor Plate Position on Viscosity Reading 
Top Portion of 
Halfway Point 
Halfway Point 
Bottom Portion 
of Halfway Point 
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Samples of propylene glycol with concentrations of 0.5, 0.67, 0.84 and 1% (w/w) 
polycarbophil were manufactured using the Ultra Turrax® manufacturing method 
and their viscosities determined.  A straight line relationship with a positive slope 
was found to exist between the viscosity of the continuous phase and the 
concentration of polycarbophil in the continuous phase (see Figure 4.9).  Each 
viscosity measurement reported in the plot represents the average of 24 readings 
and the error was calculated as the standard deviation of these readings.  The error 
is depicted in the following graphs (Figures 4.9 and 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 – Effect of Polycarbophil Concentration on Viscosity of Propylene Glycol 
0
 
However, the viscosity of neat propylene glycol did not fall on the straight line of 
the graph above (Figure 4.9).  The viscosity of propylene glycol was much lower 
than what the graph predicted (Figure 4.10).  Propylene glycol is classed as a 
Newtonian fluid (Shekarriz and Sheen, 1998; Khomami and Su, 2000).  The 
addition of polycarbophil to propylene glycol resulted in the solvent system 
displaying non-Newtonian behaviour.  A Newtonian fluid is a fluid with constant 
viscosity at a given temperature regardless of the rate of shear.  In contrast the 
viscosity of a non-Newtonian fluid changes with shear.  This would explain why 
the viscosity of propylene glycol did not lie on the trend line of the graph (Figure 
4.10) for the solvent systems containing polycarbophil.  However this was not 
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regarded as being a serious impediment to the use of polycarbophil in propylene 
glycol. 
 
 
Figure 4.10 – Comparison of Viscosity of Pure Propylene Glycol to the 
Viscosity of the Continuous Phase (i.e. Comparison of Figure 4.9 to the 
Viscosity of Pure Propylene Glycol) 
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This study confirmed the function of the polycarbophil as a viscosity inducing 
agent when it is dissolved in the propylene glycol.  Hence this continuous phase 
system can be used in the confidence that it should retard the sedimentation of any 
added hydrophilic polymer to produce a stable dispersion.   
 
 
4.2g Incorporation of the Hydrophilic Polymer into the Continuous Phase 
The next step in the formulation of the ISGM system was the incorporation of the 
insoluble and dispersed hydrophilic gelling agent, which, upon addition to tissues 
should gel to form the controlling matrix from which a drug can slowly be 
delivered.  The manufacturing method described in the Methodology Section 
(Section 3.2g) was very successful at incorporating and uniformly dispersing the 
hydrophilic polymer into the continuous phase, as issues such as clumping or 
caking of the polymer did not occur. 
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4.2h Sedimentation Behaviour of the Hydrophilic Polymers in the 
Continuous Phase 
Four hydrophilic gelling agents (xanthan gum, HPMC, PEO 303 and sodium 
CMC) were incorporated into the propylene glycol continuous phase containing 
different concentrations of polycarbophil viscosity inducing agent and left to stand 
in order to observe the sedimentation behaviour of the hydrophilic polymers.  The 
aim of the study was to identify the optimum concentration of polycarbophil that 
prevented sedimentation of the dispersed, insoluble hydrophilic polymers, yet 
remained at a viscosity low enough to allow parenteral administration through a 
syringe needle. 
 
Xanthan gum had to be eliminated as a candidate because this hydrophilic 
polymer appeared to be slowly dissolving over time in the continuous phase so 
increasing its viscosity.  A continuous phase in such a pre-gelled state would be 
too thick to inject hence the xanthan gum polymer was unsuitable.  Sodium CMC 
was also eliminated as a possible hydrophilic gelling agent because the 
hydrophilic sodium CMC polymer sedimented too rapidly despite the presence of 
the viscosity inducing agent.  The two remaining polymers, HPMC and PEO 303 
settled more slowly in contrast and were investigated further (Figures 4.11 and 
4.12).  (The screening process was conducted on all 4 concentrations of 
polycarbophil (0.5, 0.67, 0.84 and 1.0% w/w) for both HPMC and PEO 303.  The 
Figures 4.11 and 4.12 are illustrative examples of the 0.67% w/w polycarbophil 
for HPMC and 0.5% w/w polycarbophil for PEO 303). 
 
 
 
0 24 91 135 254 434 622 700 
Figure 4.11 – PEO 303 Sedimentation over Time in the Continuous Phase 
Comprising Propylene Glycol and 1% (w/w) PCP.  Time is Shown in Hours. 
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Figure 4.12 – HPMC Sedimentation over Time in the Continuous Phase Comprising 
of Propylene Glycol and 0.67% (w/w) PCP.  Time is Shown in Hours. 
700 0 18 26 42 49 66 73.5 138 194 267 314 
 
The sedimentation analysis was carried out in duplicate.  The displayed error bars 
(Figures 4.13-4.14) represent the relative standard deviation in the percentage 
sedimentation height of the replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 – Comparison of PEO 303 Sedimentation in Each Continuous Phase (n=2) 
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 Figure 4.14 – Comparison of HPMC Sedimentation in Each Continuous Phase (n=2) 
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The addition of polycarbophil successfully retarded the sedimentation of both 
HPMC and PEO 303 (Figures 4.11 - 4.14).  Addition of increasing amounts of 
polycarbophil decreased the rate of sedimentation of both hydrophilic polymers 
(Figures 4.13 and 4.14).  HPMC proved to be the ideal polymer to use as the final 
sedimentation height was greater than that of PEO 303’s.  Unlike HPMC (Figure 
4.12), PEO 303 produced a large diffuse region with no definitive line along 
which the polymer settled (Figure 4.11).  A possible reason for the diffuse region 
can be attributed to the particle size range of the polymer.  Despite the fact that the 
PEO 303 was sieved to give a particle size of less than 100 μm, the larger particles 
settled quicker than the smaller particles thus resulting in a diffuse region of 
smaller particles which remained suspended for a prolonged period.   
 
As explained in Section 4.2a, according to Stokes Law (Equation 4.1), the larger 
the particle diameter, the faster the sedimentation velocity.   
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A particle size analysis between the two possible gelling agents was carried out 
using an optical digital microscope (Figures 4.15 and 4.16) (see Section 3.2h for 
experimental details).  The error bars in Figures 4.15 and 4.16 represent the 
relative standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.15 – Comparison of HPMC and PEO 303 Particle Size 
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HPMC has a broader particle size range than PEO 303 (Figure 4.15).  This larger 
range did not cause a diffuse region in the sedimentation analysis (Figure 4.12).  
The very diffuse region seen in the sedimentation analysis for PEO 303 (Figure 
4.11) must be due to the 0 - 9 µm particle size range, as HPMC in contrast has few 
particle sizes in that size range.  This hypothesis was tested by conducting a 
particle size analysis of the PEO 303 in the disperse phase at the end of the 4 week 
sedimentation analysis. 
 
According to Figure 4.16 over 95% of the particles in the disperse phase were in 
the 0 - 9 μm range.  Consequently the diffuse region of particles in the disperse 
phase must be due to the very fine particles.  As mentioned previously (Section 
4.2a), the very fine particles will be expected to sediment more slowly.  The 
majority of the HPMC particles lie in the range of 10 – 19 µm and as a 
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consequence of the particles being in this size range, no diffuse region was 
observed in the sedimentation studies.   
 
Furthermore, the bulk densities of the polymers are in agreement with their 
sedimentation behaviour.  HPMC has a bulk density of 0.31 (Vlachou et al., 2001) 
which is lower than the bulk density of PEO 303 of 0.473 (Picker-Freyer, 2006) 
(the bulk densities were in agreement with the calculated values in Table 4.1).  
Bulk density incorporates the inter-spatial voids between the particles.  
Consequently particles which are smaller in diameter will reduce the size of these 
voids and thus increase the bulk density.  As shown in Figure 4.15 the majority of 
the HPMC particles were larger in size than the PEO particles.  Consequently 
HPMC will have greater inter-spatial voids and hence the smaller bulk density.  
Therefore the greater sediment height observed for the HPMC system can be 
attributed to the greater inter-spatial voids between the particles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 – Comparison of Particle Size of PEO 303 Itself and PEO 303 
in the Disperse Phase After the 4 Week Sedimentation Analysis 
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The observations hence made about sedimentation behaviour for the two polymers 
coupled with the particle size analysis led to HPMC being chosen as the most 
appropriate hydrophilic gelling agent for further investigation in the remainder of 
this research. 
 
The inclusion of the hydrophilic gelling agent HPMC to the ISGM system will 
result in gel formation upon addition of water.  The swelling of HPMC is mainly 
due to the disruption of hydrogen bonds between the polymer chains.  Water 
inserts itself into the hydrogen bonds between the polymer chains.  As more water 
penetrates into the polymer the forces between the chains diminish.  Consequently 
the chains gain rotational freedom and begin to occupy more space.  Water 
continues to fill the voids between the polymer chains and then diffuses into the 
denser regions of the polymer.  Water will continue to force additional chains 
apart in these denser regions (Fyfe and Blazek, 1997).  Once the hydrogen bonds 
have completely been disrupted between the HPMC chains, a chain can 
disentangle and diffuse away into the water.  Once disentangled, the polymer 
chain will become completely solvated. 
 
In summary, the ideal excipients to use for the ISGM have been determined by a 
process of systematic experimentation and elimination after consideration of the 
observations made.  The next step in the formulation process was to determine the 
ideal polycarbophil concentration to use in the ISGM system.  As shown earlier in 
Figure 4.14, a polycarbophil concentration of either 0.67, 0.84 or 1% by weight in 
the propylene glycol could have been used as the continuous phase as all 
adequately retarded the sedimentation of HPMC (the 0.5% polycarbophil system 
was not as effective at retarding the sedimentation rate).   The optimum 
percentage weight value of polycarbophil to use in the continuous phase was 
ultimately chosen after determining which of the ISGM preparations containing 
the 0.67, 0.84 and 1% by weight polycarbophil were able to have the suspended 
HPMC redisperse after 700 hours settling time.  The redispersion test was 
executed by manually shaking the suspension.  The 0.67% polycarbophil system 
proved the easiest to redisperse.  The 0.84 and 1% polycarbophil suspensions 
required much effort to redisperse and consequently were eliminated as possible 
formulations.  The 0.67% polycarbophil continuous phase was therefore chosen to 
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use in the final formulation as it was the most facile of the three formulations to  
redisperse manually and exhibited an acceptable retardation of sedimentation rate 
of the hydrophilic polymer (a more extensive study on the redispersion ability of 
the ISGM system was also conducted and this is described in Section 4.3d). 
 
In summary, as a result of conducting extensive formulation studies, the ideal 
excipients to use in the ISGM system were found. These were HPMC as the 
hydrophilic gelling agent, propylene glycol as the non-aqueous solvent and 
polycarbophil as the viscosity inducing agent. 
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4.3  Characterisation and Stability of the ISGM System 
 
4.3a Water Absorption Studies on the ISGM System 
Now that a definitive composition for the ISGM system had been established, 
further characterisation was carried out on the system to investigate stability when 
it is exposed to normal atmospheric conditions.  In previous experiments (Section 
4.2d vi) it was observed that during the manufacturing process of continuous 
phases with a mortar and pestle, moisture from the air resulted in an increase in 
weight.  Because of this observation (which has implications in any potential use 
of this formulation in open air and what protection it might need) the effect of 
exposure of the ISGM system (i.e. 10% HPMC in the continuous phase 
comprising polycarbophil (0.67%) and propylene glycol) to the atmosphere was 
assessed.   
 
The effect of HPMC concentration in the ISGM system on atmospheric water 
uptake by the ISGM system was determined by carrying out the water absorption 
experiments at different HPMC concentrations while maintaining the 
polycarbophil concentration at a constant value. However a parallel set of 
experiments in which the polycarbophil concentration was varied while holding 
the HPMC concentration constant was also carried out.  The experimental details 
of the procedures followed are described in Section 3.3a in Chapter 3. 
 
As shown in Figure 4.17 an increase in HPMC concentration in the ISGM system 
did not lead to an increase in water absorption but in fact led to a decrease.  
Placing a pure sample of HPMC in the humidity controlled oven showed that up 
to 400 hours at 60% relative humidity the HPMC did not increase in weight 
(Figure 4.18).  The observed decrease in water uptake may therefore be due to the 
non-aqueous solvent propylene glycol.  Increasing the concentration of the HPMC 
in the ISGM system meant the amount of propylene glycol in the ISGM system 
had decreased.   
 
It was noted that after 400 hours it appeared as though the rate of water absorption 
of the ISGM system was about to plateau out (Figure 4.17).  Therefore the 
humidity level was increased to 80% to determine whether a further increase in 
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humidity would result in an increase in water absorption.  Though such studies are 
not required in stability guidelines, this effect was investigated to determine 
whether an increased humidity level would result in an increased water intake.  As 
shown in Figure 4.17 after 400 hours the water absorption increased substantially.  
Water absorption also increased slightly for the pure HPMC (Figure 4.18). 
 
The percentage gain in weight shown in the following graphs (Figures 4.17 – 
4.19) is that averaged over 3 samples and the error bars shown represent their 95% 
confidence interval.  For clarity the errors bars are not shown on all the profiles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 – Gain in Weight Due to Water Absorption for the ISGM System Containing 
Varying Concentrations of HPMC (n=3) 
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Figure 4.18 – Gain in Weight Due to Water Absorption for HPMC (n=3) 
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Figure 4.19 – Gain in Weight Due to Water Absorption for ISGM System 
Containing Various Concentrations of Polycarbophil (n=3) 
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Varying the amount of polycarbophil in the continuous phase (while keeping the 
HPMC concentration fixed at 10%) did not make a significant difference to the 
water absorption (Figure 4.19).  Increasing the humidity level to 80% after 400 
hours also resulted in an increase in water absorption (Figure 4.19).  The humidity 
was increased to 80% to determine whether the increased humidity level resulted 
in an increase in water uptake.  As explained earlier in this section, though such 
studies are not part of the stability guidelines, the increased humidity level was 
investigated for scientific interest.  The exaggerated increase in the humidity 
conditions (80%) led to the expected result of an increase in water uptake. 
 
Results of the studies where the amount of polycarbophil in the ISGM system was 
varied showed a marginal trend where an increase in the polycarbophil 
concentration resulted in a slightly lower water intake.  These differences were not 
significantly different at the earlier time points (differences were within the 95% 
confidence interval as shown in Figure 4.19).  However, the differences between 
the profiles became more significant at longer times.  The propylene glycol, which 
is a hygroscopic solvent, must be the principal cause of the water absorption.  This 
conclusion is supported by the fact that increasing the concentration of the HPMC 
or polycarbophil meant the amount of propylene glycol in the ISGM system had 
decreased.  Consequently the lower propylene glycol concentration led to a 
decrease in water intake as seen in Figure 4.17.  
 
The absorption of water upon standing is not a desirable attribute of the ISGM 
system as this will lead to gelling of the ingredients resulting in difficulty of 
injecting the formulation.  
 
An additional experiment was conducted to check whether water absorption 
occurred in sealed vials (as described in Section 3.3a of Chapter 3).  A weight 
increase did not occur indicating that sealed vials were effective in preventing 
moisture intake thus preventing gelling of the suspension.  
 
It was concluded that any formulation must be stored in sealed containers and 
must not be exposed for long periods to the atmosphere.  This was due to the 
inherent water absorbing nature of the product ingredients.   
 127
There are other methods to measure water intake such as the Karl Fischer titration 
but this did not prove necessary as the monitoring of the weight clearly showed 
the ISGM system was absorbing water from the atmosphere.  Solvent evaporation 
was not an issue as the experiment was carried out at a temperature of 25ºC and 
given the boiling point of propylene glycol is much higher at 188ºC (Section 
4.1a), its vapour pressure at  25ºC is expected to be very low. 
 
 
 
4.3b Chemical Stability  
i. Hydrophilic Polymer (HPMC) 
A chemical stability study was conducted on the hydrophilic polymer, HPMC that 
formed part of the ISGM system.  This method, which was HPLC-based, was not 
a stability indicating assay and therefore the method was not validated.  The study 
was conducted to determine whether any changes in the HPMC’s HPLC profile 
occurred as a result of possible degradation.  If degradation was to occur, then 
changes to the peak height and geometry in the chromatogram would be observed. 
At the time of the study this means of assessment was deemed adequate to 
monitor the stability of HPMC.  However, if the ISGM system is developed with 
the intention of creating a commercial product, then a validated stability 
indicating method would need to be developed for this component of the ISGM 
system.  
 
Studying the potential for degradation of the polymer in the ISGM system is 
important as any degradation that may occur could compromise its role as a 
gelling agent in the ISGM system.  For example degradation to smaller fragments 
may influence gelling properties and hence limit the useful shelf-life of the 
material.  The chemical stability of the HPMC was monitored by size exclusion 
chromatography (SEC).   
 
SEC is a standard chromatography technique used to determine molecular 
weights.  Size exclusion works by separating the polymer molecule according to 
their hydrodynamic volume.  The hydrodynamic volume can be correlated to the 
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molar mass which is determined by calibration or by using molar mass sensitive 
detectors (Trathnigg, 2000). 
 
In SEC, the column is packed with a material having a well-defined distribution of 
pores.  These pores influence elution time of the molecules passing through them.  
Larger molecules elute first as they are too large to penetrate the pores and hence 
flow quickly through the SEC column.  In contrast, the smaller molecules are able 
to penetrate these pores, consequently increasing the time required to exit the 
column as a diffusional process is then set up where the smaller molecule 
penetrate or exit the porous network. 
 
In this investigation, initial polymer stability studies were conducted on an HPLC 
instrument using a T load column (as described in Section 3.3b i).  This method 
did not give any peaks in the resulting chromatrogram.  Numerous attempts were 
made to try and observe a peak where the mobile phase was altered and the 
sample concentration was altered but peaks were not detectable using the RI 
detector.   
 
Another method was, therefore, investigated to try and detect a peak due to 
HPMC.  There have been reports in the literature for using an ultrahydrogel 
column (Crowley et al., 2002; Vijayalakshmi et al., 2005) or TSK-Gel column 
(Wittgren et al., 2005; Liu et al., 2004) to analyse high molecular weight 
polymers.  Therefore an ultrahydrogel 1000 column was purchased and used on 
the Waters HPLC system (Section 3.3b i).   
 
A 0.1% (w/w) sample of HPMC was injected into the HPLC resulting in the 
detection of an asymmetrical peak at 7.4 minutes (Figure 4.20).  Due to the shape 
of the peak, it was thought the peak must be due to the HPMC as this polymer has 
a broad molecular weight.  An asymmetrical peak usually indicates a molecule 
with a broad molecular weight.   
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Figure 4.20 – Chromatogram of HPMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Water (which was initially used to prepare the HPMC sample) itself was analysed 
and the peak at 7.4 minutes was no longer observable indicating the peak had to 
be HPMC.  This was further confirmed by halving the HPMC concentration.  The 
resulting spectrum gave a peak with the same retention time but a decreased peak 
intensity as expected. 
 
Upon successfully identifying the SEC-based HPMC peak, stability studies of the 
hydrophilic polymer over time in accelerated conditions could then be conducted.  
To obtain an indication of how degradation of HPMC might appear in a 
chromatogram, a chromatogram of a sample of HPMC was run after it had been 
subjected to hydrolysis by addition of acid (see Section 3.3b i in Chapter 3 for 
details).  The resultant chromatogram (Fig. 4.21 (a)) gave a peak which had 
decreased strongly in intensity relative to the peak detected from untreated HPMC 
(Fig. 4.21 (b)) indicating that hydrolysis and therefore degradation of the HPMC 
had occurred.  The other major difference was that, though the peak remained 
asymmetrical, the geometry of the peak had altered.  A more dominant shoulder 
peak had appeared prior to the main peak (Figure 4.21(a)) which is most likely 
due to the reduction in size of the overlying main peak.   
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Figure 4.21 – Comparison of the Acid Treated HPMC Chromatogram (a) and the 
Untreated HPMC Chromatogram (b).  Both Traces are on the Same Response Scale 
where the Response value for the Acid Treated HPMC Peak (a) is 4 mV and the 
Response Value of the Untreated HPMC Peak (b) is 0.9 mV. 
(a) 
(b) 
 
The stability study which tested how stable the HPMC was on standing over time 
was conducted on samples of HPMC that were dispersed in propylene glycol and 
stored in a controlled room of 40°C / 75% relative humidity for a period of 9 
months (see Section 3.3b i in Chapter 3 for a description of the experimental 
details) .  Over this period,  samples of the polymer dispersion withdrawn for SEC 
analysis showed no discernible change in the HPMC chromatogram peak profile  
taken at time zero and after periods of  3, 6 and 9 months.  This is illustrated in 
Figure 4.22 which gives the SEC chromatogram of the HPMC/propylene glycol 
sample prior to storage (Fig. 4.22(a)) and the HPMC spectrum at the 9 month time 
point (Fig. 4.22(b)).  The spectrum shows no easily detectable alterations in the 
intensity or shape of the peak had occurred.   
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Figure 4.22 - Comparison of HPMC Chromatogram at Time 0 Months (a) and 
HPMC Chromatogram at 9 Months (b).  Both Traces are on the Same Response 
Scale and the Response Value (i.e. Maximum Peak Height) of (a) and (b) is 4 mV. 
(b) 
(a) 
 
 
The determination of the actual molecular weight of HPMC was subsequently 
attempted (see Section 3.3b i in Chapter 3). This was achieved by taking a series 
of compounds with similar molecular shape and density (i.e. hydrodynamic 
volume) which should give a sigmoidal relationship between the Kav value and the 
logarithm of the molecular weight.  However, over a considerable molecular 
weight range this relationship should be linear.  The calibration curve was 
constructed using dextran standards as dextran being a carbohydrate is expected to 
have the closest hydrodynamic volume (compared to other standards such as 
PEG) to HPMC which is a cellulose molecule.  The Kav was calculated according 
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to Equation 4.2 (Fee and Van Alstine, 2004; Amersham Pharmacia Biotech, 
1998). 
 
 
(4.2) 
 
K (V V )
(V V )av
e o
t o
= −−
Where  
Kav  =  Distribution coefficient 
Ve   =  Volume of eluent 
Vo  =  Void volume of the column 
Vt  =  Total volume of the column 
 
The  and  of the ultrahydrogel column were found to be 3 and 12.9 mL 
respectively.  The  was the total volume of the column and the  was 
calculated as the time taken for a large molecular weight molecule to pass through 
the column (the large molecular weight molecule will be too large to travel 
through the pores and consequently travel straight through the void spaces in the 
column).  The values were calculated for each dextran standard and plotted 
against the natural logarithm of the molecular weight (Figure 4.23). 
Vo Vt
Vt Vo
Kav
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 – Relationship Between Kav and ln(Molecular Weight) for 
Dextran Standards
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The Kav value for HPMC was calculated to be 0.4609.  According to the 
calibration curve in Figure 4.23, a Kav value of 0.4609 means HPMC should have 
a molecular weight of approximately 255 250.  There are reported discrepancies in 
the molecular weight of HPMC.  According to Hsaio (1985) HPMC has a 
molecular weight ranging from 20 000 to 140 000 (Hsiao, 1985).  In contrast, 
Conte et al., (1995) reported HPMC to have a molecular weight range of 1000 to 
4000 000.  The experimentally obtained value in this study (255 250) falls within 
the molecular weight range reported by Conte et al., (1995).  The molecular 
weight of HPMC will depend on the extent of substitution and the intrinsic 
viscosity of the sample.  The Mark-Houwink equation (Equation 4.3) is used to 
calculate the molecular weight of polymers using the intrinsic viscosity.  
 
η = kMα                                                                                                                                                                        (4.3) 
 
where η is the intrinsic viscosity, k and α are constants and M is the molecular 
weight.  Therefore the intrinsic viscosity is dependant on the molecular weight of 
the polymer.  The differences in the reported molecular weights of HPMC will 
depend on the viscosity and the degree of substitution (where a greater degree of 
substitution will give an increased viscosity). 
 
As mentioned earlier in this section, the 9 month stability assessment of HPMC 
showed no apparent degradation and therefore no apparent change in the 
molecular weight.    
 
 
ii. Continuous Phase 
The chemical stability of the continuous phase was monitored by evaluation of 
viscosity.  The viscosity of the system was not observed to change significantly 
over time indicating the polycarbophil remained stable at room temperature (20°C 
in sealed vials) in the propylene glycol (Figure 4.24).   The error in each viscosity 
measurement was calculated as described in Section 4.2f.  
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Figure 4.24 – The Viscosity of the Continuous Phase over a 9 
Month Period 
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4.3c Ease of Redispersion of the ISGM System 
Redispersion studies were conducted to evaluate the ease at which the 
(sedimented) ISGM system could be homogeneously dispersed after storage.  The 
study was conducted over a period of 4 weeks where each week a sample was 
taken to assess its redispersibility.   
 
In all cases the ISGM system had redispersed to give a uniformly dispersed 
suspension with minimal effort (Figure 4.25).  The error bars on the graph 
represent + 5 seconds where the time was observed on an electronic timer. 
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Figure 4.25 – The Ease of Redispersing the ISGM System after 1, 2, 3 and 
4 Weeks of Storage.   
0
1
2
3
4
1 2 3 4
Week Number
Ti
m
e 
(S
ec
on
ds
/3
0)
 
 
The samples at week 1, 2 and 3 were fully redispersed within 30 seconds (see 
Section 3.3c in Chapter 3 for experimental details).  The sample at week 4 had a 
sediment level of 0.1 cm.  After 30 seconds the sediment level had decreased to 
0.05 cm but had not yet fully redispersed.  After the second 30 second block, the 
suspension had fully redispersed to its original form.  Duro et al. (1998), 
conducted stability studies on their suspensions and found their systems varied in 
redispersion times from 0 to 35 minutes after 15 days where their systems 
consisted of aqueous suspensions of pyrantel pamoate with the inclusion of 
HPMC or sodium CMC as stabilisers.  However, the ISGM system developed in 
this study did not require as much effort to redisperse as the suspension described 
in Duro et al.’s study.  It is difficult to make a direct comparison between the two 
systems as they are not the same – the system studied in this investigation is non-
aqueous where as the system studied by Duro et al. (1998) is an aqueous 
suspension.  However there is a considerable difference in the ease of redispersion 
between the two systems.  After 4 weeks of standing, the ISGM system developed 
in this study was fully redispersed after 1 minute which is a favourable attribute 
were it to be considered for further commercial development.  This would also 
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necessitate the addition of a proviso that the ISGM system be always shaken 
immediately prior to its use.  
 
 
 
4.3d  Appearance of the ISGM System After Administration into an Aqueous 
Environment 
 
i.  In Vitro Appearance of the ISGM System After Administration into an 
Aqueous Environment 
The ISGM system (with a dye incorporated) was injected into a cellulose medium 
to observe how the formulation might form in vivo (see Section 3.3d in Chapter 
3).  Upon injection into the cellulose medium, the ISGM system gelled to form a 
sphere shaped depot as illustrated in Figure 4.26. 
 
 
 
Figure 4.26 – Injection of the ISGM System (with a Blue Dye 
Incorporated) into a Cellulose Medium 
 
 
 
 
 
 
 
 
 
 
 
 
ii.  In Situ Appearance of the ISGM System After Administration into an 
Excised Calf Ear  
The ISGM system was also injected into the ear of a dead calf at room 
temperature.  The ISGM system was injected at a reasonably rapid rate over 20 
seconds to avoid blocking of the needle during administration as a result of the 
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polymer gelling.  Water will unavoidably enter the needle as a result of injecting 
into tissue as some tissue will part resulting in some fluid going up the bore of the 
needle.  
 
Incision of the injection site (6 hours after administration) on the carcass revealed 
the depot (sphere shaped) had gelled indicating water from the internal ear tissue 
had diffused into the formulation.  The depot, itself, was then sliced open with a 
scalpel to determine the integrity of the depot contents.  The depot was found to 
have remained intact in shape and showed the formulation had also gelled inside 
the body of the depot (Figure 4.27).   
 
 
 
 
Figures 4.27 – Injection of Formulation into the Ear of a Dead Calf 
 
 
 
 
 
 
 
 
 
 
 
 
iii.  In Vivo Appearance of the ISGM System After Administration into a Rat  
The ISGM system was also injected into a rat to determine if a gelled depot would 
form (Figures 4.28a – 4.28e).  Injection via a 22 gauge needle was made into the 
area posterior to the scapulae (Figure 4.28a).   
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4.28a  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28d – Removal of the Injected 
Depot 
4.28b 4.28c 
4.28d 4.28e 
Figure 4.28a – The Injection Site in the Shaved Region of the Rat’s Shoulder 
Figure 4.28b - Incision of the Rat 
Revealing the Injected Depot 
Figure 4.28c – Further Opening of the 
Incision Site 
Figure 4.28e – The Depot Removed From 
the Injection Site  
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The rat was dissected (6 hours after injection) to observe and remove the depot 
(Figure 4.28b and 4.28c).  6 hours after injection, the depot had successfully 
gelled (semi-solid) and was easily removed from the body (Figure 4.28d and 
4.28e).  The histology report found mild diffuse inflammation at the injection site 
of the rat.  Histology of injection sites almost always indicates inflammation.  
This can be due to the trauma of injection rather than the actual formulation 
(Baggot and Brown, 1998).  The aim of the experiment was to determine if the 
depot would form in vivo.  The results proved that the ISGM system successfully 
formed a gelled depot at the site of injection.  
 
During this investigation it was also found that the injection of the ISGM system 
did not result in bleed back of the formulation through the injection tract (which is 
clearly shown in Figure 4.26).   
 
The depot formed after injection appeared as though it would break down easily 
via a process of polymer chain disentanglement (as discussed in Section 4.2h) 
despite the presence of a high molecular weight polymer.  During the in vitro 
trials (Section 4.5), the gel was left in the dissolution apparatus to determine how 
long it would take for the gel to break down.  Four weeks after injecting the 
formulation into the dissolution apparatus, the depot appeared fluid in nature and 
was no longer viscous.  Obviously the residence time of the depot can be 
manipulated by increasing the concentration of the hydrophilic gelling agent.  
Fernandez-Vigo et al., (1990) conducted studies to show the residence time of the 
HPMC may be able to be controlled in the vitreous cavity.  Elimination of HPMC 
was established to occur by first order kinetics.  HPMC with a molecular weight 
of 86 000 had a half life of 10.4 days while the higher molecular weight HPMC 
(of 120,000) had a half life of 38.4 days (in the vitreous cavity).  This indicates 
therefore that a higher molecular weight polymer should give a longer residence 
time for the gelled depot.  Nafee et al., (2004) conducted studies to determine the 
residence time of mucoadhesive tablets.  A 180 mg mucoadhesive HPMC tablet 
had an in vitro residence time of 8 hours.  The residence time of the HPMC depot 
injected intramuscularly or subcutaneously will not be the same (as the residence 
times reported by Nafee et al. (2004) and Fernandez-Vigo et al. (1990)) as 
different sites and different dosage forms may exhibit different residence times.  
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However, it gives an indication on the relative time frame involved and the effect 
of the molecular weight will be the same regardless of the site of administration.  
The residence time of a gelled depot can be manipulated by the amount and 
molecular weight of the hydrophilic gelling agent. 
 
This study has shown that the ISGM system offers the potential as a controlled 
release bolus.  In a cellulose medium, excised calf ears and in rats, the ISGM 
system was observed to form a gelled depot.  These experiments demonstrated 
that the ISGM system was performing its physicochemical role of forming the 
depot so allowing the drug contained with it to be trapped thus acting as the 
retarding agent for its release.  It was now important to test how good a retarding 
agent the depot would be by assessing its performance using the drug propranolol. 
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4.4 Formulation and Characterisation of the Final Product 
As discussed in Section 3.4 of Chapter 3 the drug release performance of the 
ISGM system was assessed using propranolol HCl which has veterinary 
applications (Section 2.6).  The physicochemical properties of propranolol are 
given in Table 4.9. 
 
Table 4.9 - Physicochemical Properties of the Drug Propranolol 
Properties 
Drug Structure State Colour Molecular 
Weight 
Melting 
Point 
(ºC) 
Solubility pKa 
(24ºC) (20ºC) 
 
 
 
 Propranolol 
HCl 
 
 
(Thevis et al., 2001) 
Powder White 295.81 162-165  9.5 1 g in 20 mL of water 
 
 
 
 
 
4.4a Incorporation of the Drug into the ISGM System 
The propranolol was added as a solid to the propylene glycol and shaken by hand, 
followed by the addition of the hydrophilic polymer to create the ISGM system 
with drug incorporated into it.  The solubility of the drug in the continuous phase 
was found to be 0.003 g mL-1 which was determined by continuous addition of 
drug to the continuous phase until a saturated solution of drug was obtained. 
 
 
 
4.4b Differential Scanning Calorimetry (DSC) Analysis 
DSC studies were conducted to determine whether interactions between the 
excipients of the formulation and the chosen drug existed. Such interactions are 
detected by appearance, disappearance, or shifting of endothermic or exothermic 
peaks and/or variations in the relevant enthalpy values.  DSC measures the energy 
required to establish a near zero temperature difference between an inert reference 
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material and the sample when subjected to identical temperature regimes in an 
environment heated or cooled at a controlled rate.  The temperatures of the sample 
and reference are made identical by varying the power and the energy required to 
do this is a measure of the enthalpy (or heat capacity) changes in the sample 
relative to the reference.  The difference in the heat flow to a sample and reference 
is monitored against time or temperature (Verma and Garg, 2005). 
 
If interactions, as mentioned above, between the drug and the excipient exist, the 
stability and / or bioavailability of the drug may be altered i.e. there may be 
changes in the chemical nature, solubility and absorption and therapeutic response 
of the drug (Mura et al., 1995).  This may affect the safety and/or efficiency of the 
drug in the formulation.   
 
DSC is a rapid response technique which evaluates any physiochemical 
interactions between the drug and excipients and hence provides information on 
potential physical or chemical incompatibilities.  Careful interpretation of DSC 
results is required to avoid misinterpretation of the data.  To confirm whether any 
incompatibilities or otherwise do exist, DSC studies need to be used in 
conjunction with other analytical tools such as IR spectroscopy (Mura et al., 
1998).  Investigation of drug-excipient compatibility is very important but has no 
universal protocol available to conduct such investigations.   
 
DSC studies were conducted on the drug itself and physical mixtures of the ISGM 
system excipients and the drug.  The thermogram of the propranolol on its own 
showed a melting endotherm at 165°C.  The melting point peak of the drug did 
not shift and peaks did not disappear or appear in the thermograms of the HPMC 
and propranolol (Figure 4.29) as well as polycarbophil and propranolol (Figure 
4.30) indicating that interactions between these excipients and the drug did not 
appear to exist.  The thermogram of HPMC showed a very low intensity broad 
peak at 55°C (Figure 4.29).  This broad endotherm was attributed to moisture loss 
from HPMC (Ford, 1999).  Interactions also did not appear to exist between 
propylene glycol and the drug as well as the final product itself.   
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Figure 4.29 – DSC Thermogram of HPMC (A), Propranolol (B) and 
Propranolol + HPMC (C) 
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Figure 4.30 – DSC Thermogram of Polycarbophil (A), Propranolol (B) and 
Propranolol + Polycarbophil (C) 
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 144
Contrary to this finding, the in vitro studies (to be discussed in Section 4.5) 
suggested interactions may exist as the formulation was not giving 100% release 
of the drug.  The interaction must have occurred after water had diffused into the 
formulation.  Therefore DSC studies were repeated on formulations that had been 
gelled by the addition of water.  
 
The resulting DSC curve no longer revealed a melting endotherm at 165°C 
(propranolol melting point peak) but an endotherm at 146.1°C (Figure 4.31) was 
present indicating some form of interaction was occurring.  To verify the water 
was responsible for the interaction the experiment was repeated where pH buffers 
of 1 and 4.5 were added instead of water to give a gelled depot.  The release 
profile of the drug using pH 1 and 4.5 buffers as the dissolution test medium 
resulted in 100% release (see Section 4.5b vi.).  Consequently anomalies in the 
DSC thermogram should not occur.  This was found to be the case as the 
propranolol peak was observed for both pH 1 and 4.5 systems.  The introduction 
of water to the formulation resulted in an interaction between the drug and a 
formulation excipient.  A detailed discussion of the effect of pH is given in 
Section 4.5b vi.  The gel without the drug was also analysed.  The peaks at 165 or 
146.1°C were not observed indicating the interaction did involve the drug.  
 
 
 
 
 
 
 
Figure 4.31 – DSC Thermogram of Gelled Formulation 
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Interactions between propranolol and anionic polymers such as polyacrylic acids 
(for example polycarbophil) can occur (Taylan et al., 1996; Wang et al., 2003) 
(This is discussed in more detail in Section 4.5b vi.).  Therefore an interaction 
could be occurring between polycarbophil and propranolol.  Propranolol is 
effectively a cationic drug when introduced as the hydrochloride salt in which the 
propranolol itself would exist as the conjugate acid, propranolol-H+.  
Consequently there may be a propranolol-H+-anionic polymer binding interaction.  
DSC studies alone cannot confirm this interaction and so careful interpretation of 
DSC results is required to avoid misinterpretation. Use of another analytical 
technique such as IR spectroscopy is necessary to provide further evidence to 
refute or support DSC observations.  Consequently the observed interaction was 
verified by conducting an infra-red scan of the gelled ISGM to determine if any 
new absorption bands due to a possible polycarbophil-propranolol complex appear 
(see Section 4.4c). 
 
 
 
4.4c Infra-Red (IR) Analysis 
An IR study was conducted to determine whether a possible 
propranolol/polycarbophil interaction existed (as discussed in Section 4.4b) in the 
ISGM as suggested by DSC studies.  The IR spectrum of the pure drug recorded 
as a KBr disk is shown in Figure 4.32 and the band assignments described in 
Table 4.10.  
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 Figure 4.32 – IR Spectrum of Propranolol 
Propranolol Structure (Thevis et al., 2001) 
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Table 4.10 – Key for Figure 4.30 Identifying the Peaks in the IR Spectrum of Propranolol 
Frequency Assignment 
Broad and strong band due to OH 
stretches as well as N-H (and C-H 
stretches. 
3330 - 2500 
1400 – 1600 Aromatic C=C stretch 
1080 – 1360 C-N stretch 
1150 - 1080 C-O stretch 
Aromatic character due to out-of-
plane proton-carbon bending. 900 - 670 
 
 
If the drug and polycarbophil exhibit an interaction then the functional groups in 
the IR spectrum of the combined two species may reveal the emergence of new 
bands or alterations in wavenumber position or broadening when compared to the 
spectra of the pure polymer and the drug (Takka, 2003).  
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The IR spectrum of the gelled formulation was compared to the spectrum of the 
pure drug (Figure 4.33a) and polycarbophil (Figure 4.33b) (and also the spectrum 
of the formulation without the drug).  A new but weak absorption band was found 
at approximately 1557 cm
-1
 (Figure 4.33c) which is thought to be a result of salt 
formation.  The formation of a salt can occur by addition of an amine group to the 
carboxylic acid (Takka, 2003; Taylan et al., 1996).   
 
 
Figure 4.33a – The Propranolol Spectrum Showing the Absence of the        
Peak at 1557 cm -1
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Figure 4.33b – The Polycarbophil Spectrum Showing the Absence of the        
Peak at 1557 cm -1
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Figure 4.33c – New Absorption Band at 1557 cm -1 Possibly Due to the 
Propranolol / Polycarbophil Complex 
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Although the observed band was weak, the IR study has given some ancillary 
evidence to the DSC studies for showing an interaction between polycarbophil 
and propranolol.  
 
 
 
4.4d   Electrospray Mass Spectrometry (ESMS) Analysis 
Propranolol was also analysed on an electrospray mass spectrometer as one other 
possible means of characterising the drug.  This technique was also used in the 
degradation studies (Section 4.6a).  The propranolol electrospray mass spectrum is 
shown in Figure 4.34.   
 
 
Figure 4.34 – Electrospray Mass Spectrum of Propranolol 
260.5  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The spectrum was in agreement with the previously reported propranolol 
spectrum where the characteristic peaks of 116 (Figure 4.35), 157, 183 and 260 
(Figure 4.36) m/z were observed.  The peak at 260 m/z was the [M + H]
+
 species.  
The peak at 183 m/z is the result of elimination of water (18 amu (atomic mass 
units)) followed by elimination of the isopropyl amine group (59 amu), which 
gives a total loss of 77 amu, resulting in the structure [M + H]
+
 - 77 (Figure 4.37).  
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However a different structure for the 183 peak has also been proposed by 
Upthagrove et al.  (1999).  The structure at 183 m/z could be a result of intra-
molecular rearrangement through a 6-membered transition state, resulting in the 
addition of the 3-carbon portion of the side chain to the 2’-position located on the 
naphthalene ring (Figure 4.38).  Therefore it is possible the product ions of 
propranolol can arise from dissociation of an ether oxygen-protonated species 
rather than protonation of the amine nitrogen.  
 
 
 
Figure 4.35 – [M – ROH]+.  This Structure is Assigned to the Peak at 116 m/z 
(Thevis et al., 2001) 
R =  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36 –The Structures for [M + H]+ at 260 m/z (Upthagrove et al., 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.37 – [M + H]+ - 77 amu.  This is the Proposed Structure for the Peak at 183 m/z 
(Thevis et al., 2001) 
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 et al. (1999) Proposed Structure for the Species at 183 m/z 
 
Figure 4.38 – Upthagrove 
 
 
 
 
 
 
4.4e Ultra-Violet (UV) Analysis 
UV analysis was conducted to characterise the excipients of the final formulation.  
Propranolol (Figure 4.39) has absorbance maxima at 214 and 290 nm.  The data 
from this investigation was used for the in vitro drug release studies (Section 4.5). 
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Figure 4.39 – UV Spectrum of Propranolol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.40 – UV Spectrum of Polycarbophil 
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Figure 4.41 – UV Spectrum of Propylene Glycol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.42 – UV Spectrum of HPMC  
 
 
The polycarbophil also exhibited UV absorbance as shown in the spectrum 
(Figure 4.40).  Propylene glycol (Figure 4.41) and HPMC (Figure 4.42), in 
contrast, had no UV absorbance in the region of interest.   
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4.5 Drug Release Studies on the Final Product 
An in vitro study is one which is conducted in isolation from a living organism, 
literally “in glass” the term implies.  The biological processes and reactions are 
carried out in simulated in vivo conditions such as in synthetic mixtures of cell 
components.  An in vivo study is one which is conducted within a living organism 
(Godman and Payne, 1981). 
 
The ideal aim of an in vitro test is to achieve a 1:1 in vitro : in vivo correlation.  
The attainment of the 1:1 ratio is important as it serves as a quality control 
procedure during the manufacturing of the product.  Such tests are employed to 
assess lot-to-lot variability and product shelf life (Clark et al., 2005; Baxter, et al., 
2005; Morita et al., 2003; Ouriemchi et al., 1995; Peltonen et al., 2003; Qureshi 
and Shabnam, 2001; Schliecker et al., 2004; Schmidt and Glombitza, 1995; 
Siewert et al., 2002; Souliman, 2006). 
  
In the early 1960’s disintegration tests were the only official means of conducting 
in vitro experiments.  The tests were used to predict in vivo release and assessment 
of product performance.  Despite the disintegration test being only indirectly 
related to drug bioavailability (Cohen et al., 1990) it was still the preferred choice 
for pharmaceutical industries as the test was inexpensive and quick. 
 
Due to the advancement of research and modernisation of technology dissolution 
tests are the preferred choice of in vitro testing.  Dissolution is described as the 
process by which a solid substance enters a solvent to give a solution i.e. the solid 
dissolves in the solvent.  Upon administration, a dosage form undergoes 
dissolution into body tissue or other media and the drug will ultimately be 
absorbed into the systemic circulation (Banakar, 1992).   
 
Dissolution tests are recognised as an official in vitro test in the United States 
Pharmacopoeia (USP, 1994).  When conducting dissolution studies, several 
parameters such as geometry, dimensions and materials must be controlled to 
obtain reliable results.  The release profile is obtained by measuring the 
absorbance of the drug over time (in the case where UV spectrophotometry is 
used).  The concentration of the drug released is then calculated using the 
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absorbance values.  The dissolution tests have been successfully applied to 
conventional dosage forms.   
 
It is very difficult to completely simulate in vivo conditions in vitro (due to factors 
such as the presence of enzymes).  This is especially the case for controlled 
release formulations because they are designed for prolonged release and 
variables in in vivo conditions such as the presence and nature of food in the 
gastrointestinal tract, time of day and dosage administered may affect the drug 
release.  For example, Vidgren et al. (1991) found an oral dosage form could 
reach the intestine in 10 minutes on an empty stomach but in a fed stomach, the 
times were 119 - 285 minutes depending on the size of the meal consumed (Davis 
et al., 1984). 
 
The aim of conducting in vitro drug release studies in this research was to assess 
whether the ISGM system fulfilled its expected role of being a controlled release 
agent using the drug.  
  
 
 
4.5a Drug Release Studies Conducted on the Hanson Dissolution Apparatus 
Drug release studies were conducted on the final product (the ISGM system and 
the drug propranolol) using the Hanson Dissolution apparatus.  Initial work 
involved determining the ideal method of introducing the final product to the 
dissolution apparatus and ascertaining the reproducibility of the system. 
 
 
i. Mode of Formulation Introduction to the Hanson Dissolution Apparatus 
When the formulation was introduced from above the vessel, the milky white 
suspension (the formulation) was instantly dispersed into the dissolution test 
medium by the paddle and eventually settled onto the bottom of the vessel.  
Injection from the top also resulted in a much higher initial concentration of drug 
(Figure 4.43) which can be attributed to the greater surface area of the dispersed 
formulation.  The greater surface area allows more of the drug to be released 
compared to the depot introduced at the bottom of the vessel which has a much 
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smaller surface area.  Injection of the formulation onto the bottom of the vessel 
produced a globular shaped depot.  Therefore the ideal method of introducing the 
formulation is by injection at the bottom of the vessel, avoiding contact with the 
paddle.  There was a visible effect of the paddle on the depot, as the top of the 
depot appeared to be disturbed by shear from the rotating paddle (for both modes 
of introducing the formulation to the vessel).   
 
The errors shown in the following graphs (Figures 4.43 – 4.56) represent the 
standard deviation of the percentage release as calculated from the 6 replicates. 
 
 
 
Figure 4.43– Effect of Introducing the Formulation at the Top or Bottom of 
Vessel on the Drug Release Profile (n=6) 
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ii. Effect of the Hydrophilic Gelling Agent 
These experiments were conducted to show the role of the hydrophilic gelling 
agent in controlling the release of drug into the receptor medium. The omission of 
the hydrophilic gelling agent from the formulation caused instantaneous release of 
the drug whereas inclusion of the gelling agent gave a much slower release profile 
indicating the gel was retarding the release of the drug (Figure 4.44).  Upon 
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injection of the formulation without the hydrophilic gelling agent, the suspension 
spun with the rotating blade and within 20 minutes had completely dispersed and 
dissolved.  This was reflected in the spectrophotometric results where within 10 
minutes complete release of the drug had occurred (Figure 4.44).  In contrast the 
formulation with the gelling agent exhibited sustained release and had not reached 
60% release after even 2 hours (Figure 4.44). 
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Figure 4.44 – Effect of Hydrophilic Gelling Agent on Drug Release Rate (n=6) 
 
During the run it was found the drug release did not reach the expected 100%.  
This was found to be the case for each run where the release profile reached a 
maximum of approximately 80% (Figure 4.44).  It was thus determined that the 
100% release was not obtained due to some form of drug interaction in the 
formulation.  It is possible the propranolol which is a cationic drug may have 
formed a complex with the polycarbophil as this is an anionic polymer.  However 
as described in Section 4.4b, initial DSC results had indicated interactions 
between the drug and polymer did not exist.  The DSC experiment was repeated 
but with addition of water to the system to determine if the presence of water in 
the formulation was responsible for the interaction.  The introduction of water 
proved to have an effect (Section 4.4b) indicating an interaction between the 
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polycarbophil and the drug may have occurred.  To ensure the maximum release 
obtained was not due to an artefact of incomplete incorporation of the correct 
amount of drug, a drug release experiment was conducted without the 
polycarbophil in the continuous phase.  In this case, 100% release of the drug was 
observed.  A DSC analysis of the formulation (where 100% release was not 
observed) remaining in the glass tube at the end of the in vitro release experiment 
was carried out.  The peak at 146°C was found indicating an interaction may be 
occurring and thus why full release of the drug was not observed. 
 
The effect of changing the gelling agent to an anionic polymer (sodium CMC and 
xanthan gum) was also investigated as discussed in Section 4.5b x. 
 
 
iii. Basket Method (USP Apparatus I) 
The basket method was investigated (see Section 3.5a iii in Chapter 3 for 
experimental details) but proved not ideal as introduction of the formulation into 
the basket posed problems.  This was because the basket must be held in the 
dissolution test medium when injecting the formulation to allow the formulation 
to gel upon contact with water.  However, this was not successful as the 
formulation did not gel instantaneously upon contact with the dissolution test 
medium and consequently the formulation ran out through the pores in the basket 
and slowly settled towards the bottom of the vessel.  Upon stirring, the 
formulation became dispersed and resembled the dissolution profile of the 
formulation when it was injected from above the vessel (Figure 4.43).  The basket 
method also proved disadvantageous in regard to agitation of the gel depot.  As 
the basket was spinning around, the gel depot was also spinning around thus 
increasing chances of disturbing the depot.  This caused the pores in the basket to 
become clogged with the gelling agent ultimately affecting the diffusion of the 
drug from the gel system.  As a result, the release profile using the basket was 
variable (Figure 4.45). It was thus abandoned as a viable method.  
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Figure 4.45 – Drug Release Experiment Conducted using the Basket Method (n=6) 
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The rotating cylinder (Apparatus 6) is used for the assessment of drug release 
from transdermal patches (USP, 1994).  The difference between this apparatus and 
the basket is that the basket is replaced with a steel cylinder.  With a rotating 
cylinder, the adhesive side of the transdermal patch is placed on a piece of 
cuprophan (membrane).  The system is then attached onto the exterior of the 
cylinder which is then placed into the dissolution test medium.  This method 
would not allow the system to have a constant surface area and the system would 
be disturbed by the rotating motion of the cylinder. 
 
 
iv. Reproducibility of Release Trials Conducted on the Hanson Dissolution 
Apparatus 
As a result of the above trials using the Hanson dissolution apparatus, it was 
obvious that this approach of investigating in vitro release was proving 
unsuccessful as results were not reproducible (where each run involved 6 
replicates to check the consistency of the results).  There was a significant 
observed variation for intra-day trials (Figure 4.46).  Injecting the formulation 
directly into the vessel was not regarded as an ideal method to conduct in vitro 
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trials as the propensity for the ISGM system to behave unpredictably is far greater 
due to the actions of the stirrer causing varying surface area of the depot 
generated.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.46 – Intra-Day Reproducibility using the Hanson Dissolution Apparatus 
(Mean Curve of 6 Samples) 
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There are numerous reports in the literature indicating the considerable level of 
variability and unpredictability in dissolution profiles where a stirrer has been 
used (McCarthy et al., 2004; Kukura et al., 2004; Cox et al., 1982; McCormick, 
1995; Moore et al., 1995).  The mass transfer in a stirred system will be dependent 
on the fluid flow and hydrodynamics.   
 
With dissolution testing many solid dosage forms will disintegrate into smaller 
fragments and particles.  These particles will continually decrease in size during 
the course of the dissolution, thus changing the surface area from which the drug 
can diffuse. 
 
Cammarn and Sakr (2000) reported differing dissolution rates with differing size 
of the dosage form.  They attributed this to the increased linear velocity around 
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the dosage form and an increased cross-sectional area blocking the flow.  
Therefore the shape of the dosage form (i.e. length, thickness and width) will 
affect the dissolution profile.  Injection of the formulation did not give consistent 
shapes, adding to the variability of the release profile. 
 
The uncontrolled variability in the dissolution test may also be a result of the 
hydrodynamic factors for example, fluctuations in flow introduce random 
variations in factors such as de-agglomeration of particles and mass transfer 
(Kukura et al., 2004). 
 
A different method of conducting in vitro trials was thus required.  Any new 
method should ensure the surface area of the exposed depot to the dissolution test 
medium remains fixed over the period of the release experiment.  The injected 
formulation must also remain isolated from the stirrer to prevent spurious 
hydrodynamic factors influencing the release. 
 
 
 
4.5b Drug Release Studies Conducted on the Modified Dissolution 
Apparatus 
As mentioned in Section 4.5a, the Hanson Dissolution Apparatus was not an ideal 
means of carry out drug release experiments.  There was variation in the results as 
a result of the depot being exposed to the effects of the stirrer.  Furthermore, there 
were issues regarding the surface area of the depot, where the surface area did not 
remain fixed during the release experiment as a result of swelling. 
 
A new means of carrying out drug release studies was therefore required.  Initially 
dialysis membranes with clips on either end were investigated (but not used any 
further).  The formulation was injected into a dialysis bag and the ends of the bag 
were sealed off with plastic clips.  The dialysis bag was then placed into the 
dissolution test medium.  In this case, though the surface area of release remained 
fixed, there was no space to allow the gel to expand as a result of swelling.  
Therefore this approach was not ideal.   
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A dialysis membrane enclosed by a plastic frame was also investigated.  This 
provided sufficient room for the gel to swell, but, had the drawback that the 
surface area did not remain fixed.  This approach was also abandoned. 
 
Clearly the dialysis membrane would be an ideal means to carry out release as it 
has the potential to maintain a fixed surface area.  However, accommodation for 
swelling is needed so that the depot can expand.  Therefore a novel means of 
carrying out release was developed by having a glass tube with a dialysis 
membrane at one end.  The injected formulation would have a fixed release 
interface and at the same time the glass tube would allow for swelling in the axial 
direction only. 
 
As a result, in this part of the study in vitro drug release studies were conducted 
on a modified dissolution apparatus (see Figures 3.7a and 3.7b in Chapter 3).  The 
modified dissolution apparatus allowed the formulation to be “protected” from the 
stirrer (paddle) and the apparatus also ensured the drug diffusion site had a fixed 
surface area. 
 
 
i. Reproducibility of Release Trials Conducted on the Modified Dissolution 
Apparatus 
Both intra- and inter-day trials produced reproducible release profiles (Figures 
4.47 and 4.48) over the 6 replicates for each of the 3 runs separate runs.  100% 
release of the drug was not observed (as discussed in Section 4.5a ii). 
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 Figure 4.47– Intra-Day Reproducibility usi
 
ng the Modified Dissolution Apparatus 
(Mean Curve of 6 Samples) 
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10
20
30
40
50
60
70
80
90
1
0 1000 2000 3000 4000 5000 6000
Time (mins)
Pe
rc
en
ta
ge
 R
el
ea
se
 (%
)
00
Figure 4.48 – Inter-Day Reproducibility using the Modified Dissolution Apparatus 
(Mean Curve of 6 Samples) 
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ii. Effect of the Hydrophilic Gelling Agent 
As expected the presence of the gelling agent markedly reduced the drug release 
rate (as described in Section 4.5a ii) (Figure 4.49).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.49 – The Effect of the Hydrophilic Gelling Agent on the Drug Release Profile 
(n=6)
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It was at this stage after developing the new modified dissolution apparatus and 
confirming its inter- and intra-day reproducibility with respect to drug release to a 
satisfactory standard, that subsequent release experiments were carried out for 
approximately 600 minutes.  This was chosen because at this stage, approximately 
50% of the drug had been released (Figure 4.48).  This was considered adequate 
to define the profile and allow comparisons between different profiles run under 
different conditions.  This time period was also ideal for the modelling of the 
release data conducted in Section 4.5c as modelling of release is generally 
conducted up to 60% release (Nam et al., 2004; Perez-Marcos et al., 1996).   
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iii. Effect of Volume of Water in Tube 
The addition of water to the glass tube prior to formulation introduction was 
investigated to determine whether the formulation in a pre-gelled state had any 
effect on drug release rates.  In the case of a depot where water was not 
introduced, the gel progressively formed as water diffused into the depot from the 
dissolution test medium.  It was apparent that the more water that was added, the 
slower rate of diffusion of the drug within the gel to the surface from which it can 
be released (Figure 4.50).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The addition of water prior to release resulted in the depot having a larger volume 
than that for the depot where water was not added before release.  Consequently, 
the drug had a greater distance to travel before it reached the diffusion site (i.e. the 
dialysis membrane).  Therefore the primary difference between the two systems 
was the volume of the depot during the release of the drug.  The more water added 
to the system prior to release, the greater the volume of the depot, the further the 
Figure 4.50 – Effect of Volume of Water in Tube on Drug Release (n = 6) 
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drug had to diffuse to reach the release interface, and the slower rate of diffusion 
of the drug within the gel to the surface from which it can be released. 
 
It is also apparent in the release profiles that drug release was not instantaneous.  
The observed lag time may be due to the time taken for the water to diffuse into 
the formulation and for the gelling agent to hydrate.  
 
 
iv. Effect of Tube Height 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.51 – Effect of Tube Height on Drug Release (n = 6) 
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Altering the height of the tube containing the formulation was investigated to 
determine whether a change in the distance between the stirrer and the diffusion 
surface affected the drug release rate.  Ideally, the distance should not affect the 
release as the stirrer is merely employed to homogenise the test system and thus 
the position of the donor chamber should not matter.  This was observed to be the 
case (Figure 4.51) as the slope of the release curves was constant with height of 
the tube. 
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Another means of assessing the “closeness” or similarity of the dissolution 
profiles is by calculating the difference factor between the two curves (Moore and 
Flanner, 1996).  This method calculates a difference factor f1 (Equation 4.4) and 
similarity factor f2 (Equation 4.5) to compare the dissolution profiles. 
 
The difference factor f1 represents the percentage error between the two curves.  If 
the percentage error is calculated to be zero then the two dissolution profiles can 
be said to be equal.  The dissolution profiles can be said to be similar if f1 is in the 
range of 0-15. 
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where  
f1 = difference factor 
n = number of points 
R  = reference assay at time point t t
T  = test assay at time point t t
 
The similarity factor f2 is the logarithmic transformation of the sum of the squared 
error and represents the similarity between the two curves.  If f2 is found to be 100 
then the two dissolution profiles can be said to be equal.  For two dissolution 
profiles to be similar, the f  value must be in the range of 50 - 100. 2
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where 
 = similarity factor f2
n = number of points 
R  = reference assay at time point t t
T  = test assay at time point t t
 167
Consequently though a graphical representation of the dissolution profiles may 
show how similar the curves are, it can cause problems in regards to quantitating 
the closeness.  Therefore, this comparative mathematical tool, allows one to 
comment on the similarity between the curves.   
 
As mentioned earlier in this section, the effect of the height of the tube did not 
appear to have an effect on the release profile (Figure 4.51).  This was tested using 
the mathematical model to calculate the difference factor f1 and the similarity 
factor f2 (Table 4.11) (the reference assay was the 0.7 cm tube height).   
 
 
Table 4.11 - f1 and f2 Values for Effect of Tube Height  
f1 f2
3.38 89.16 
 
 
Consequently, because the difference factor f1 is close to 0 and the similarity 
factor is in the accepted range, the two dissolution profiles for the effect of tube 
height can be said to be similar. 
 
 
v. Stirring Rate 
The effect of stirring speed on the release rate of propranolol is shown in Figure 
4.52.  Increasing the stirring speed from 50 to 100 to 150 RPM resulted in slightly 
faster drug release as expected.  Moore et al. (1995) investigated various stirring 
speeds from 20 – 80 RPM and found increasing stirring rates gave a faster release 
rate.  They attributed the faster release to the thickness of the boundary layer at 
the surface of the gel which had formed due to the accumulation of disentangled 
micelles.  The thickness of this boundary layer decreased with increasing stirring 
speeds and the disentangled micelles accumulating at the gel surface would be 
removed faster at the higher stirring speeds.  The drug was thus released at a faster 
rate.  In the current case the propranolol system is enclosed by a membrane but 
there will be a static boundary layer on the dissolution test medium side of the 
dialysis membrane leading to non-zero drug concentrations at the interface.  
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Increased stirring rates may “thin” this boundary layer and therefore increase the 
release rate as observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The similarity and difference factors between profiles (the reference assay was 
100 RPM) were calculated using Equations 4.4 and 4.5 and the values are shown 
in Table 4.12.  
 
Table 4.12 - f1 and f2 Values for Effect of Stirring Rate 
Stirring Rate f1 f2
50 RPM 4.32 86.67 
150 RPM 7.94 77.92 
 
The dissolution profiles for each stirring rate can be said to be similar.  However, 
it can be seen that the increased stirring rate of 150 RPM resulted in the profile 
being less similar than the profile at 50 RPM (but can still be regarded as similar 
as the values are within the ranges specified in Section 4.5b iv). 
 
Figure 4.52 – Effect of Stirring Rate on Drug Release (n = 6) 
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vi. Effect of pH of the Dissolution Test Medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An effect on drug release was observed when the pH of the dissolution test 
medium was altered (Figure 4.53).  The constituents of the final formulation 
which may be affected by the pH are the drug propranolol and the viscosity 
inducing agent polycarbophil, so, pH may play a decisive role in the drug release 
capability of the formulation as both possess acid-base properties.  Upon 
investigation of the pH effect, it was found the lower pH resulted in faster release.  
It has been reported (Taylan et al., 1996; Wang et al., 2003) that interactions 
between propranolol and anionic polymers such as polyacrylic acids (for example 
polycarbophil) can occur.  HPMC is not affected by pH (Perez-Marcos et al., 
1996).  The propylene glycol should not affect drug release as it is a non-ionic 
compound.  Hence, the change in release rate is likely due to the polycarbophil 
and/or drug.  Polymers such as polycarbophil which have a carboxylic group are 
affected by the pH (Wang et al., 2003).  
 
For instance, at pH 1 the polycarbophil would almost totally be non-ionised as the 
pKa of polycarbophil is 4.3 (Bologna and Levine, 2000).  The polycarbophil will 
Figure 4.53 – Effect of pH of Dissolution Test Medium on Drug Release (n = 6) 
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therefore not hydrate and release of the drug will be almost completely controlled 
by the HPMC (the compact nature of the dosage form may also retard the release 
rate).  Full release of the drug should be however observed as the polycarbophil 
being in its non-ionised form will not interact with the drug as it does in the ISGM 
system and this was observed to be the case. 
 
The Henderson-Hasselbalch equation (Equation 4.6) is used to calculate the pH 
and also the extent of ionisation (Martinez and Amidon, 2002; Driscoll, 2003; 
Ansel and Popovich, 1990).  The Henderson-Hasselbalch equation was thus 
rearranged to calculate the percentage ionised (Equation 4.7). 
 
 
pH =  pKa + log [salt]
[acid]
pH =  pKa -log [acid]
[salt]
pKa -  pH =  log [acid]
[salt]
10 [acid]
[salt]
[salt]10 [acid]
Fraction of [salt] [acid] 1
(pKa pH)
(pKa pH)
−
−
=
=
+ =
(4.6)   
 
 
 
 
 
 
 
 
 
 
 
 
[acid] 1 [salt]
[salt]10 1 [salt]
[salt]10 [salt] 1
[salt](10 1) 1
[salt] 1
1 10
(pKa pH)
(pKa pH)
(pKa pH)
(pKa pH)
= −
= −
+ =
+ =
= +
−
−
−
−
 
 
 
 
 
 
 
 
 
[salt] 1 [acid]
(1 [acid])10 [acid]
10 - [acid]10 =[acid]
[acid](1 10 ) 10
[acid] 10
1 10
(pKa pH)
(pKa pH) (pKa pH)
(pKa pH) (pKa pH)
(pKa pH)
(pKa pH)
= −
− =
+ =
= +
−
− −
− −
−
−
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% Ionised [salt]
[acid] [salt]
% Ionised
1
1 10
10
1 10
1
1 10
% Ionised
1
1 10
10 1
1 10
% Ionised
1
1 10
1
% Ionised 1
1 10
(pKa pH)
(pKa pH)
(pKa pH) (pKa pH)
(pKa pH)
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(pKa pH)
(pKa pH)
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= +
+ + +
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−
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−
−
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(4.7) 
 
 
It should be noted that this formula when used to calculate the percentage of 
ionisation for an acid, is strictly only applicable to monoprotic acids.  
Polycarbophil is a polymer with more than one carboxylic group and each of these 
groups are separated by a methylene group.  Therefore polycarbophil can be 
described as a polyprotic acid.  As mentioned earlier in this section, the pKa of 
polycarbophil was reported to be 4.3 (Bologna and Levine, 2000).  However this 
is only an estimate and not an accurate value due to the polycarbophil being 
polyprotic.  The calculation of the pKa for a polyprotic acid is complex as when 
one carboxylic group comes off, it will affect the pKa of the remaining protonated 
groups on the polymer.  Consequently each time a carboxyl group is removed, the 
pKa will change.  Therefore the weakness of this equation is that it can only be 
taken at best as an estimation of the percentage ionised.   
 
At pH 4.5 approximately 60% of the polycarbophil will be ionised (calculated 
according to Equation 4.7).  Therefore there will be some interaction between the 
drug and polycarbophil.  The pH 4.5 dissolution test medium was created using 
phosphate buffer.  It has been reported (Mitchell et al., 1990; Perez-Marcos et al., 
 172
1996) the presence of phosphate ions can retard the hydration of HPMC leading to 
an increased release rate.  This factor may explain why the release rate of the drug 
at 1 and 4.5 were closer than expected due to the additional effect of phosphate.  
 
When distilled water was employed as the dissolution test medium, the 
polycarbophil will be 99% ionised.  Therefore the polycarbophil will hydrate and 
retard the release of the drug as well as interacting with the drug. 
 
The formation of complexes between cationic drugs and anionic polymers is 
documented (Wang et al., 2003).  Propranolol can form an anionic-cationic 
complex with polyacrylic acid affecting the drug release from the matrix (Perez-
Marcos et al., 1994; Perez-Marcos et al., 1996; Wang et al., 2003) as explained in 
Section 4.4b.  This interaction would explain the observation of the inability of 
the formulation to release the total amount of the drug.  This was confirmed by 
conducting a DSC analysis of the formulation remaining in the glass tube at the 
end of the in vitro release experiment (Section 4.4b).  A peak at 146°C was found 
indicating there may be an interaction occurring. 
 
Propranolol is a weakly basic drug with a pKa of 9.5 (see Table 4.9).  Although 
the dissolution of the drug into the distilled water (pH = 6.85) will lead to the 
dissociation of some propranolol-H+ into free propranolol and H+ which would 
reduce the pH (measured pH = 6.5), the dissociation is negligible so that the 
equilibrium will lie mainly to the left, i.e. the drug will exist mainly in its 
protonated form when dissolved in the distilled water.   
 
The graphical representation of the dissimilarity of the dissolution profiles (the 
reference assay was pH 6.85) was verified by calculating the similarity and 
difference factors using Equations 4.4 and 4.5. 
 
Table 4.13 - f1 and f2 Values for Effect of pH on the Dissolution Test Medium 
pH f1 f2
4.5 23.18 49.98 
1 28.07 47.46 
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The release profiles at each pH were different from each other especially for the 
case where a pH 1 dissolution test medium was used.  This was also reflected in 
the f1 and f2 values (Table 4.13) which indicated the profiles were dissimilar from 
each other - more so in the case for the pH 1 dissolution test medium. 
 
 
vii. HPMC (Gelling Agent) Concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.54 – Effect of HPMC Concentration on the Drug Release Profile (n = 6) 
0
60
50
40
30
20
10
0 100 200 300 400 500 600 700
Time (mins)
Pe
rc
en
ta
ge
 R
el
ea
se
 (%
)
25% HPMC
 
Increasing the hydrophilic gelling agent concentration should decrease the drug 
release rate (Reza et al., 2003; Tapia-Albarran and Villafuerta-Robles, 2004) 
which was proven to be the case as shown in Figure 4.54.  A higher HPMC 
concentration resulted in a thicker gel slowing the diffusion of the drug.  The 
appearance of the suspension prior to injection and at the end of experiments was 
recorded as shown in the Table 4.14. 
 
10% HPMC 5% HPMC
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Table 4.14 – Effect of HPMC Concentration on the State of the Formulation Prior to Injection and 
at Completion of the Experiment  
Observation HPMC 
Concentration 
(% w/w) Prior to Injection Completion of Experiment 
5 Very fluid Watery depot 
10 Fluid Gelled depot 
25 Thick.  Barely fluid. A thick unmoveable depot 
 
 
At the completion of each experiment the depot was poured out to observe its 
fluidity.  The 5% HPMC formulation poured out with ease much like water.  This 
indicated a very weak gel had formed, consistent with the fast release of the drug 
from this system.  With 10% HPMC, the depot was more viscous, with a slower 
release rate.  The 25% HPMC formulation could not be poured as it was very 
thick and had a much slower release rate than the 5% HPMC formulation.  
 
The Moore and Flanner Equations (Equations 4.4 and 4.5) were used to calculate 
the difference and similarity factors (Table 4.15) (the reference assay was 10% 
gelling agent concentration). 
 
Table 4.15 - f1 and f2 Values for Effect of Gelling Agent Concentration 
Gelling Agent (HPMC) 
Concentration f1 f2
5% 12.48 65.66 
25% 45.14 40.71 
 
 
In the case of the formulation where a 5% gelling agent was used, the release 
profile can be said to be just within the range of being similar.  The difference 
factor f1 was found to be 12.48 (accepted range 0-15% - as discussed in Section 
4.5b iv) and the similarity factor f2 65.66 (accepted range 50 - 100).  The 
difference is more apparent in the graphical representation of the profiles (Figure 
4.54).  When the gelling agent concentration was increased to 25%, it resulted in 
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 value of 45.14 and an fan f1 2 value of 40.71 (Table 4.15). This strongly indicated 
that the two release profiles were indeed very different. 
 
 
viii. Polycarbophil (Viscosity Inducing Agent) Concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As expected, increasing the polycarbophil concentration resulted in a slower rate 
of release of the drug (Figure 4.55).  Polycarbophil is a hydrophilic polymer and 
therefore will also thicken in the presence of water.  Therefore increasing amounts 
of polycarbophil will result in a more viscous gel (due to hydration of the 
hydrophilic polymer) thereby decreasing the drug release rate.  In the case of the 
formulation containing 0.5% polycarbophil, a lag time was not observed as a less 
viscous gel had formed. 
 
The similarity and difference factors were similar (just within the accepted range 
discussed in Section 4.5b iv) to one another between the release profiles 
(Equations 4.4 and 4.5 and Table 4.16) (the reference assay was 0.67% 
Figure 4.55 – Effect of Polycarbophil Concentration on the Drug Release Profile (n = 6) 
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polycarbophil).  The differences between the profiles were more apparent in the 
graphical representation (Figure 4.55). 
 
Table 4.16 - f1 and f2 Values for Effect of PCP Concentration 
PCP Concentration f f1 2
0.5% 14.78 67.00 
1% 12.26 66.46 
 
 
 
ix. HPMC Viscosity Grade 
 
Figure 4.56 – Effect of HPMC Grade on the Drug Release Profile (n = 6) 
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The effect of the viscosity grade of the HPMC on the drug release rate was 
investigated.  HPMC 90SH has a higher viscosity than HPMC 60SH (for an 
equivalent amount of material dispersed in the formulation which gels).  The 
graph (Figure 4.56) shows the higher viscosity grade HPMC resulted in a 
marginally higher drug release (though the increase was close to the margin of 
error), contrary to what was predicted, as the high viscosity grade HPMC should 
give a slower release.  Upon initial contact with water, HPMC 90SH should be 
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more viscous than HPMC 60SH thus producing a thicker gel and hindering the 
release of the drug.  However as shown in the profile above (Figure 4.56) this was 
not the case.  Huang et al. (2004) conducted a full release profile on 3 viscosity 
grades of HPMC: 4 000, 15 000 and 30 000 (in HPMC matrices tablets).  Their 
results were in agreement with the findings of this study where the initial release 
was faster for the higher viscosity grade. They attributed the faster release of the 
drug in the higher viscosity grade (during the initial release process) to the lack of 
ease (compared to the low viscosity grade) that the higher viscosity grade spread 
over the matrix surface. This had the effect of leading to a brief period of 
enhanced dissolution until the higher viscosity grade HPMC began to have a more 
widespread effect on viscosity.  They also found that as the release progressed the 
lower viscosity grade HPMC ultimately gave a faster release.  The slower release 
for the higher viscosity grade would be due to the more viscous, thicker and 
stronger hydrogel structure that eventually formed (Huang et al., 2004; Zuleger 
and Lippold, 2001).  Therefore the higher viscosity grade HPMC initially gives a 
faster release but with time slows down as the strong hydrogel network forms to 
retard the drug release.  In Figure 4.56, it can be seen that the slope of the release 
curve for 90SH drops more than 60SH after approximately 170 minutes indicating 
with time the release rate for 90SH may decrease to below that of 60SH.  
 
 
Table 4.17 - f1 and f2 Values for Effect of HPMC Viscosity Grade 
f1 f2
8.34 76.12 
 
 
The release profile (Figure 4.56) is shown to be similar as shown in the results of 
the calculated values of f1 and f2 (Table 4.17) using Equations 4.4 and 4.5 (the 
reference assay was 60SH). 
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x. Different Gelling Agents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug release studies were conducted on a formulation containing a different 
hydrophilic gelling agent (all at the same concentration of 10%) to observe how 
the release profile would change.  It was observed earlier (Section 4.5a ii) full 
release of the drug did not occur as the propranolol was interacting with the 
anionic polycarbophil (viscosity inducing agent).  The gelling agent was altered to 
determine whether the presence of an anionic gelling agent would have the same 
effect (sodium CMC and xanthan gum) (PEO 303 was also investigated as an 
additional non-ionic polymer).  As shown in Figure 4.57, the different gelling 
agents produced markedly different release profiles.  PEO 303 released the drug at 
a similar rate at the start to the formulation containing HPMC, but as time 
proceeded, the release rate decreased.  Xanthan gum and sodium CMC were 
markedly different.  10% drug had not been released when over 50% of the drug 
had been released in the formulation containing HPMC. The drug may have been 
interacting with the gelling agents xanthan gum and sodium CMC.  Xanthan gum 
and sodium CMC are both anionic polymers.  As mentioned earlier (Section 4.4b) 
Figure 4.57 – Effect of the Type of Hydrophilic Gelling Agent in the Final 
Product on the Drug Release Profile (n = 6) 
0
0
0
0
0
0
0
0 100 200 300 400 500 600 700
Time (mins)
Pe
rc
en
ta
ge
 R
el
ea
se
 (%
)
6
5
4
3
2
1
PEO HPMC Xanthan Gum Sodium CMC
 179
propranolol, a cationic drug, appeared to exhibit a binding interaction with anionic 
polymers.  The amount of gelling agent in the formulation was 10% which was 
much higher than the 0.67% of the anionic polycarbophil (the viscosity inducing 
agent) which resulted in a maximum of 80% drug release.  Because the gelling 
agent is present at a higher concentration than the polycarbophil (viscosity 
inducing agent), the interaction between the propranolol and anionic gelling agent 
will be markedly greater.  This is apparent in the release profile (Figure 4.57) as 
the anionic polymers xanthan gum and sodium CMC gave slower release profiles. 
 
Table 4.18 - f1 and f2 Values for Effect of Gelling Agent 
Gelling Agent f1 f2
PEO 8.53 73.57 
Xanthan Gum 94.26 24.12 
Sodium CMC 99.97 22.82 
 
The difference and similarity factors were calculated (Table 4.18) according to 
Equations 4.4 and 4.5 (the reference assay was HPMC as the gelling agent).  PEO 
had a similar release profile to HPMC, but the release profiles for the gelling 
agents xanthan gum and sodium CMC were markedly different.  This was also 
very much evident in the release profile (Figure 4.57).  As already mentioned in 
this section, this vast difference was most likely due to the polymers being 
anionic. 
 
The in vitro drug release tests have shown that the ISGM system developed in this 
study performed its intended role as it retarded the release rate of propranolol into 
the receptor medium.  The in vitro tests constituted a means of assessing the effect 
of various factors on the release rate of propranolol but it is important to note that 
they are not indicative of the drug release behaviour in vivo.  Indeed, the in vitro 
drug release experiment imposed restrictions which would not be the case in vivo.  
For instance, the effect of swelling was minimised as it was constrained to occur 
only in the axial direction.  Were this formulation to be injected into the body, 
both radial and axial swelling of the depot can realistically be expected.  The 
release interface may also be different from the in vitro situation as drug release 
would not necessarily occur from a single interface with a fixed surface area (as 
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was the case in the experimental set-up).  Another point of difference between in 
vitro and in vivo release trials is that the release experiments in vitro were 
conducted using water as the dissolution test medium.  The release of drug in vivo 
would not occur into a “pure” water medium as there are tissues and other fluids 
which would affect the drug release as well as polymer dissolution/gelling into 
these tissues.  Distilled water has been used as a dissolution test medium for 
release experiments (Miranda et al., 2006; Anderson et al., 2001; Lee and Peppas, 
1987; Korsmeyer et al., 1983; Grassi et al., 2004; Colombo et al., 1997; Moore et 
al., 2000).  In general, in vitro drug release experiments functioned as a 
comparative tool to observe how various factors affected the release rate of 
propranolol.  It can be said that as a result of conducting the in vitro drug release 
experiments, that the ISGM system functioned as intended in that it interacted 
with water resulting in a gelled depot which retarded the release rate of 
propranolol.   
 
 
4.5c Modelling of the Drug Release Data 
Mathematical modelling of the drug release data was conducted to determine if a 
relationship between the release rate and the tested parameter existed.  The 
modelling algorithms incorporate many assumptions/parameters that are made or 
set for the system under study and serve to allow predictions on how the system 
changes its release behaviour in response to these changes in parameters.  As such 
they constitute an in silico approach to understanding drug release better.  
 
The development of mathematical models has included factors such as swelling 
and erosion into the model.  The inclusion of such factors can make the 
mathematical modelling more complex as the mathematical  equations involved 
are altered to take into account any such complications. 
  
In systems where swelling of the drug delivery matrix occurs, there are two major 
factors which control the drug release rate.  The first factor is the rate of aqueous 
medium infiltration into the matrix followed by a relaxation process, i.e. 
hydration, gelation or swelling.  The second factor is the rate of erosion of the 
matrix.  Consequently, there are two fronts – a swelling front (glassy polymer / 
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gel interface) and an eroding front (gel/medium interface).  The term front 
indicates the position in the matrix where the physical conditions change sharply 
(Colombo et al., 2000).  The distance between the gelling and swelling front 
depends on the relative rates at which these fronts move in relation to each other 
(Tahara et al., 1995).  There are many mathematical models proposed to describe 
such systems: (Peppas and Sahlin, 1989; Ford et al., 1991; Ritger and Peppas, 
1987b; Harland et al., 1988; Lee and Peppas, 1987; Korsmeyer et al., 1983). A 
discussion on examples of modelling approaches is given below. 
 
Grassi et al., (2000) proposed a new model to describe drug release from an 
ensemble of swellable cross-linked polymer particles.  The model takes into 
account factors such as particle size distribution and the visco-elastic properties of 
the polymer-penetrant system among many others.  The detailed description of the 
mechanism and phenomena, involved the use of many parameters.  Certain 
parameters were estimated due to the practical difficulty in determining their 
actual values.  The model proposed in their study was able to describe the drug 
release kinetics from delivery systems containing cross-linked polymer particles.   
  
Wu et al., (2005) developed a model to describe the transport phenomenon of a 
water soluble drug from a swellable and dissoluble tablet.  The model considers 
factors such as swelling of the matrix, water penetration and concentration 
dependent water and drug diffusion and polymer dissolution.  A parameter not 
incorporated into the model was the diffusion coefficient which is related to the 
microstructure of diffusion components and the polymer in a system.  The 
experimental results were found to be in agreement with Wu’s model, despite not 
including the parameter of the diffusion coefficient.   
 
Siepmann et al., (1999) developed a model combining diffusion, swelling and 
dissolution mechanisms.  The model was a 2-dimensional approach which takes 
into account axial and radial swelling. 
 
Another means of modelling the data is to simplify the experiment to minimise 
the effects of certain parameters.  Grassi et al., (2004) minimised the effects of 
swelling from HPMC tablets by coating the tablet with an impermeable layer so 
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that swelling occurred from one area only.  Consequently solvent penetration and 
drug release was constrained to occur in one direction only (Colombo et al., 1990; 
Colombo et al., 1996).  
 
An issue concerning modelling of in situ systems is the gels which form can often 
have irregular geometries which are difficult to predict prior to injection.  The 
modelling to take into account such phenomena thus becomes more complex as 
the irregular geometry can lead to a non-uniform drug distribution in the gel (Lin 
and Metters, 2006).   
 
Therefore there are various means of modelling release data.  As discussed earlier 
in this section, a very comprehensive approach can be taken where many 
parameters are considered such as in the study conducted by Grassi et al., (2000).  
The study by Wu et al., (2005) showed that despite not including all the 
parameters such as the dissolution coefficient, results were still in agreement with 
the model.  Therefore it is not always critical to include all the possible parameters 
in the model. 
 
In studies where both simplified and comprehensive models were used to analyse 
the data, it was found the comprehensive models gave a very good fit to the 
release data.  However, the simplified models when used anyway were still found 
to be in good agreement with the experimental data.  Therefore, simplified models 
such as the Higuchi equation are still able to be used with the confidence that that 
they will provide important information on the systems under study (Faisant et al., 
2003). 
 
In the modelling study carried out on the ISGM system developed in this research, 
the release experiment was deliberately modified to simplify the modelling 
process.  Swelling was minimised by ensuring swelling only occurred upwards 
(i.e axially).  Any radial swelling that might also have occurred was prevented due 
to the constraints of the glass tube that the ISGM system was resident in.  In 
addition, an erosion event of the polymer into the dissolution test medium could 
not occur as the polymer would not be able to diffuse through the dialysis 
membrane (Section 4.5b).  The surface area of the drug release interface would 
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thus remain fixed.  This more simplified experimental scenario for carrying out 
release experiments meant that a less complex approach of modelling the data 
could then be undertaken by using the Higuchi Equation and the power law.  
These modelling equations were deemed appropriate as they are the frequently 
used models (Sung et al., 1996; Schliecker et al., 2004; Miranda et al., 2006; 
Moore et al., 2000; Tahara et al., 1995).   
 
 Drug release rate data were thus modelled first using the widely applied Higuchi 
equation (Higuchi, 1961) (Equation 4.8a) for release from a matrix solution 
(Siepmann and Peppas, 2001). 
 
 
M
M
k tt
∞
= (4.8a) 
 
 Mt = absolute cumulative amount of drug released at time t
M∞ = ∞absolute cumulative amount of drug released at time 
 
 
k = constant which incorporates the design variables of the system 
 t = time
 
When modelling data using the Higuchi equation the following assumptions must 
be considered, (Siepmann and Peppas, 2001): 
 
• The initial drug concentration in the system is higher than the solubility of the 
drug. 
 
• The suspended drug particles must be smaller in diameter than the thickness of 
the system. 
 
• The drug diffusivity is constant. 
 
• Perfect sink conditions (i.e., the volume of medium at least 3 times greater 
than that required to form a saturated solution of a drug) are maintained. 
 
• The mathematical analysis assumes a 1-dimensional diffusion. 
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The gel depot in this study has the shape of a cylinder but because release of 
the drug is only occurring at one end of the cylinder, the geometry of the 
release interface is essentially a slab.  Consequently, release can be regarded 
as 1-dimensional diffusion.  It should be noted that this is a major 
simplification from the expected in vivo process, as in such a case, the gel 
depot would be 3-dimensional and swell in all directions.  
  
• Swelling or dissolution of the polymer is also assumed to be negligible. 
However in the case of the ISGM system being modelled, this is the main 
problem involved in applying the Higuchi equation to model the data.  
Swelling of the polymer in the ISGM system is not negligible during the 
release experiment; it increases in size as a result of swelling.  However due to 
the fact that swelling occurs only in the axial direction (because of the 
experimental constraints) and does not alter the surface area of the release 
interface, the impact of swelling  is perhaps not as critical as might be 
expected.  Therefore the Higuchi equation was used to model the data. 
 
Some of the assumptions listed above are not necessarily valid for most controlled 
drug delivery systems which incorporate HPMC (Siepmann and Peppas, 2001). 
This is because with the Higuchi equation, a linear plot of the fraction of drug 
released against the square root of time may be extract which superficially would 
signify a diffusion controlled system.  However, any modelling results should be 
viewed with caution even if such a straight line relationship is found.  The 
Higuchi equation assumes constant geometries during drug release and constant 
diffusivities of the drug and water.  HPMC swells considerably and the diffusion 
co-efficient of the drug and water are strongly concentration dependent (Siepmann 
et al., 1999) and HPMC also dissolves (Siepmann and Peppas, 2001).  Therefore 
an apparent straight line can still result from the superpositioning of various 
effects and is not necessarily going to be an indication that the release behaviour 
is diffusion controlled.  Because swelling was not regarded to affect the release 
interface area (as the surface area remained fixed as described in Section 4.5b) the 
Higuchi equation (Equation 4.8a) was used to model the release data.   
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The percentage release versus square root of time plot (Figures 4.58 – 4.65) 
produced straight line graphs for the majority of parameters tested.  The errors 
were calculated as described earlier (Section 4.5a i.).  For clarity the errors bars 
are not shown on all the profiles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.58 – Effect of Height of Water in Tube on Drug Release Rate (n=6) 
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Figure 4.59 – Effect of Tube Height on Drug Release Rate (n=6) 
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Figure 4.60 – Effect of Stirring Rate on Drug Release Rate (n=6) 
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Figure 4.61 – Effect of pH of Dissolution Test Medium on Drug Release Rate (n=6) 
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Figure 4.62 – The Effect of HPMC Concentration on Drug Release Rate (n=6) 
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Figure 4.63 – Effect of Polycarbophil Concentration on Drug Release Rate 
(n=6) 
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Figure 4.64 – Effect of HPMC Viscosity Grade on Drug Release Rate (n=6) 
0
10
20
30
40
50
60
0 5 10 15 20 25 30
Square Root of Time (mins1/2)
Pe
rc
en
ta
ge
 R
el
ea
se
 (%
)
90SH  60SH  
 189
 
 
  
Figure 4.65 – Effect of Hydrophilic Gelling Agent on Drug Release Rate (n=6) 
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Figures 4.58 – 4.65 were consistent with modelling by the Higuchi equation up to 
50% release.  The value of k (release rate constant) was determined from each plot 
by calculating the gradient.  As previously mentioned in this section the Higuchi 
equation is modelled using data up to 60% release.  Swelling of the gel depot 
occurred throughout the duration of this release analysis period.  Therefore a 
different mechanism of drug release (such as polymer dissolution) post gelling 
may have occurred after the 60% release period (after this time period the Higuchi 
equation was no longer linear).  Consequently the time points chosen for the 
modelling analysis were appropriate.  It was observed after a period of 4 weeks 
that the gel had degraded to a fluid (Section 4.3d iii).  Therefore once the swelling 
had ceased it is likely that the drug release mechanism would have predominately 
been structural breakdown.  Therefore, because swelling occurred throughout the 
duration of the release analysis period, a single mechanism rather than a change in 
mechanism was assumed to occur during the experiments. 
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The value of k was used to illustrate the significant difference the gelling agent 
had on the release rate.   
 
Table 4.19 - Effect of Gelling Agent on the Value of k 
Standard Error in the Calculated 
Parameter (% minParameter k (% min
-0.5) -0.5) 
+No Gelling Agent 8.35  0.33 
+ Gelling Agent 2.49 0.31 
 
 
 
As shown in Table 4.19 it is apparent that the presence of the gelling agent greatly 
reduces the value of k by a factor of 3.35.  The standard error (calculated using 
regressional analysis) shows the k values are significantly different. 
 
The values of k were also used to determine if a relationship between k and each 
parameter existed. 
 
 (4.8b) 
 
The original form of the Higuchi equation (Equation 4.8b) can be rearranged to 
the commonly used form (Equation 4.8a).  As mentioned earlier in this section, k 
is a constant which reflects the design variables of the system.  Therefore the 
value of k will incorporate parameters such as the surface of the release interface 
(A), the drug diffusivity (D) and drug solubility in the polymer (c ).   s
 
The value of k for each concentration of HPMC was determined from their 
respective graphs (Figure 4.62).  A plot of k against the HPMC concentration 
(Figure 4.66) revealed a linear relationship with an R2 value of 1.  Hence, the 
release rate of any system containing between 5 and 25% HPMC can be predicted 
by interpolation from the straight line illustrated in Figure 4.66 (for systems using 
the specific combinations of propranolol and excipients in this formulation).  A 
linear relationship also existed between k and the stirring rate (Figure 4.67).  
Therefore the release rate of a system for a particular stirring rate can also be 
predicted from the plot.  This result suggests that there is a mass transfer 
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limitation on the sink side of the device.  When the stirring rate is increased, the 
effect of the boundary layer is reduced so affecting k.  As mentioned earlier in this 
section, k depends on the design variables of the system.   
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Figure 4.66 – Comparison of the Release Rate Constant and HPMC Concentration.  
The Graph Shows a Trend Line Running Through the Data Points. 
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3
Figure 4.67 – Comparison of the Release Rate Constant and Stirring Rate.  The 
Graph Shows a Trend Line Running Through the Data Points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.68 depicts the release of drug from the ISGM system.  When the drug is 
dissolved in the matrix, (i.e. drug concentration is less than the solubility of the 
drug in the continuous phase) the diffusion rate of the drug will not necessarily be 
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Figure 4.68 - Schematic of Drug Release From the ISGM System 
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constant.  In contrast, when the drug is homogeneously dispersed throughout the 
ISGM system (i.e. drug concentration is greater than the solubility of the drug in 
the continuous phase), the drug will exist both in solution and as discrete solid 
particles.  The drug release process will involve dissolution of the drug into the 
ISGM system surrounding the drug particle and then partitioning of the drug into 
the aqueous environment.  In such a case the diffusion rate of the drug will be 
constant and a linear concentration gradient is maintained in the diffusion region.   
 
In this system the initial drug concentration is greater than the solubility of the 
drug in the continuous phase (0.003 g mL-1).  The drug release mechanism will 
therefore tend to follow that of the dispersed system.   
  
As the Higuchi equation assumes diffusion is the rate limiting step, it cannot give 
conclusive evidence of the mechanism of release.  The more general power law 
(Korsmeyer et al., 1983) (Equation 4.9) was therefore used to explore the release 
rate more fully. 
 
(4.9) 
 
M
M
ktt n
∞
=
 Mt = absolute cumulative amount of drug released at time t
 M∞ = ∞absolute cumulative amount of drug released at time 
k =
n = release exponent indicating mechanism of release
t = time
constant which incorporates the structural and geometric 
characteristics of the device
 
 
 
 
Equation 4.9 is identical to the Higuchi equation if n = 0.5. When n = 0.5, it 
indicates an internal (gel-side) diffusion controlled release mechanism (in 
accordance with the Higuchi equation) and when n = 1 it is indicative of a 
swelling controlled drug release.  Values of n which lie between 0.5 and 1 are 
referred to as anomalous transport.  Anomalous transport is the superpositioning 
of both diffusion controlled and swelling controlled release.  However these 
values of n are only valid for matrices assumed to have a slab geometry.  This fact 
is not always taken into consideration and consequently leads to misinterpretation 
of results.  Different values of n have been derived for cylinders (Table 4.20) and 
spheres (Ritger and Peppas, 1987a; Ritger and Peppas, 1987b).  The gel depot in 
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this study is cylindrical in shape.  According to Ritger and Peppas, one 
dimensional release from a cylinder can only occur if the cylinder is long and thin, 
where release from the ends of the cylinder is therefore negligible as the majority 
of release will occur radially not axially.  In such a geometry, release can be 
regarded as one dimensional as the release rate will be constant over the whole 
radial surface.   
 
Table 4.20 – Values of n for Cylinders 
n value Release Mechanism 
0.45 Diffusion Controlled (Fickian) 
0.45-0.89 Anomalous Transport 
0.89 Case 2 Transport (swelling controlled) 
 
 
The gel depot in this study has the shape of a cylinder, but, because release of the 
drug is only occurring at one end of the cylinder, the geometry of the release 
interface is essentially a slab (as described earlier in this section).  Consequently, 
the values of n obtained from the experimental data should be compared to the 
value of n for a slab (Table 4.21). 
 
Table 4.21 – Values of n for Slabs 
n value Release Mechanism 
0.5 Diffusion Controlled (Fickian) 
0.5-1.0 Anomalous Transport 
1.0 Case 2 Transport (swelling controlled) 
 
 
The effect of swelling in this system was limited, where radial swelling did not 
occur (due to constraints of the glass tube).  Swelling only occurred in one 
direction (axial).  Therefore the swelling in this system would not affect the 
surface area of the release interface but would affect the concentration of the 
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release component in the gel by increasing the volume of the depot.  Therefore 
swelling will affect the release component concentration over time but not the 
release area.  
 
ln       was plotted against      for each experiment to determine if a straight line 
relationship existed.  A straight line graph would indicate the power law modelled 
the data adequately.  
ln t
Mt
∞M
 
The Final Formulation 
The final formulation gave a straight line graph (Figure 4.69) with an R2 value of 
0.9987.  Therefore the power law (as stated in Equation 4.9) appears to 
successfully model the release data.  The value of n from this profile was found to 
be 0.6.  The 0.6 value indicates the formulation exhibits an anomalous transport 
type release mechanism - not strictly diffusion controlled as thought with the 
Higuchi equation but close to it.  This seems plausible because diffusion alone 
cannot dictate the release, given the observation that the HPMC in the system 
swells.  The swelling in this regards will only affect release in terms of the greater 
distance the drug must diffuse to reach the release interface.   
 
 
Figure 4.69 – Modelling of the Final Formulation using the Power Law. 
The Graph Shows a Trend Line Running Through the Data Points. 
R2 = 0.9987 
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HPMC Concentration 
The 5% HPMC system gave a value of n of 0.5 indicating a diffusion controlled 
release mechanism.  Because there is less polymer in the formulation, the swelling 
of the HPMC has less of an effect on the release mechanism.  Increasing the 
HPMC concentration to 25% resulted in a larger n value of 1.0.  This value 
indicates a swelling controlled mechanism, consistent with the high degree of 
swelling of HPMC with water. 
 
Polycarbophil Concentration 
Decreasing the polycarbophil concentration to 0.5% caused a marginal deviation 
from a straight line (where the R2 value decreased from 0.9987 (for the 
formulation containing 0.67% polycarbophil) to 0.9924 (for the formulation 
containing 0.5% polycarbophil)).  Increasing the polycarbophil concentration to 
1.0% still gave a straight line.  However the value of n was found to be 1.9, much 
higher than the 1.0 value indicating a swelling controlled mechanism (Table 4.21).  
It is uncertain what the cause of the high value of n is.  Obviously factors other 
than swelling and diffusion are contributing to the release mechanism.  It is 
possible distortion of the matrix is occurring which may explain this deviation 
from expected behaviour.  In the case where n is greater than 1, there may be a 
late stage acceleration in the permeation rate (this has also been referred to as 
Super-case II transport) (Tanchak and Barrett, 2004).  
 
pH 
Though altering the pH gave a completely different release profile (Figure 4.53), 
the power law still produced a straight line graph.  Decreasing the pH from 6.85 to 
4.5 and 1 gave straight lines with an n value of 0.7.   
 
Discussion 
Siepmann and Peppas noted that the application of the power law to HPMC 
systems can only give a limited insight into the exact release mechanisms 
(Siepmann and Peppas, 2001).  The Higuchi equation and power law assume 
constant geometries during drug release and constant diffusivities of the drug and 
water.  HPMC swells considerably and the diffusion co-efficient of the drug and 
water are strongly concentration dependent (Siepmann et al., 1999) and HPMC 
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also dissolves (Siepmann and Peppas, 2001).  In the case of the Higuchi equation 
an apparent straight line can still result from the superposition of various effects 
and is not necessarily diffusion controlled (as mentioned earlier in this section). 
 
The more comprehensive power law has provided information indicating diffusion 
was not the only mechanism involved in the release of the drug.  Much research 
has been conducted on HPMC based drug-release systems (Rekhi et al., 1999; 
Colombo et al., 1999; Grassi et al., 2004; Siepmann and Peppas, 2001).  The 
subsequent modelling has led to varied values of n where some claim the system 
to be predominately diffusion controlled (Rekhi et al., 1999), whereas others have 
found n to be anomalous transport from a swellable matrix (Colombo et al., 
1999).  Consequently a range of n values for HPMC systems was obtained 
suggesting a wide range of possible drug release mechanisms.  In this study the 
radial swelling was prevented (as the glass tube prevented the gel expanding 
radially), however axial swelling still occurred.  Though swelling did not affect 
the release interface, the axial swelling would have increased the distance which 
the drug would have to diffuse and therefore may contribute to the release 
mechanism.  This would explain why the power law indicated a swelling type 
mechanism for drug release in this system.   
 
The entire percentage release versus square root of time profile will not be linear 
as the thickness of the diffusional path in the drug depletion zone increases with 
time (Figure 4.70) (Chien, 1980) and this diffusional path also increases as the 
axial swelling occurs.  In the case of the final formulation, the release profile gave 
a constant release up to approximately 50%.  This was considered adequate to 
define the profile and allow comparisons between different profiles (as described 
previously in Section 4.5b) as release up to 60% is usually used to model the data 
(Ritger and Peppas, 1987a, Nam et al., 2004; Perez-Marcos et al., 1996). 
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Figure 4.70 – How an Actual Release Profile Will Deviate From the Ideal Release 
(Chien, 1980). 
 
 
 
 
 
 
 
 
 
As a result of the modelling, the formulation allows the release rate to be 
calculated.  A release experiment was conducted to determine if k and n remained 
constant for a formulation with a different initial drug concentration. 
 
The initial drug concentration was reduced by a third. The values of n and k were 
found to be 0.57 (+ 0.02) and 1.72 (+ 0.27) respectively (Figure 4.71).  The value 
of n remained constant but k changed slightly (Table 4.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.71 – Formulation Containing a Lower Drug Concentration 
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Table 4.22 - Comparison of n and k  
Parameter The Final 
Formulation 
Formulation With 
Reduced Drug 
Concentration 
Standard Error in 
the Calculated 
Parameter 
n 0.57 0.57 + 0.02 
k 1.40 1.72 + 0.27 
 
 
The value of n should remain constant as the geometry of the system and all other 
factors remained unchanged.  Consequently, the release mechanism should not 
change and this was in agreement with findings (Table 4.22).  Designing a 
formulation to give a drug release over a desired time period for example 10 days 
may be possible as the difference in the k values were not significantly different 
as the values overlapped within the error range (Table 4.22).  The error in k was 
calculated using a linear regression analysis program (Microsoft Excel-based) and 
was found to be + 0.27.  The value of k is a constant which incorporates the 
structural and geometric characteristics of the device (Siepmann and Peppas, 
2001).  The possible variation in k could be a result of the swelling in the system.  
Altering the drug load of a system, will affect the water absorbing capacity (if the 
drug is water soluble).  Therefore the driving force for drug release (i.e. 
concentration gradient) will be affected, which in turn may affect the release rate 
of the drug, thus altering k. 
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4.6 Stability Assessment of the Final Product 
4.6a Drug Stability  
According to the US-FDA (United States – Food and Drug Administration), a 
stability indicating assay is a validated quantitative analytical method which can 
detect changes in the chemical, physical or microbiological properties of the drug 
substance and  drug product over time.  The assay is so specific that the contents 
of the active ingredient, degradation products and other components can be 
accurately measured without interference (Bakshi and Singh, 2002). 
 
Bakshi and Singh (2002) conducted a review of the literature and found that very 
few methods which claimed to be stability indicating actually fitted the definition 
of a stability indicating assay given above.  Some methods did not even include 
forced drug degradation studies. 
 
Titrimetric, spectrophotometric and chromatographic techniques have all been 
used in stability studies.  Spectrophotometric and titrimetric methods are 
inexpensive and simple but not always sensitive or selective.  Consequently very 
few reports exist in the literature on their use today. However, there are some 
reports on the use of derivative spectrophotometry (Dabbene et al., 1994; Forsyth 
and Ip, 1994; Walash et al., 1994; Khamis et al., 1993). 
 
In contrast, chromatographic techniques are the main stability analysis method.  
Chromatographic methods can separate multiple components, are more accurate 
and more sensitive. 
 
Drug stability analysis is vital in pharmaceutical studies as increased degradation 
will decrease the potency of the drug and may also result in compounds which 
could give undesirable pharmaceutical side-effects (Andrisano et al., 1999).   
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i. Method Development 
There are many reported methods in the analysis of propranolol by HPLC 
(Modamio et al., 1996; El-Saharty 2003; Venkatesh et al., 2007; Botterblom et 
al., 1993).  The variations in the mobile phases are given in Table 4.23. 
 
Table 4.23 – Reported Mobile Phases for Analysis of Propranolol 
Mobile Phase Reference 
Acetonitrile and phosphate buffer with 
0.2% (w/v) triethylamine. Modamio et al., (1996). 
0.02 M potassium dihydrogen phosphate 
and acetonitrile (80:20 v/v) adjusted to 
pH 4.5 
El-Saharty (2003). 
Ammonium acetate and acetonitrile 
30:70 (v/v) Venkatesh et al., (2007). 
Acetonitrile and sodium 
dihydrogenphosphate – triethylamine 
(35:65:0.1 v/v) 
Botterblom et al., (1993). 
1 g of sodium dodecyl sulphate in 36 mL 
of 0.15 mol L
-1
 phosphoric acid, 180 mL 
of methanol, 180 mL of acetonitrile and 
104 mL of water to give a final volume  
of 500 mL. 
USP (1994). 
 
 
However many of these methods include simultaneous detection of propranolol 
with other betablockers.  This study involves the analysis of only one active agent 
- propranolol, therefore the USP method was adopted for HPLC analysis.  
Development and validation of the HPLC method was conducted on the pure 
drug.  Extracting the drug from the formulation involved addition of methanol.  
This is discussed in further detail in Section 4.6a iv. 
 
A peak was observed in the chromatogram for propranolol (see Section 3.6a i for 
experimental details).  To verify the peak was due to propranolol, another sample 
of propranolol was passed through the column at a lower concentration.  The 
corresponding peak signal decreased.  To further confirm the observed peak was 
propranolol, the UV spectrum of the peak was analysed.  The UV spectrum of the 
observed peak matched the UV spectrum of propranolol thereby verifying the 
detected peak was propranolol (Figures 4.72 and 4.73). 
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Figure 4.72 – UV Spectrum of the Observed Peak in the HPLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.73 – UV Spectrum of Propranolol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After confirming the detected peak was propranolol, method development was 
conducted by carrying out robustness, drug degradation and linearity studies.  
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Linearity and Calibration 
A straight line relationship was found for 6 concentrations (see Section 3.6a i for 
experimental details) of propranolol indicating the peak area was proportional to 
the concentration (Figure 4.74).  The error bars displayed in Figure 4.74 
represents the relative standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.74 – Peak Area versus Concentration for 6 Concentrations of Propranolol 
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The method development has shown to give a linear response between peak area 
and propranolol concentration.  The R2 value should be greater than or equal to 
0.999 (Center for Drug Evaluation and Research, 2000) and this was found to be 
the case (Figure 4.74) with the experimental value being 0.9997.   
 
The next stage in the method development involved assessing the specificity to 
ensure degradation peaks do not interfere with the peak of interest. 
 
Forced Drug Degradation Study 
A forced drug degradation study was conducted to assess the ability of the 
analytical procedure to accurately and quantitatively measure the concentration of 
the analyte in the presence of any degradants.  Degradation studies of propranolol 
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have been conducted (Uwai et al., 2005; Salomies, 1987; Sortino et al., 2002; 
Modamio et al., 1996). 
 
Modamio et al., (1996) conducted an accelerated drug stability of propranolol by 
subjecting the drug in a water bath at temperatures of 60, 70 and 90ºC.  The 
analysis was conducted by measuring the percentage of unaltered concentration of 
the drug.  Their study found no apparent degradation. 
 
The degradation studies carried out in this research were based on those described 
in the literature (Bakshi and Singh, 2004; Marin and Barbas, 2004).  In each 
degradation method (see Section 3.6a i for experimental details), no degradation 
peaks were found.  The amount of drug remaining after degradation was 
calculated according to Equation 4.10 (based on the equation given by Ceschel et 
al., 2003): 
 
 
                                                                                                                            (4.10)
  
% Drug Remaining =  
Initial Drug Amount  Amount of Drug After Degradation
Initial Drug Amount
 x 100
−
 
The amount of drug remaining after each degradation treatment carried out it this 
study is illustrated in Figure 4.75.  The error bars on the graph represent the 
relative standard deviation. 
 
Figure 4.75 – Amount of Drug Remaining After Each Degradation Treatment 
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Addition of the base to the propranolol resulted in precipitation most likely caused 
by deprotonation of the propranolol hydrochloride so decreasing its solubility in 
the medium.  The supernatant of the propranolol sample was separated from the 
precipitate and passed through the electrospray mass spectrometer.  The ESMS 
spectrum revealed the dominant propranolol peak (at 260 m/z) was no longer 
present (Figure 4.76) indicating all the propranolol had precipitated leaving no 
drug in the supernatant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.76 – Mass Spectrum of Propranolol Subjected to Basic Conditions 
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Addition of acid resulted in some precipitation, which would explain why much 
of the drug had degraded.  This could be due to degradation by acid hydrolysis at 
the ether linkage in the propranolol. 
 
Placing the drug in front of a UV source (254 nm) resulted in the drug changing 
from a colourless solution to a light orange colour.  A colour change was also 
reported by Uwai et al., (2005) where their work was conducted on propranolol 
tablets.  Propranolol is known to be photosensitive.  The HPLC did not show the 
presence of any degradation peaks.  However the HPLC showed that some form 
of degradation had occurred as the amount of drug remaining had decreased 
(Figure 4.75).  However, because the HPLC showed some form of degradation 
had occurred and the propranolol solution had changed to an orange colour, 
degradation or some other reaction had obviously occurred.  Given the HPLC 
analysis was conducted on a PDA detector, degradation peaks were screened for 
under the wavelength range of 200 - 410 nm.  However, degradation peaks were 
not observed.  If any peaks due to degradation were present, they may have eluted 
in the solvent front.  This would occur if the degradant was much more polar than 
the compound of interest.  Alternatively, the degradant may be less polar than the 
analyte and therefore be retained by the column.   
 
Propranolol is known to be a photosensitising agent and light unstable (Uwai et 
al., 2005).  The instability is a result of the napthalene skeleton which is a UV 
chromophore (Uwai et al., 2005).  Uwai et al. (2005) conducted TLC analysis and 
found photo-degradation products of propranolol after 10 days of UV treatment.  
However structural analysis proved difficult as the rate of photoproduct formation 
from pharmaceutical preparations was too slow to isolate enough degradation 
products.  Therefore concentration of the degradation products may be an issue.  
This would explain why degradation peaks in the HPLC or ESMS were not 
observed. 
 
Napthalene, 1,4-napthoquinone (Salomies, 1987), 6-hydroxy-1,4-napthoquinone 
(Sortino et al., 2002), 1-napthol, N-acetylpropranolol and N-formylpropranolol 
(Uwai et al., 2005) have all been reported as photodegradation products of 
propranolol.  Each study found different photodegradation products.  Uwai et al. 
 207
(2005) attributed the difference to the conditions which the propranolol was 
irradiated.  Therefore propranolol does degrade in UV light but the products 
formed depend on the treatment method. 
 
In the investigation reported in this thesis, heat and H2O2 treatment did not result 
in degradation as shown in Figure 4.75.  Though degradation peaks were not 
detected, the HPLC analysis indicated (by means of monitoring the intensity of 
the propranolol peak) that some form of degradation had occurred because the 
amount of drug remaining in the sample decreased from its original concentration.  
The assay itself would not have contributed to a change of response in the HPLC 
as the degradation study was conducted in triplicate and the results were the same 
for each sample. 
 
A stability indicating assay is an assay which is a validated quantitative procedure 
that can detect changes with time in the pertinent properties of the drug substance 
and product.  The assay has the ability to accurately measure the active ingredient 
without interference from the factors such as the degradation by-products.  In this 
study, peaks identifiable as degradation products were not detected.  Degradation 
peaks were searched for under the wavelength range of 200 - 410 nm, but 
degradation peaks were not found.  If any peaks due to degradation were present, 
they may have eluted in the solvent front or may have been retained by the 
column as mentioned earlier in this section.  Alternatively they may have occurred 
in a higher wavelength range if they possessed absorptions in the visible region of 
the spectrum.  The stability assay described in this section is not a true stability 
indicating assay in terms of the definition given in this discussion as degradation 
peaks were not detected.  However, it can be argued that because there were no 
degradation peaks detected, there will be no interference with the peak of interest.  
Consequently, in this regard it can be claimed that the method is stability 
indicating.  Therefore, drug stability studies can still be conducted using the 
method described in this section, as the peak of interest is void of interference and 
the drug remaining can be quantified.  It is also possible the retention times of any 
degradation products may possess visible absorption maxima and hence occur 
outside the range of wavelengths investigated (200 – 410 nm).  In such a case, the 
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main propranolol peak could still be used as a means of quantifying the 
concentration of the drug as it would not have any interference from other species.     
 
 
Robustness 
The robustness of the method (see Section 3.6a i) was tested by determining the 
effect of varying the mobile phase composition on the retention time of a 5 mg 
mL
-1
 sample of propranolol.  The results of this investigation are shown in Tables 
4.24 – 4.26. 
 
Table 4.24 – Effect of Acetonitrile Concentration in the Mobile Phase on the Retention Time 
Mobile Phase Retention Time (mins) 
Mobile phase (containing 36% 
acetonitrile) 8.045 
Mobile phase (containing 66% 
acetonitrile) 8.049 
 
 
Varying the amount of acetonitrile in the mobile phase did not affect the retention 
time of the drug (Table 4.24).  The retention times had a small relative standard 
deviation of 0.1%. 
 
Table 4.25 - Effect of Methanol Concentration in the Mobile Phase on the Retention Time 
Mobile Phase Retention Time (mins) 
Mobile phase (containing 36% 
methanol) 8.045 
Mobile phase (containing 66% 
methanol) 6.546 
 
 
Varying the amount of methanol in the mobile phase resulted in a change in the 
retention time of the drug (Table 4.25).  This was also found to be the case when 
the strength of acid in the mobile phase was altered (Table 4.26). 
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Table 4.26 - Effect of Phosphoric Acid Concentration in the Mobile Phase on the Retention Time 
Retention 
Time (mins) Mobile Phase 
Mobile phase (containing 0.15 mol L-1 
phosphoric acid) 8.045 
Mobile phase (containing 0.30 mol L-1 
phosphoric acid 6.645 
 
 
Therefore in the HPLC method employed for the drug stability studies, the 
retention time of the drug was not affected by the amount of acetonitrile in the 
mobile phase.  In contrast the retention time of propranolol was affected by the 
amount of methanol and the strength of phosphoric acid in the mobile phase.  
There are few reports in the literature on such observed occurrences.  The mobile 
phases in the HPLC analysis of beta blockers often use methanol or acetonitrile as 
a means of controlling the retention (Basci et al., 1998).  The polarity of the 
mobile phase can have a major effect on the chromatographic behaviour of the 
solutes.  Basci et al. (1998) found increased concentrations of acetonitrile in 
phosphate buffer reduced the capacity factor of beta blockers (including 
propranolol) due to the decreased polarity of the mobile phase.  The capacity 
factor was calculated according to Equation 4.11 (Basci et al., 1998): 
 
k (t t )
t
' R 0
0
= −                                                                                                       (4.11) 
where  
k'  = the capacity factor 
t0  = retention time of the unresolved peak 
 = retention time of the solute tR
 
Therefore because the capacity factor is dependant on the retention time, a change 
in capacity factor indicated a change in the retention time.  Though acetonitrile 
affected the retention time in Basci et al.’s study it did not affect the retention 
time in this study.  Consequently the experiment varying the acetonitrile 
concentration was repeated to verify the findings of this study.  Once more the 
retention time did not change with a change in concentration of acetonitrile. 
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Another possible cause of the shift in retention time of the propranolol with 
altering concentrations of methanol may be due to hydrogen bonding between the 
amine group of propranolol and the hydroxide group of methanol.  Such an 
interaction will not occur between acetonitrile and propranolol.  
 
A buffer is also commonly employed to control the ionic strength and pH of the 
mobile phase.  Therefore altering the acid concentration in the mobile phase will 
change the pH of the mobile phase.  Results showed (Table 4.27) that altering the 
acid concentration resulted in a change in retention time.  Basic drugs such as 
propranolol are positively charged at low pH due to the amine group which 
becomes protonated.  The pH of the mobile phase was altered from 3.20 to 2.03. 
This shift in pH may have altered the extent of protonation thus affecting the 
retention time of propranolol.  In theory, at a lower pH the propranolol will be 
more protonated.  A more protonated substance will have a stronger affinity for 
the mobile phase and therefore should have a faster retention time.  This was 
found to be the case as decreasing the pH lead to a decrease in the retention time 
from 8.045 to 6.045 minutes (Table 4.26). 
 
 
ii. The Final Method 
As a result of conducting the method development study (Section 4.6a i), the drug 
stability will be assessed using the following method (Table 4.27): 
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Table 4.27 – The Final Method used in the Analysis of Propranolol 
Parameter Description 
Column Nova-Pak C18 column (8 x 100 mm) 
Guard 
Column Nova-Pak, 4 μm, 60 Å, C18 Guard-Pak Insert 
Mobile Phase 
Prepared according to USP (1994) by dissolving 1 g of sodium 
dodecyl sulphate in 36 mL of 0.15 mol L
-1
 phosphoric acid 
(Merck, Germany) in a glass vessel.  To this glass vessel, add  
180 mL of HPLC grade methanol (Scharlau, Spain) and HPLC 
grade acetonitrile (Burdick and Jackson, USA) as well as 104 
mL of water to give a final volume of 500 mL. 
Flow Rate 1 mL min-1
Temperature The temperature was not varied during the development as the column was not heated.   
Injection 
Volume 20 µL 
Detector PDA 200 – 410 nm 
 
 
Upon finding the ideal method to analyse the drug, the method was then validated. 
It is necessary to validate the HPLC method to ensure it is accurate and 
reproducible over the concentration range which the analyte will be analysed.   
 
 
iii. Method Validation 
Method validation was conducted by assessing the linearity, accuracy, precision, 
limit of quantitation, limit of detection, robustness and specificity.   
 
Linearity 
A linear relationship was found between concentration and peak area (Figure 
4.77).  The R2 value was 0.9996 which is above the 0.999 value required as 
mentioned earlier in the linearity test described in the method development section 
(Section 4.6a i). 
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Figure 4.77 – Method Validation to Assess the Linearity of the Final Method 
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Accuracy 
The accuracy of the method was tested by running samples of propranolol with 
known concentrations of 2, 9 and 17 mg mL
-1
 (in triplicate) to determine if the 
peak area gave the correct concentration.  The method was accurate as the area of 
the peak from the graph (the graph plotted when testing the linearity, Figure 4.77) 
corresponded to the actual concentrations of 2, 9 and 17 mg mL-1 (within the 
percentage relative standard deviation as shown in Table 4.28). 
 
Table 4.28 – Comparison of the Reference Concentration and the Average Experimental 
Concentration for Propranolol 
Reference 
Concentration 
(mg mL
Average Concentration (mg mL-1) 
(Determined from Calibration 
Curve)  
% Relative 
Standard 
Deviation -1) 
2 1.992 0.42 
9 8.998 0.16 
17 17.006 0.22 
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Precision 
-1
Repeatability: 6 samples with a concentration of 0.5 mg mL  and 6 samples with 
a  concentration of 5 mg mL
-1
 had a relative standard deviation of 0.48 and 0.62% 
which were well within the 10% confirming the good precision of the method 
(Rao et al., 2005).  
 
Intermediate Precision: Figure 4.78 shows the analytical method was reliable in 
that the method provided similar calibration curves on 3 different days which 
agreed within error (for propranolol concentrations of 0.25, 1, 5, 10, 15 and 20 mg 
mL-1 as described in Section 3.6a iii).  The error bars displayed in Figure 4.78 
represents the relative standard deviation.   
 
 
 
Figure 4.78 – Intermediate Precision of the Final HPLC Method for Propranolol 
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LOD and LOQ 
The LOD was calculated according to Equation 4.12: 
 
LOD = 3.3 SD/S                                                                                                  (4.12) 
 
where SD is the standard deviation of the response and S refers to the slope of the 
calibration curve.  The LOD was found to be 0.0481 mg mL
-1
 which is the lowest 
concentration of propranolol that can be detected.  The lowest concentration 
which can be quantitatively detected (i.e. LOQ) was found according to Equation 
4.13: 
 
LOQ = 10SD/S                                                                                                   (4.13) 
 
The LOQ was calculated to be 0.145 mg mL
-1
.  Therefore the concentration of 
drug to use in the stability test should be above this concentration. 
 
To verify the limit of detection, a sample with a concentration of 0.040 mg mL
-1
 
was injected into the column.  A peak was not detected.  A more concentrated 
sample of 0.055 mg mL
-1
 was injected into the column, resulting in the detection 
of a peak.  Therefore the calculated limit of detection (LOD) value of 0.0481 mg 
mL
-1 
is in agreement with the experimental findings.   This limit of detection is 
quite high.  It is uncertain as to the cause of this high value.   
 
 
iv. Extraction of the Drug from the Final Formulation 
In this initial study, extraction of the drug from the formulation was attempted by 
size exclusion chromatography (SEC) using the KS-803 sugar column.  The 
formulation consists of the continuous phase (propylene glycol and 
polycarbophil), the hydrophilic gelling agent (HPMC) and the drug (propranolol).  
In order to extract the drug, the initial approach was to dilute the formulation to 
the extent where the HPMC was no longer viscous (as it is a hydrophilic gelling 
agent) so that the formulation could be introduced to the HPLC.  The formulation 
components would then be separated according to size which was the basis of 
choosing the size exclusion column.  Therefore, the size exclusion method could 
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be a means of extracting the drug from the formulation and then introducing the 
extracted drug into the C18 column using the developed and validated method 
described in Sections 4.6a i and 4.6a iii.   
 
Injection of the final product into the column, would result in the large molecular 
weight polymers HPMC and polycarbophil eluting at the start (due to their large 
size) leaving the low molecular weight propylene glycol and propranolol.  
Propylene glycol and propranolol would be identified by the detectors, where the 
PDA (photo diode array) and RI (refractive index) detectors were both used (the 
detectors were placed in series).  Initial results showed 2 peaks in the RI 
chromatogram and only 1 peak in the PDA chromatogram.  Propylene glycol does 
not have UV absorbance peaks in the region of interest, therefore the peak present 
in the RI chromatogram which did not have a corresponding peak in the UV 
chromatogram was due to propylene glycol.  The peak observed in both the RI 
and UV chromatogram was therefore due to propranolol.  This was further 
confirmed by the molecular weights of propranolol and propylene glycol.  
Propylene glycol being smaller than propranolol should have a longer retention 
time and this was observed to be the case.  Hence, this size exclusion column was 
able to separate the drug from the excipients of the formulation.  However, this 
approach was not used further as a problem arose concerning the retention time of 
the drug.  During the development process, it was found there was intra-sample 
(Table 4.29) variation in the peak area.  It was also found that the retention time of 
the drug increased with increasing concentration (Table 4.30). 
 
Table 4.29 - Intra-Sample Variation for a 5 mg mL
-1
 Propranolol Sample                                        
using the KS-803 Column 
Sample 
Number
Peak 
Area 
Retention Time 
(mins) 
1a 244200 6.334 
1b 129034 6.337 
1c 237423 6.337 
1d 214700 6.335 
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The effect of intra-sample variation on a further concentration of propranolol (15 
mg mL-1) was also assessed.  There was once more variation in the peak area.   
 
Table 4.30 - Change in Retention Time for Varying Concentrations of Propranolol                    
using the KS-803 Column 
Propranolol 
Concentration (mg mL-1) 
Retention Time 
(mins) 
0.5 5.942 
1 6.042 
5 6.333 
10 6.503 
20 6.723 
 
 
Table 4.31 - Extent of Peak Area Variation for 5 mg mL
-1
 Propranolol (Intra-Sample)  
 Intra-Sample Analysis 
Mean 206339.3 
Standard Deviation 53058.6 
% Relative Standard Deviation (%RSD) 25.7 
 
 
 
Table 4.32 - Extent of Retention Time Variation for Different Concentrations of Propranolol  
 Retention Time for the Different Concentrations of Propranolol 
Mean 6.309 
Standard Deviation 0.322 
% Relative Standard Deviation (%RSD) 5.1 
 
 
As shown in Table 4.31, the extent of variation in for the intra-sample analysis 
was very high (%RSD of 25%) hence the data was highly variable and a cause for 
concern.  A change in the method was thus required.  In the case where the 
concentration of the propranolol was varied, the variation in the retention time 
was not that high (%RSD of only 5.1% - Table 4.32).  However, the cause of the 
increased retention time with increasing concentration was not known.  Various 
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factors were tested such as decreasing the injection volume to ensure the column 
was not being overloaded, ensuring the injector was adequately purged, 
determining whether the pressure fluctuated during the HPLC run and whether 
there were any leaks in the system.  However, altering the injection volume did 
not have an effect.  The pressure did not fluctuate during the run and there were 
no leaks in the system.  The shifting in retention time may be a result of the 
mobile phase.  No other reports in the literature have indicated the use of water on 
its own as a mobile phase for propranolol.  Consequently, an acidified mobile 
phase was used.  As the KS-803 can only have water as the mobile phase, a 
reverse phase C18 column was used. 
 
As a result of the peak shifting and variations in the peak area, the size exclusion 
method of extracting the drug was not continued.  The peak shifting and the 
variations in the peak area meant the extraction method would not have been 
efficient.  Consequently, a new means of extracting the drug was investigated.   
 
Addition of methanol to the formulation resulted in the hydrophilic gelling agent 
HPMC dropping out of solution.  This observation was used to develop a new 
method of extracting the drug using the C18 column. 
 
Extraction of the drug from the formulation involved addition of methanol which 
resulted in the HPMC dropping out of solution.   The sample was then centrifuged 
to collect the HPMC, leaving the drug (which is soluble in methanol) in solution 
with the rest of the propylene glycol/drug mix.  The supernatant was injected into 
the HPLC and a peak due to propranolol was observed. 
 
The extraction efficiency was determined by addition of methanol to a 
formulation with a known concentration of drug.  The supernatant (containing the 
dissolved drug) was passed through the HPLC.  The peak area gave a 
concentration off the calibration curve which matched the true concentration of 
the drug in the formulation.  This was repeated with 3 other samples to ensure the 
result was reproducible.  The results were reproducible with a relative standard 
deviation of 0.8%.  This was repeated for a drug concentration of 1 mg mL-1 and 
results were reproducible with a relative standard deviation of 0.97%. 
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v. Accelerated Stability Study of the Drug in the Formulation 
Upon validation of the HPLC method, a stability assessment of the drug in the 
formulation was conducted.  Extraction of the drug from the formulation involved 
addition of methanol which resulted in the HPMC dropping out of solution.  The 
sample was then centrifuged to collect the HPMC, leaving the drug (which is 
soluble in methanol) in solution.   
 
Upon finding a method to extract the drug from the formulation (as described in 
Section 3.6a v), samples (triplicate) of the final product with a known amount of 
drug were placed in accelerated conditions (40°C / 75% relative humidity) and 
each week samples were taken to monitor the drug level. 
 
A 4 week accelerated study of the final product was carried out.  A 4 week time 
period was chosen as the delivery of propranolol using the developed technology 
will be packaged as a two component system (as described in Section 2.6) where 
the dry powder is packaged separately along with the liquid for use at the time of 
reconstitution.  Consequently, a 4 week time period is a sufficient length of time 
for the accelerated stability study. 
 
Over the 4 week accelerated study it was found the level of drug remained 
constant within the calculated error of 0.8% for each of the 3 samples (Figure 
4.79).   
 
The peak area gave a concentration from the calibration curve which correlated to 
the actual concentration in the final product of 5 mg mL-1. 
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Figure 4.79 – Peak Area of Propranolol Over Time 
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As a result of conducting an accelerated stability study of the final product in 
accelerated conditions, it can be concluded that the final product is stable over the 
4 week period studied as the drug level remained unchanged indicating 
degradation had not occurred. 
 
 
 
4.6b Appearance of the Final Product 
The appearance of the final product stored in accelerated conditions was recorded 
each week for 4 weeks (Table 4.33).   
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Table 4.33 - Appearance of Formulation Over Time After Storage in Accelerated Conditions 
Observations* 
Week 
Colour Caking Air Bubbles Particulate Matter 
0 White No caking present 
No air bubbles 
observed 
1 White No caking present 
No air bubbles 
observed 
2 White No caking present 
No air bubbles 
observed 
3 White 
Slight caking 
with a sediment 
height of 0.05 
cm which was 
readily 
dispersed. 
No air bubbles 
observed 
4 White 
Slight caking 
with a sediment 
height of 0.1 cm 
which was 
redispersed with 
minimal 
shaking. 
No air bubbles 
observed 
The presence of particulate 
matter was not measurable 
for this system due to the 
two particulate materials 
suspended in the final 
product (the drug and the 
hydrophilic polymer). 
* The observations for each of the 3 samples were identical 
 
 
 
The stability studies have shown effectively that the drug remained stable in the 
final formulation over the 4 week period as little degradation of the drug had 
occurred.  There was also no visible degradation of the formulation over time in 
the accelerated conditions employed.  Previous reports state that systems able to 
withstand degradation under accelerated conditions should be stable under normal 
storage conditions (Davis, 1987).  Therefore it can be concluded that the 
HPMC/propylene glycol/polycarbophil ISGM formulation should also be stable 
under normal (i.e. ambient) storage conditions for at least 4 weeks.  
CHAPTER FIVE 
Summary and Conclusions 
 
 
5.1 Summary of Findings  
This thesis reports the ab initio formulation and characterisation work surrounding  
a recently described new and novel in situ gelling matrix (ISGM) system  that has 
been patented by Bunt et al. in 2003.   Converting the conceptual ideas outlined in 
the patent into a practical technology was the main aim of the research.  This was 
because the patent gave only a broad description of what the ISGM could 
incorporate, i.e. a suspension of almost any hydrophilic polymer in any non-
aqueous solvent.  As a result, extensive formulation studies had to be carried out 
to find the ideal excipients to use in the ISGM system.   
 
Initial studies involved conducting a biocompatibility study based on the HET-
CAM test to determine whether any of the possible candidates for the technology 
exhibited an immunological response.  NMP was found to cause a severe reaction 
in the HET-CAM test and was hence removed from the non-aqueous solvent 
candidate list for the ISGM system.  The remaining non-aqueous solvents and 
polymers were subsequently carried forward to the screening process.    
 
The screening process involved addition of various hydrophilic polymers to non-
aqueous solvents.  This was found to result in rapid sedimentation of the 
hydrophilic polymer, which was not ideal from a usage point of view.  A 
physically stable suspension should remain suspended for as long a period as 
possible at least to allow administration.  Furthermore, rapid sedimentation may 
lead to caking of the settled particles, which is not desirable as redispersal (the 
simplest temporary remedy for a sedimented system) would not be completely 
feasible. 
 
Hence, in order to retard the sedimentation rate, the physicochemical properties of 
the non-aqueous solvent were modified by addition of a density inducing or 
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viscosity inducing agent.  The density/viscosity of the non-aqueous solvent was 
increased initially by addition of various amounts of glycerin and as this occurred, 
a decreased sedimentation rate was observed.  However, despite the success in 
retarding the sedimentation rate, ISGM systems with high glycerin content tended 
to become pre-gelled because of the hygroscopic nature of glycerin, which led to 
moisture uptake during handling, causing the hydrophilic polymer to gel. Gel 
formation in a formulation prior to injection is undesirable as it would be too thick 
to flow through a syringe.  As a result of this outcome, viscosity modification of 
the non-aqueous solvent by addition of a solid polymer was considered as a means 
of retarding the sedimentation rate. 
 
The viscosity of the non-aqueous solvent was manipulated by addition of a 
viscosity inducing agent, polycarbophil.  An initial inspection of the manufactured 
continuous phase revealed the existence of clumps of polycarbophil.  Such clumps 
are undesirable in a final product as properties of the system including the 
viscosity will vary.  Consequently numerous manufacturing methods were 
attempted to avoid or prevent the formation of these globules.  After attempting 
many methods to overcome this problem, a solution was found by utilising a high 
speed dispersion tool called the Ultra Turrax®.  The Ultra Turrax® was found to be 
an effective tool which produced a small vortex into which to sprinkle the 
polycarbophil and this prevented globule formation by efficient and rapid 
dispersion into the medium. 
 
As a result of this extensive study, the ideal constituents to use in the formulation 
were found.  Investigations into the biocompatibility, the ideal manufacturing 
method (to prevent the formation of globules of polycarbophil) and physical 
sedimentation analysis were carried out to find the ideal excipients for the 
formulation.  This was a significant result as there is little information on the 
stabilisation of suspended matter in non-aqueous systems (compared to aqueous 
systems) for pharmaceutical applications.  
 
After a careful and systematically thorough investigation, the excipients for the 
ISGM system were ultimately determined.  The final formulation consisted of the 
hydrophilic gelling agent HPMC (10%), the continuous phase (comprising of the 
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viscosity inducing agent polycarbophil (0.67%) and the non-aqueous solvent 
propylene glycol) and the drug propranolol.  The time for HPMC to fully 
sediment was increased from 6 hours in propylene glycol to approximately 314 
hours by addition of polycarbophil (0.67%).  As a result of this study the 
sedimentation rate of the hydrophilic gelling agent has been significantly 
decreased to give a physically stable suspension which was still able to be 
redispersed after 700 hours. 
 
The ISGM system was assessed by carrying out characterisation studies.  Water 
absorption studies were conducted to show the formulation (if open to the 
atmosphere) would absorb moisture.  Studies were conducted in a controlled 
environment.  Water absorption did occur due to the hygroscopic propylene 
glycol.  Therefore it is essential to seal the vial containing the formulation to 
ensure the suspension does not gel and adversely affect the injectability of the 
formulation. 
 
The chemical stability of the hydrophilic polymer and the continuous phase was 
determined.  The stability of the hydrophilic polymer was assessed by size 
exclusion chromatography.  Over a period of 9 months the HPMC did not appear 
to degrade, indicating the polymer was fairly stable.  Therefore the HPMC should 
not limit the shelf life of the final formulation.   
 
The stability of the continuous phase was assessed by viscosity.  Over a period of 
9 months the viscosity of the continuous phase remained constant within 
experimental error and therefore can be regarded as chemically stable.   
 
The ease of redispersing the ISGM system was also assessed.  The vials 
containing the ISGM system were stored at room temperature.  Redispersion was 
achieved by controlled rotation of the vial.  After 4 weeks, the ISGM system 
could be redispersed within 60 seconds indicating the ISGM system was still 
physically stable and that caking (which can prevent complete redispersion) had 
not occurred. 
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To determine how the ISGM system would appear when injected, the ISGM 
system was introduced via a syringe into a cellulose medium.  The ISGM system 
gelled to form an intact bulb.  Injection into the ear of a dead calf also led to a 
gelled depot.  Consequently the ISGM system was injected into a live rat.  
Dissection of the rat showed the ISGM system had gelled and was easily removed 
after 6 hours.  This experiment showed the ISGM system functioned adequately 
where injecting a suspension of the hydrophilic gelling agent in the continuous 
phase resulted in an intact gel in the body.  The aim of the study was to find an 
ISGM system that would be capable of achieving this.  
 
To ensure incompatibilities between the drug and the excipients of the formulation 
did not exist, DSC studies were conducted.  The formulation itself showed no 
interactions with the drug but addition of water to give a gelled formulation 
resulted in shifting of the melting point peak from 165°C to 146.1°C.  This 
interaction was thought to be a propranolol-anionic polymer binding interaction.  
IR studies also showed a possible interaction as a new absorption band was found 
at ca. 1557 cm-1.  The complex formation may be a result of the bonding between 
the amine group of propranolol and the carboxyl group of polycarbophil.     
 
Mass spectroscopy analysis was conducted to analyse the drug propranolol and 
UV analysis was conducted on the constituents of the final formulation.  The UV 
analysis also determined which wavelength to use to carry out the in vitro drug 
release studies. 
  
The feasibility of the ISGM system was assessed using the drug propranolol.  
Propranolol was chosen as the model drug as this ISGM technology will provide 
an ideal means of delivering propranolol where factors such as the first pass 
effect, skin permeation and short plasma half life are no longer an issue. 
 
The initial in vitro drug release studies were conducted on the Hanson dissolution 
apparatus.  The Hanson dissolution apparatus was not an ideal means of 
conducting drug release studies as the USP dissolution test was designed for 
tablets not gel depot technology, as studied in this project.  Results were not 
reproducible as the formulation was exposed to the stirrer and a constant surface 
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area of the injected depot was not maintained.   As a result the USP protocol 
needed to be modified to accommodate the different technology.    
 
The development of an in vitro experiment to obtain a reproducible release profile 
was difficult.  Many methods were attempted before development of the modified 
release apparatus.  The modified dissolution apparatus proved successful in 
obtaining a drug release profile for the controlled release formulation.   
 
During the release experiment, it was found that 100% drug release was not 
obtained.  A combination of DSC and IR studies led to the finding that it was 
likely an interaction between the drug and polycarbophil was occurring which was 
preventing 100% drug release.   
 
The effect of parameters such as stirring rate, pH of release assessment media, 
omission of gelling agent, gelling agent concentration, distance between stirrer 
and diffusion site and polycarbophil concentration on the drug release 
characteristics of the ISGM system were assessed separately using the modified 
dissolution apparatus.   
 
The drug release results showed the gelling agent greatly reduced the release rate 
of the drug.  Of the gelling agent concentrations tested, the ISGM system with the 
10% weight loading of HPMC was found to perform the best.  The ISGM system 
containing 5% (w/w) HPMC did not form a strong enough gel to hinder release 
for an appropriate time.  ISGM systems containing too much hydrophilic gelling 
agent such as 25% (w/w) HPMC were found to be too thickly gelled and although 
the drug release was reduced in line with expectations, the formulation was no 
longer injectable with a hypodermic syringe due to its lack of fluidity.   
 
An anionic constituent of the formulation (polycarbophil) was found to be 
interacting with the drug and the extent of the interaction appeared to depend on 
the pH of the media.   
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As a result of conducting the in vitro drug release experiments, the ISGM system 
proved to be feasible as the release rate of propranolol was retarded upon 
formation of a gelled depot. 
 
Modelling of the release data was carried out to determine if a relationship 
between drug release and each parameter existed.  The initial modelling approach 
involved using the Higuchi equation.  The Higuchi equation gave a straight line 
relationship (up to 50%) indicating the fraction of drug released was proportional 
to the square root of time.  Modelling was also conducted using a more general 
power law relationship.  The power law indicated the release mechanism of the 
drug was anomalous transport, i.e. the release mechanism was a combination of 
swelling-controlled and diffusion-controlled release.   
 
The modelling showed that n did not change when altering the amount of drug in 
the formulation.  This was ideal as the release mechanism will remain constant.   
 
The final aspect of this research involved evaluating the stability of the final 
formulation.  The stability of the drug in the formulation was monitored by 
HPLC.  The main issue with the stability assessment was that degradation peaks 
were not detected during the development of the stability method.  If degradation 
products did exist, they may have eluted with the solvent front or been retained in 
the column.  The absence of degradation peaks meant that there was no 
interference with the peak of interest, thus allowing the stability of the drug to be 
investigated by monitoring the drug level in the formulation.  The 4-week 
accelerated stability indicated drug degradation had not occurred as the drug level 
in the formulation remained unchanged.   
 
The appearance of the formulation stored in the accelerated “ageing” conditions 
was also monitored.  Visible signs of degradation such as a change in colour were 
not observed, indicating the formulation had apparently not degraded (over the 4-
week study).  Therefore as a result of conducting a stability analysis of the final 
formulation, it can be concluded that the formulation should be stable under 
normal storage conditions (for at least 4 weeks), which are less severe than the 
“accelerated storage conditions”. 
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This study has shown that the ISGM system as a concept is technically workable 
with the optimised set of constituents determined in this study as these were found 
to retard the release rate of propranolol.  Therefore there is much potential for this 
ISGM system concept from a practical point of view and it should be investigated 
further.  These future studies should not be restricted to the delivery of 
propranolol.  Other drugs such as hydrophobic or non-ionic drugs should also be 
investigated.  Hydrophobic drugs will have a different release mechanism than 
propranolol (which is a hydrophilic drug) where instead of diffusion, the release 
mechanism may be dictated by break down of the polymer.  Non-ionic drugs 
would be advantageous in this system as the drug would not interact with the 
anionic viscosity inducing agent polycarbophil so that 100% release may be 
realised.  
 
Though this study has shown that the ISGM system is practically workable, it is 
not known whether the technology will be able to deliver propranolol at an 
appropriate rate to be useful.  Assessment of the appropriate rate would require in 
vivo studies (which have been recommended as future studies).  The in vitro drug 
release experiment was used as a comparative tool to assess how different 
parameters would affect the drug release rate.  The in vitro release experiments 
were not indicative of the drug release behaviour in vivo as certain restrictions 
such as the surface area of the release interface and swelling of the system were 
enforced.  This study has shown that injection of the formulation results in the 
formation of a gelled depot in vivo.  However, further, more prolonged studies 
into the in vivo release behaviour need to be conducted before determining 
whether the ISGM system will release the drug at a rate that is useful and whether 
it can be well tolerated by the body.  This will include studies into the appropriate 
amount of drug and gelling agent to incorporate into the formulation to achieve 
the desired release of the drug over the required treatment time. 
 
In closing, formulation challenges were met and a critical assessment of the 
chemical and physical stability of the product was made.  The research 
successfully converted the ISGM system from a concept delivery system with 
little supporting experimental investigation into a practical technology that is 
worthy of further investigation and development as an animal health product. 
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Further investigation of the ISGM system should include: 
 
 Mechanistic Studies of the ISGM System 
Carry out mechanistic, rheological and physicochemical studies of the ISGM 
system to identify how certain formulation variables influence depot 
formation.  This could provide information on how to manipulate the ISGM 
system when incorporating different bioactive agents. 
 
 Biocompatibility of the Final Formulation in Live Animals   
The degree of tissue site reactions and inflammatory responses (such as 
swelling and redness), if any, should be assessed in vivo. 
 
 In Vivo Trials 
In vivo trials should initially be conducted on small animals where the drug 
level in the blood is monitored over time.  The trial should then move on to 
larger animals to examine the effect of scale. 
 
 Incorporation of Different Bioactive Agents  
Various bioactive agents (other than the hydrophilic drug used in this study) 
such as other hydrophilic drugs, hydrophobic drugs, proteins and peptides 
(though these latter two agents would carry special challenges due to their 
greater degree of metabolism) should be investigated as possible agents to use 
in this formulation.  If the formulation is able to deliver a wide array of 
bioactive agents then it can be applied to the treatment of many diseases.   
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5.2 Conclusions 
 
The research achieved several aims.  These included: 
 
 Research of a broad definition of an ISGM system and its conversion from 
a conceptual idea into a practical system  
 
 Demonstrating that all ingredients of the ISGM system were 
biocompatible. 
 
 Successfully formulating the continuous phase into which both the 
hydrophilic polymer and drug could be incorporated. 
 
 Successfully assessing the resultant suspensions to demonstrate their 
physical and chemical stability. 
 
 Demonstrating the ISGM technology worked when injected into an 
aqueous environment as a gelled depot formed. 
 
The significant contributions of this research to science were:  
 
 The research identified a potentially useful polymer with which to modify 
the viscosity of a non-aqueous solvent and demonstrated that it could be 
readily manufactured and used to retard sedimentation of a range of 
polymers and drugs.  This was a significant achievement, given the fact 
that the literature is sparse with respect to the reporting of compounds 
which increase the viscosity of non-aqueous solvents. 
 
 The research successfully developed a novel method for determining the in 
vitro drug release of in situ forming gel technologies.   This was a 
particularly significant achievement since the difficulty in developing an in 
vitro method for this type of controlled release delivery system is generally 
acknowledged as being very difficult.  This contribution is again supported 
by the fact that the literature is sparse on reported methods. 
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 This research has successfully converted a novel idea for a technology that 
had been broadly described in the patent literature (Bunt et al., 2003) into 
a practical system.  This was a technological achievement since there is 
little literature regarding the formulation on non-aqueous suspensions.  
The studies conducted in this research have shown that the ISGM 
technology is feasible, whereby introduction of the formulation to an 
aqueous environment resulted in a gelled depot which retarded the release 
rate of the drug, propranolol.  Consequently this research has found that 
the ISGM technology has much potential and should be further 
investigated to develop it into a commercial product for the veterinary 
field.   
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 A1  – Comparison of Sedimentation Profiles for HPMC at each Glycerin 
Concentration in Alcohol (n=2) 
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S10 Vibro-Viscometer Standard Operating 
Procedure 
 
The following method describes how to carry out measurements on the S10 
Vibro-viscometer. 
 
1. The small sample cup is placed in the large sample holder.  The test 
sample is then poured in to the 10 mL mark as close as possible.  Addition 
of sample by weight is not required.  Once the sample has been added, a 
lid is placed on top. 
 
2. Before conducting any measurements ensure the air conditioner is 
switched off. 
 
3. Ensure the temperature of the room is between 18 and 21 °C.  If necessary 
heat/cool the room for a short time beforehand. 
 
4. 16 mL of water is added to the water jacket which is sitting on the 
platform below the sensor plates of the viscometer. 
 
5. The water bath should be continuously running 24 hours a day.  Do not 
switch it off. 
 
6. Ensure the water bath has been set to the required temperature. 
  
7. Push the on/off button to turn the viscometer on. 
 
8. Ensure the protector (metal covering around sensor plates) is lowered to 
prevent accidental bumping of the sensor plates.   
 
9. Place the sample holder in the water jacket.   
 
 263
10. On top of the lid there are two screw holes – one at the front and one at the 
back.  There is only one white screw and this should be placed in the back 
hole leaving the front one empty.   
 
11. Raise the protector.  Lower the sensor plates into the sample by releasing 
the lever on the side and then while holding the top unit squeeze the two 
flaps at the back and lower the sensor plates until the sensor plates are 
about 1 cm from the sample cup.  Secure the top unit by locking the lever.   
 
12. Place the magnifying glass in front of the sample cup.  Then raise the 
platform by turning the knob on the right hand side until the probe is 
covered over the half way point as shown in the diagram below.  Use the 
bottom of the meniscus for leveling. 
 
 
 
 
 
 
 
 
 
 
 
 
13. Wrap tissue around the sensor plates to prevent contact with air.   
 
14. Open the RsVisco program on the computer by double clicking the icon on 
the desktop. Make sure Auto stop is not selected. 
 
15. Click the start button and allow the sample to equilibrate for 30-45 
minutes or until the temperature is 25.0 °C.   
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16. Click on stop.  Then click on file and select New.  A window will appear 
asking if you want to clear the data.  Click Yes.  Type in the required 
parameters i.e. auto stop on, a 2 minute run time with 5 second sampling.  
Click the start button.     
 
17. When the sample run is complete remove tissue, lower the platform to the 
bottom.  To obtain another reading of the same sample repeat steps 11 - 
12.  Then click start to commence a new run. 
 
18. Repeat step 14 as many times as required (5 times recommended). 
 
19. To save the data, click on File and select Save.  Type in the appropriate 
name of your file and click Save. 
 
20. To introduce a new sample, lower the platform, raise the sensor plates by 
unlocking the lever as mentioned earlier and squeeze flaps, raise the top 
unit and then tighten the lever once more.   
 
21. Clean sensor plates and temperature probe by wiping with a tissue wetted 
with alcohol.  Wipe carefully – try to avoid movement of sensor pates and 
temperature probe.  Repeat once more.  Once cleaned lower the protector 
back into place. 
 
22. Unscrew the white cap and remove sample holder.   
 
23. Add the new sample holder with the fresh sample.  Repeat steps 9 – 12.  
Open a new file for the new data by clicking on File and selecting New. 
 
24. Enter the required parameters and repeat steps 17 -19. 
 
25. Once the user has completed using the viscometer repeat steps 20 - 22. 
 
26. To remove water from the water jacket remove the water jacket and pour 
out the water. 
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27. Push the on/off button on the viscometer. 
 
28. Close the program but do not shut down the computer. 
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